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Abstract 
Anoctamin 5 (ANO5) is the causative gene underlying limb girdle muscular dystrophy 
type 2 (LGMD2L), a highly heterogeneous musculoskeletal disease characterised by 
weakness of the shoulder and hip musculature, generally increasing in severity with age. 
A re-examination of ANO5 prevalence in previously undiagnosed patients has found 
that LGMD2L is the third most prevalent LGMD in the North East of England. 
However, very little is known about ANO5 or of possible treatment strategies for 
LGMD2L patients. 
Anoctamin 5 is one of a ten-member family of proteins, some of which have confirmed 
biochemical or physiological functions. Anoctamin 6, the most closely related family 
member, has been suggested to be a phospholipid scramblase. Deficiency of anoctamin 
6 causes Scott syndrome, a blood clotting disorder caused by failure to expose 
phosphatidylserine (PS) on the external plasma membrane of red blood cells. More 
widely, PS exposure is also required to identify and remove apoptotic cells in many cell 
types. One hypothesis for anoctamin 5 function is that of a phospholipid scramblase in 
muscle tissue; a dystrophic phenotype resulting from impaired PS exposure leading to 
an increased inflammatory response and a failed muscle repair process overall. 
To clarify our understanding of anoctamin 5, this hypothesis was investigated along 
with general examination into potential interacting proteins and the subcellular 
localisation of anoctamin 5. 
Lacking a suitable antibody against anoctamin 5, subcellular localisation was 
investigated using co-expression of fluorescently tagged ANO5 constructs with both 
organelle specific markers and GFP-tagged dysferlin constructs. Dysferlin (DYSF) is of 
interest as mutations are causative for LGMD2B which has an overlapping phenotype 
with LGMD2L. ANO5 localises to the sarcoplasmic reticulum and t-tubules in the 
C2C12 myoblast cell line, overlapping with the dysferlin expression pattern. 
Anoctamin 5 function was investigated using ANO5 knock down C2C12 cell lines 
developed during this project. These cell lines were characterised using 2-dimensional 
electrophoresis followed by MALDI-MS/MS of selected protein spots. Expression of 
annexin A2 (ANXA2) in C2C12 is affected when anoctamin 5 is knocked down. 
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Anoctamin 5 function as phospholipid scramblase was investigated in ANO5 knock 
down C2C12 using an annexin V apoptosis detection kit, modified to include a stain for 
active caspase 3, another marker of apoptosis. The number of annexin V-positive and 
caspase 3-positive cells were then assessed using fluorescent microscopy. Significantly 
fewer annexin V-positive cells were found in ANO5 knock down C2C12 compared to 
Control C2C12. However, there was no significant difference between the number of 
active caspase 3-positive cells, suggesting that the knock down of anoctamin 5 has a 
specific effect on PS exposure and not a general effect to apoptotic processes.  
These data suggest a possible extension to the initial anoctamin 5 as phospholipid 
scramblase hypothesis, reconciling the observations that anoctamin 5 is internally 
localised but also has a significant effect on PS exposure at the plasma membrane. This 
interpretation suggests that ANO5 functions within a novel subcellular vesicle 
population activated by apoptotic triggers. These hypothetical vesicle populations, 
containing ANO5, ANXA2 and PS, transit to the external plasma membrane when 
required where ANXA2 binds to the plasma membrane. Activation of ANO5 leads to 
normalisation of PS between the inner and outer leaflets of the vesicle, which is inserted 
into the membrane in a process requiring ANXA2 and /or dysferlin, identifying the cell 
as dead marking it for phagocytosis. 
This project investigates novel avenues of anoctamin 5 research and suggests potential 
future research directions.  
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Chapter 1 Introduction 
1.1 Muscular Dystrophies 
Muscular dystrophies are a group of rare, highly heterogeneous diseases (Emery, 2002). 
While they share progressive weakness of voluntary muscles and are genetically 
inherited, muscular dystrophies vary in inheritance pattern, pattern of muscle 
involvement, age of onset, rate of progression and associated phenotypes such as heart 
or lung disease (Emery, 2002; Mercuri and Muntoni, 2013).  
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy 
(prevalence - 1 in 3,600 to 1 in 6,000 male births (Bushby et al., 2010)) and was the 
first to be characterised. DMD is named after Guillaume Duchenne who conducted 
detailed characterisation of the disease in the 1860s, though it has since been recognised 
that reports of DMD patients had been described earlier, notably by Conte and Gioja in 
1836 and Meryon in 1852 (Meryon, 1852; Emery and Emery, 1993). As an X-linked 
disease, the majority of patients are male and experience muscle weakness from a young 
age, typically losing ambulation before their early teens (Laing et al., 2011). In the 164 
years since the description and characterisation of DMD, several other groups of 
muscular dystrophy, themselves often comprised of multiple subtypes, have been 
identified (Table 1.1).  
Of these groups, Oculopharyngeal (OPMD) and the Myotonic dystrophies (DM1 and 
DM2) both have an autosomal dominant pattern of inheritance while the Congenital 
muscular dystrophies (CMD) have a recessive pattern. The CMDs are a heterogeneous 
group of muscular dystrophies connected by severe hypotonia from birth and the onset 
of muscle weakness within a year (Bonnemann et al., 2014). The increased 
understanding in the subtleties between different muscular dystrophies is in large part 
thanks to the implementation of molecular genetics techniques such as next-generation 
sequencing (Thompson and Straub, 2016).  
In the case of Facioscapulohumeral dystrophy (FSHD), while it is also autosomal 
dominantly inherited, it has only been after several decades of genetic and clinical 
investigation that a consensus on its pathophysiology has recently been reached (Tawil 
et al., 2014). FSHD was formally characterised in the 1950s (Tyler and Stephens, 1950) 
but until recently, the two genetically distinct FSHD subtypes (FSHD1 and FSHD2) 
were clinical indistinguishable. It is now thought that changes in the expression of 
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DUX4, caused by disruption to the repression of D4Z4 macrosatellite repeats, leads to 
FSHD in skeletal muscle (Tawil et al., 2014). Similarly, the increased utility of 
molecular genetic techniques has greatly increased the identification and understanding 
of the many different subtypes of limb girdle muscular dystrophies. The limb-girdle 
muscular dystrophies are of particular interest to this project and are discussed in further 
detail in the following section. 
There are currently no cures for any muscular dystrophy, though therapies and 
management options are available for several which have increased patient life 
expectance and greatly improved quality of life for sufferers (Eagle et al., 2002; Bach 
and Martinez, 2011). For DMD, the treatments developed since its first discovery 
include steroid therapy (Daftary et al., 2007; Markham et al., 2008) and ventilators 
(Eagle et al., 2002). Current DMD research is exploring effective prediction of muscle 
loss using MRI (Kinali et al., 2011; Wokke et al., 2014) and treatment options for 
muscle loss including exon skipping, a form of gene therapy to effectively turn DMD 
into its less severe form, Becker muscular dystrophy (BMD) (Niks and Aartsma-Rus, 
2017). Due to the relatively rare prevalence of many of the muscular dystrophies 
research into muscular dystrophies, and the LGMDs in particular, are greatly supported 
by the establishment and expansion of clinical registries and networks (Thompson and 
Straub, 2016).  
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Dystrophy Prevelance 
(per 100,000) 
Location Identified Protein (Gene Name) 
Congenital (CMD) 
MDC1A 
Walker-Warburg 
syndrome 
Ullrich (UCMD) 
 
 
 
 
 
Rigid spine (RSMD1) 
 
0.60 
0.03 
 
0.13 
 
 
 
 
 
0.13 
 
6q22.33 
9q34.13 
 
2q37.3 
 
21q22.3 
 
 
 
1p36.11 
 
Laminin alpha-2 (LAMA2) 
Protein O-Mannosyltransferase 1 
(POMT1) 
Collagen, type VI, alpha-3 
(COL6A3) 
Collagen, type VI, alpha-1 
(COL6A1) and 
Collagen, type VI, alpha-2 
(COL6A2) 
Selenoprotein N, 1 (SEPN1) 
Dystrophinopathies 
Duchenne (DMD) 
Becker (BMD) 
 
8.29 
7.29 
 
Xp21.2-p21.1 
 
Dystrophin (DMD) 
Facioscapulohumeral 
(FSHD) 
1 
2 
 
3.95 
 
 
 
 
4q35 
18p11.32 
 
 
Currently Unclear, hypothesised  
to involve DUX4 
Limb Girdle Muscular 
Dystrophies 
2.27 Detailed in full in Table 1.3 
Oculopharyngeal  
(OPMD) 
0.13 14q11.2 Polyadenylate-binding protein, 
Nuclear 1 (PABPN1) 
Myotonic 
DM1 
 
DM2 
 
10.4 
 
0.17 
 
19q13.32 
 
3q21.3 
 
Dystrophia myotonica protein 
kinase gene (DMPK) 
Zinc Finger Protein 9 (ZNF9) 
Table 1.1 List of the six most common muscular dystrophy groups in the North East of England  
Table compiled from data in Norwood et al. (2009), with additional facioscapulohumeral 
information from Richards et al. (2012) and “Location” information (chromosome position) 
from OMIM (http://omim.org/). Information for LGMD is omitted from this table as it is 
detailed more fully separately in Table 1.3. Groups are arranged alphabetically and not in 
order of frequency. The prevalence (per 100,000 people in the population), gene position and 
causative protein (if known) are listed.  
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1.2 Limb Girdle Muscular Dystrophies 
The limb girdle muscular dystrophy (LGMD) group is characterised by wasting of the 
limb-girdle musculature, typically sparing the facial muscles (Walton and Nattrass, 
1954). Diagnosis of specific LGMD subtypes has always been challenging due to the 
high phenotype heterogeneity seen within the group and potentially within each subtype 
(e.g. location of muscle weakness, age of onset, severity of disease and rate of 
progression; (Bushby, 1999; Thompson and Straub, 2016)). Additionally, other 
muscular dystrophies, for example FSHD and the dystrophinopathies (DMD and BMD), 
present with similar weakness and are more common in clinical populations than the 
LGMDs (Bushby, 2009). Exclusion of these alternative muscular dystrophies must 
therefore be achieved before a LGMD diagnosis can be reached. The majority of 
LGMD diagnostic issues are now resolved by investigation and identification of 
causative genes, often through use of next generation sequencing techniques 
(Narayanaswami et al., 2014; Ghaoui et al., 2015; Kuhn et al., 2016). 
However, access to advanced molecular diagnostic tools such as immunohistochemistry, 
immunoblotting and next generation whole exome sequencing, varies between and 
within countries. As a result it is very difficult to fully assess the global prevalence of 
LGMDs. Furthermore robust methods of reporting suspected cases have not been 
established in all countries making establishment of cohorts and corroboration of 
candidate genes very difficult (Bastian et al., 2015). The lack of robust universal 
diagnosis also extends to understanding the progression of identified subtypes in 
successfully diagnosed patients. 
Despite these difficulties, current advancements in molecular research techniques have 
so far allowed for identification of thirty two distinct LGMD subtypes, many with an 
identified causative gene (Table 1.3). These subtypes are grouped into autosomal 
dominant (LGMD1 [MIM# 159000]) and recessive (LGMD2 [MIM# 253600]) subtypes, 
with recessive subtypes being more prevalent than dominant forms making up 
approximately 90% of the diagnosed patient population (Cotta et al., 2014; Nigro and 
Savarese, 2014). 
LGMDs as a group however are still rare. For example in a 2009 snap shot of the 
clinical population of the North East of England attending specialist muscle clinics, the 
LGMDs as a whole made up 6.2% of the clinical population (or 2.27/100.000 
prevalence of the general population) while the commonest form of muscular dystrophy, 
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Duchenne muscular dystrophy, typically appeared with a frequency of 8.29/100,000 in 
the general population, or 11.2% of the muscle patients (Norwood et al., 2009). 
In all LGMDs, the identification of causative genes and correct differential diagnosis 
allows for a better understanding of disease progression, associated complications and 
most importantly, therapeutic possibilities and improved patient care (Bushby, 1999; 
Cotta et al., 2014). However the function of many of these causative genes is still 
unknown and it is estimated that 30% of patients lack a definitive diagnosis of their 
particular LGMD even following genetic testing (Bushby, 2009). 
1.2.1 Autosomal dominant LGMDs 
There are currently eight identified dominant limb girdle muscular dystrophy subtypes, 
1A-1H. Two of these eight subtypes have been identified only in single families in 
Spain (LGMD1F (Gamez et al., 2001; Peterle et al., 2013) and Italy (LGMD1H 
(Bisceglia et al., 2010)). LGMD1G had also initially only been identified within a 
single Brazilian family but has since been identified in a family in Uruguay (Starling et 
al., 2004; Vieira et al., 2014). Conversely LGMD1A has been described in a number of 
families worldwide including North America (Gilchrist et al., 1988; Hauser et al., 2000), 
Argentina (Hauser et al., 2002) and Japan (Shalaby et al., 2009). 
Generally, dominant LGMDs have a later age of onset and slower disease progression 
than the recessive LGMDs, though the age of onset varies greatly both between and 
within sub-types (Bastian et al., 2015). A variety of symptoms such as toe and finger 
flexion limitation (LGMD1G (Starling et al., 2004; Vieira et al., 2014)), contractures 
(LGMD1B (van der Kooi et al., 1996)), tight Achilles tendons (LGMD1A (Gilchrist et 
al., 1988)) and calf hypertrophy (LGMD1C and LGMD1H (Minetti et al., 1998; 
Bisceglia et al., 2010)) have been recorded in some sub-types along with the expected 
proximal weakness. LGMD1B is notable for the addition of cardiac involvement, 
including arrhythmias, conduction disturbances and dilated cardiomyopathy which in 
LGMD1B can lead to sudden death (van der Kooi et al., 1996).  
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Autosomal Dominant 
Subtypes Location Identified Protein (Gene Name) 
LGMD1A 5q31.2 Myotilin (TTID) 
LGMD1B 1q22 Lamin A/C (LMNA) 
LGMD1C 3p25.3 Caveolin 3 (CAV3) 
LGMD1D 7q36 DnaJ heat shock protein family member B6 (DNAJB6) 
LGMD1E 2q35 Desmin (DES) 
LGMD1F 7q32.1 Transportin 3 (TNPO3) 
LGMD1G 4p21.22 Heterogeneous nuclear ribonucleoprotein D-like 
protein (HNRNPDL) 
LGMD1H 3p25.1-p23 Unknown 
Table 1.2 List of the eight autosomal dominant LGMD subtypes currently identified. Table 
compiled from data in Nigro and Savarese (2014) and additional “Location” information 
(chromosome position) from OMIM (http://omim.org/), though the classification of the 
LGMD1E nomenclature appears to be just in Nigro and Savarese (2014). The currently 
identified LGMD subtypes are listed along with their mode of inheritance, chromosome position 
and causative protein (and gene). 
1.2.2 Autosomal recessive LGMDs 
There are currently twenty four autosomal recessive subtypes of LGMD which, as with 
the autosomal dominant subtypes, have a wide variation in population frequency and 
range of pathologies. LGMD2A is estimated to be the most common form of recessive 
LGMD, accounting for approximately 30% of all recessive LGMD cases (Richard et al., 
2016). LGMD2A has also been reported as the most common LGMD in in Spain, Italy, 
Czech Republic and Romania (Fanin et al., 2005; Cotta et al., 2014; Stehlikova et al., 
2014; Bastian et al., 2015). LGMD2I is reported to be the most common in Denmark 
(Sveen et al., 2006), LGMD2B the most common in the United States (Moore et al., 
2006) and LGMD2C, 2D, 2E and 2F (the sarcoglycanopathies) are common in Turkey, 
North Africa (Bushby, 1995; Zatz et al., 2003) and Brazil (Cotta et al., 2014).  
LGMD2I was initially reported as the most common LGMD in the UK (Poppe et al., 
2003), but specific investigation of the patient population in the North of England now 
suggests that LGMD2A is the most common in this particular sub-population (Norwood 
et al., 2009). Follow up in this geographic region has also identified increased 
prevalence of other recessive LGMDs such as LGMD2L which is now suggested to 
have a prevalence of 0.27/10,000 potentially making it the third most common form of 
 7 
LGMD in the UK (Hicks et al., 2011). The LGMD2L subtype was first identified in a 
cohort of eight families of French-Canadian descent based on linkage analysis to 
chromosome 11 (Jarry et al., 2007). Since then, populations of LGMD2L patients have 
been identified in several European populations including Holland (van der Kooi et al., 
2013), Finland (Penttila et al., 2012), France (Behin et al., 2011), Italy (Magri et al., 
2011) as well as the aforementioned prevalence in the UK (Hicks et al., 2011).  
Increased identification of the number of affected individuals has increased our 
understanding of the range and historical progression of the geographic distribution of 
some LGMDs. For example LGMD2H was initially thought to appear only in the 
Hutterite ethnic group in Manitoba, Canada (Shokeir and Kobrinsky, 1976) but has now 
been recorded in other European non-Hutterite patients such as Croatia (Saccone et al., 
2008). Additionally, all patients in the Manitoba population were found to have the 
same causative c.1459G>A mutation in the gene TRIM32 (Weiler et al., 1998; Frosk et 
al., 2002). This is of particular interest as LGMD2I is also present in both Hutterite and 
European populations. Indeed, the c.826C>A (L276I) mutation causative for LGMD2I 
in Hutterite populations is the same as that identified in European patient populations, 
suggesting a European founder event (Frosk et al., 2005). A similar founder event may 
have occurred for LGMD2H, but has gone unreported as the representatives in the 
European populations remain undiagnosed. Similarly a common c.191dupA mutation 
has been identified in many LGMD2L patients. The distribution of this common 
mutation as well as other identified causative LGMD2L mutations suggests a founder 
effect in Northern European populations (Hicks et al., 2011).   
 8 
Autosomal Recessive 
Subtypes Location Identified Protein (Gene Name) 
LGMD2A 15q15.1 Calpain 3(CAPN3) 
LGMD2B 2p13.2 Dysferlin (DYSF) 
LGMD2C 13q12.12 Sarcoglycan, Gamma (SGCG) 
LGMD2D 17q21.33 Sarcoglycan, Alpha (SGCA) 
LGMD2E 4q12 Sarcoglycan, Beta (SGCB) 
LGMD2F 5q33.2-q33.3 Sarcoglycan, Delta (SGCD) 
LGMD2G 17q12 Titin-Cap (TCAP) 
LGMD2H 9q33.1 Tripartite Motif-Containing Protein 32 (TRIM32) 
LGMD2I 19q13.32 Fukutin-Related Protein (FKRP) 
LGMD2J 2q31.2 Titin (TTN) 
LGMD2K 9q34.13 Protein O-Mannosyltransferase 1 (POMT1) 
LGMD2L 11p14.3 Anoctamin 5 (ANO5) 
LGMD2M 9q31.2 Fukutin (FKTN) 
LGMD2N 14q24.3 Protein O-Mannosyltransferase 2 (POMT2) 
LGMD2O 1p34.1 Protein O-Mannose Beta-1, 2-N-
Acetylglucosaminyltransferase (POMGNT1) 
LGMD2Q 8q24.3 Plectin 1(PLEC1) 
LGMD2R 2q35 Desmin (DES) 
LGMD2S 4q35.1 Trafficking Protein Particle Complex, subunit 11 
(TRAPPC11) 
LGMD2T 3p21.31 GDP-Mannose Pyrophosphorylase B (GMPPB) 
LGMD2U 7p21.2 Isoprenoid Synthase Domain-Containing Protein 
(ISPD) 
LGMD2V 17q25.3 Acid Alpha-Glucosidae (GAA) 
LGMD2W 2q14.3 LIM and senescent cell antigen-like-containing domain 
protein 2 (LIMS2/ PINCH2) 
LGMD2X 6q21 Popeye domain–containing 1 (POPDC1) 
LGMD2Y 1q25.2 Torsin A-Interacting Protein 1 (TOR1AIP1) 
LGMD2Z 3q.13.33 Protein O-Glucosyltransferase 1 (POGLUT1) 
Table 1.3 List of the twenty five autosomal recessive LGMD subtypes currently identified. Table 
compiled from data in Nigro and Savarese (2014), Schindler et al. (2016), Ghaoui et al. (2016), 
(Servian-Morilla et al., 2016) and additional “Location” information (chromosome position) 
from OMIM (http://omim.org/). The currently identified LGMD subtypes are listed along with 
their mode of inheritance, chromosome position and causative protein (and gene). 
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1.2.3 LGMDs have overlapping phenotypes and pathways with other muscular 
dystrophies 
Due to the interplay between proteins and pathways involved in correct muscle function 
a few dominant and recessive LGMDs share overlapping phenotypes to both other 
LGMDs and other muscular dystrophies. For example, the dystrophin glycoprotein 
complex (DGC) is a sophisticated organisation of protein subunits which connects the 
extracellular matrix of muscle to the cytoskeleton (Ervasti and Campbell, 1993; 
Rybakova et al., 2000) and together correctly regulates the constant contraction and 
elongation required of skeletal and cardiac muscle (Gumerson and Michele, 2011). 
Muscular dystrophy often results from mutations in genes which code for proteins 
required for correct function of the DGC.  
For example, four transmembrane sarcoglycans, alpha, beta, delta and gamma, form a 
subunit within the DGC, the sarcoglycan complex (Yoshida et al., 1994). The 
sarcoglycan complex is thought to assist in the stability of the plasma membrane though 
the precise function is not clear (Durbeej and Campbell, 2002). Mutations in the gamma, 
alpha, beta and delta sarcoglycans disrupt the plasma membrane of skeletal and cardiac 
muscle leading to the LGMDs 2C (Noguchi et al., 1995), 2D (Roberds et al., 1994), 2E 
(Bonnemann et al., 1995) and 2F (Nigro et al., 1996) respectively. Differential 
diagnosis between the sarcoglycanopathies and DMD, now routinely achieved through 
genetic screening (Grimm, 1984), is often required as mutations to dystrophin, another 
key DGC protein, lead to DMD and BMD  
Caveolin 3 is another protein required for the correct functioning of the DGC (Song et 
al., 1996), indeed upregulation of the protein has been associated with DMD (Repetto et 
al., 1999). Caveolin 3 is the muscle-specific member of the caveolin family and the 
principle component of caveolae; invaginations of the plasma membrane involved in 
cellular trafficking and correct muscle development (Simionescu et al., 1975; Parton 
and Simons, 2007). Caveolin 3 is coded for by CAV3, mutations to which are causative 
for LGMD1C (Minetti et al., 1998) but mutations to which have also been identified in 
familial isolated hyperCKemia (Carbone et al., 2000), rippling muscle disease (Betz et 
al., 2001; Vorgerd et al., 2001) and a form of distal myopathy (Tateyama et al., 2002; 
Gonzalez-Perez et al., 2009). Evidence for an interaction between CAV3 and DYSF, 
mutations to which are causative for LGMD2B (Bashir et al., 1998), comes from the 
discovery that CAV3 co-immunoprecipitates with dysferlin in human skeletal muscle, 
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dysferlin localisation is altered in LGMD1C muscle and several amino acid sequences 
in dysferlin correspond to binding motifs in CAV3 (Matsuda et al., 2001).  
Other LGMD not directly involved with the DGC also have overlapping pathologies 
with other forms of muscle weakness and muscular dystrophies. For example, mutations 
to the gene for myotilin are causative for LGMD1A but have also been identified as 
causative for a subgroup of myofibril myopathy (MFM/MYOT) which present with a 
distal pattern of muscle weakness (Selcen and Engel, 2004; Olive et al., 2005). Another 
example is LGMD2I which is caused by mutations in the Fukatin Related Protein 
(FKRP) and is allelic with the congenital muscular dystrophy, MDC1C (Brockington et 
al., 2001a). Generally the pathology of LGMD2I is much less severe than MDC1C, 
with later age of onset (late child or adulthood compared to first few months of life) and 
reduced risk of ambulation loss, which is likely due to the secondary deficiency of α-
dystroclycan (Brockington et al., 2001b). Additionally a genotype/phenotype 
correlation is present within LGMD2I patients as the causative 826C>A FKRP mutation 
leads to a more severe phenotype when compound heterozygous (Brockington et al., 
2001b; Walter et al., 2004). 
In all, several of the genes responsible for LGMDs are causative for other 
musculoskeletal diseases. Indeed, several of these diseases are now considered to be 
parts or ends of spectrums of disorders, rather than distinct diseases (Linssen et al., 
1997; Gazzerro et al., 2010; van der Kooi et al., 2013). Of particular interest to this 
research project is gene coding anoctamin 5 (ANO5), mutations for which are causative 
for limb girdle muscular dystrophy type 2L (LGMD2L) and Myoshi Myopathy Type 3 
(MMD3) (Bolduc et al., 2010).  
1.2.4 LGMD2L similarity to LGMD2B 
LGMD2B is also allelic with a distal myopathy (Emery, 2002). Missense and frameshift 
mutations in the dysferlin gene (DYSF, MIM# 603009) cause LGMD2B as well as 
Miyoshi myopathy 1 (MMD1). Furthermore, both LGMD2L and 2B present with very 
similar phenotypes. Both have a variable, late onset, infrequent cardiac and respiratory 
involvement and muscle wasting initially of the lower limbs which may present 
asymmetrically, with potential progression to the shoulder musculature (Jarry et al., 
2007; Urtizberea et al., 2008). Like anoctamin 5, the function of dysferlin is not fully 
understood but is strongly suspected to be involved in muscle cell repair (Bansal et al., 
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2003). Similarities between LGMD2L/MMD3 and LGMD2B/MMD1 phenotypes, as 
well as relevant data on cell repair in dysferlin deficient and non-dysferlin deficient 
cells has suggested that anoctamin 5 may act in the cell repair pathway with dysferlin 
(Mahjneh et al., 2010).  
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1.3 The anoctaminopathies - LGMD2L and MMD3 
1.3.1 Recessive anoctamin 5 mutations are causative in LGMD2L and MMD3 
Several recessive mutations in the anoctamin 5 gene (ANO5 (MIM# 608662)) have 
been found to be causative for LGMD2L (Bolduc et al., 2010; Hicks et al., 2011; Magri 
et al., 2011; Milone et al., 2012; Penttila et al., 2012; Little et al., 2013) and MMD3 in 
Dutch and Finnish families (Linssen et al., 1998; Jaiswal et al., 2007; Bolduc et al., 
2010; Penttila et al., 2012) as well as isolated hyperCKaemia (Milone et al., 2012) and 
collectively these disease are termed the anoctaminopathies (Marlow et al.). 
ANO5 maps to chromosome 11p14.3 (Katoh and Katoh, 2004). There are currently 71 
reported unique sequence variants (www.lovd.nl/ANO5) distributed across the length of 
the gene, 41 of which are considered pathogenic. A common point mutation (c.191dupA) 
has been identified and appears at a relatively high frequency in several populations and 
in homozygous, heterozygous and compound heterozygous states (Hicks et al., 2011; 
Sarkozy et al., 2013). The c.191dupA mutation on exon 5 of ANO5, results in a 
frameshift and premature termination of the protein leading to a loss of function of 
ANO5 (Bolduc et al., 2010). However, in Finnish populations the c.2272C>T mutation 
is more common though this does not appear to be due a founder event in Finland 
(Penttila et al., 2012). The c.2272C>T mutation is a missense mutation located on exon 
20 and also appears in homozygous, heterozygous and compound heterozygous states 
(Penttila et al., 2012; Sarkozy et al., 2013). Other identified variants in ANO5 appear as 
splice site, nonsense stop, synonomous and intronic mutations (Sarkozy et al., 2013).  
However, there has yet to be any identified genotype/phenotype correlation in 
anoctaminopathy patients. For example, Penttila et al. (2012) found in an analysis of 
Finnish patients both c.191dupA and c.2272C>T mutations are causative for severe to 
mild distal, proximal and proximodistal phenotypes. While the mutation frequency for 
ANO5 has been suggested to be high (Hicks et al., 2011; Penttila et al., 2012) it is still 
difficult to accurately assess due to high heterogeneity of phenotypes and the subclinical 
presentation of many patients, despite homozygosity or compound heterozygosity for 
known pathogenic mutations (Liewluck et al., 2013; Savarese et al., 2015). 
1.3.2 Increased understanding of anoctaminopathy phenotype 
As the number of diagnosed patients has increased, the symptoms of LGMD2L have 
become better defined. It presents predominately in adults with a mean age of onset of 
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32.7 years (Jarry et al., 2007), though the range has been recorded as between 11 and 70 
years (Jarry et al., 2007; Sarkozy et al., 2013). Male predominance is significant with 
most female patients positive for ANO5 mutations being either asymptomatic or 
presenting with only mild symptoms (Sarkozy et al., 2013). MRI investigation has 
confirmed that muscle pathology is asymmetrical, though it predominantly affects the 
quadriceps femoris (Sarkozy et al., 2012). Myalgia following exercise is common and a 
high creatine kinase (CK) level of above 1000 U/L has been recorded in the majority of 
patients (Milone et al., 2012). Interestingly, asymptomatic patients positive for the 
causative mutations have been recorded with similarly high CK levels (Milone et al., 
2012; Sarkozy et al., 2013). Additionally, a cohort of Dutch patients newly diagnosed 
with LGMD2L were found to have engaged in extensive physical activity before the 
onset of symptoms (van der Kooi et al., 2013). The contractures, facial weakness and 
cardiomyopathy seen in other muscular dystrophies, are very rare.  
MMD3 (MIM# 613319) patients share similar phenotypes with LGMD2L patients 
namely initial, often asymmetric, weakness of the leg muscles with potential 
progression to upper arm musculature, elevated CK levels (above 2000 U/l), male 
predominance and an adult age of onset (mean age of onset = 34, range of 13-52) 
(Linssen et al., 1997; Linssen et al., 1998). Some diagnosed LGMD2L patients have 
been shown to present with distal as well as proximal muscle weakness (van der Kooi et 
al., 2013) and some Dutch MMD3 patients also develop proximal weakness of the hips 
and shoulders (Linssen et al., 1997). Therefore, MMD3 and LGMD2L are more 
accurately described as opposing ends of a pathological spectrum rather than distinct 
disorders.  
1.3.3 Gnathodiaphyseal Dysplasia 
Dominant missense ANO5 mutations have found to be causative for the rare bone 
syndrome Gnathodiaphyseal dysplasia (GDD, MIM# 166260) (Riminucci et al., 2001; 
Tsutsumi et al., 2004). Causative heterozygous missense mutations have been identified 
in a number of geographically diverse families though two different mutations have 
been identified in the same cysteine residue of amino acid 356. In a large Japanese 
family (21 affected members) c.1066T>G has been identified while in two members of 
an African-American family the mutation is c.1066T>C (Akasaka et al., 1969; Tsutsumi 
et al., 2004). More recently a c.1538C>T mutation in exon 15 has been identified in a 
large Italian family (Marconi et al., 2013). Unlike recessive ANO5 mutations, these 
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dominant mutations lead to disease phenotypes in both male and female patients 
(Ahluwalia et al., 2007).  
Furthermore, the cysteine residue at amino 356 where the GDD mutations are found, is 
conserved throughout vertebrate (human, mouse and zebrafish) and invertebrate (fruit 
fly and mosquito) species, and located to the proposed extracellular loop between 
transmembrane domains one and two (Tsutsumi et al., 2004). This extracellular loop 
location has been noted as similar to mutations for MMD3 which are found on the loop 
between transmembrane domains seven and eight (Bolduc et al., 2010). 
GDD patients present with deformities of both jaw and long bones and skeletal fragility 
(Akasaka et al., 1969; Riminucci et al., 2001). Many patients suffer from frequent 
fractures of femur, radius/ulna and vertebrae bones from trivial trauma at a young age 
though with apparently normal healing. Cortical thickening and bowing of the tubular 
bones can also occur, with bowing being caused by asymmetrical healing of the bones. 
The spine and growth plates however appear to develop normally and growth of the 
patients appears to be unaffected. As patients age cemento osseous lesions of the 
jawbone occur, often from poor healing following tooth extraction, causing deformity of 
the jawbone. Examination of the lesions has shown them to be formed from a 
combination of fibroblasts and mineralisation of blood vessels (Akasaka et al., 1969; 
Riminucci et al., 2001; Marconi et al., 2013). Initially named “hereditary gnatho-
diaphyseal sclerosis” (Akasaka et al., 1969), GDD was renamed to a dysplasia when it 
was noted that sclerosis (increases in bone density or hardening) was not associated 
with the jaw deformations (Riminucci et al., 2001).  
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1.4 The Anoctamin family 
Anoctamin 5 was previously named TMEM16E (Trans MEMbrane domain containing 
family 16, member E) due to its close homology to the TMEM16 family of proteins 
(Katoh, 2004; Katoh and Katoh, 2004). At the time, this family included the previously 
described genes TMEM16A (FLJ10261 or ORAOV2), TMEM16B (C12orf3), 
TMEM16C (C11orf25) and TMEM16D (FLJ34272), characterised by the eight 
transmembrane domains that they code for, with both the NH2 and COOH termini 
located within the plasma membrane (Tsutsumi et al., 2004) (Figure 1.1). The 
TMEM16 family currently contains 10 members (1-10) and is now collectively known 
as the anoctamin family, with ‘ANO’ replacing the ‘TMEM16’ nomenclature. Several 
assumptions about anoctamin 5 function have been made but currently, a 
comprehensive understanding of the range of ANO5 functions remains elusive. 
However, a number of other anoctamins have been extensively investigated.  
 
Figure 1.1 Predicted topology of anoctamin 5. Figure created using information from Penttila 
et al. (2012) and Savarese et al. (2015). The approximate positions of c.191dupA (the most 
common causative mutation for LGMD2L in most European populations) and c.2272C>T (the 
most common mutation for LGMD2L in Finnish populations) are labelled in orange. The 
approximate positions of known GDD mutations c.1066T>C and c.1066T>G are labelled in red.  
Phylogenetically, the anoctamin family is highly conserved, retaining considerable 
protein homology between vertebrate species (Duran and Hartzell, 2011) (Figure 1.2). 
Early research on anoctamin 1 (MIM# 610108), found to be upregulated in cancer 
tumours (West et al., 2004; Carles et al., 2006), led to the suggestion that this protein 
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forms a calcium activated chloride channel (CaCC) at the cell membrane, which led to 
the assumption that all anoctamins fulfilled the same function (Caputo et al., 2008; 
Yang et al., 2008). However, another anoctamin associated with disease, ANO6, was 
soon identified as a phospholipid scramblase (Suzuki et al., 2010; Castoldi et al., 2011) 
and an unconfirmed ion channel (Scudieri et al., 2015). Current research into 
nhTMEM16 and afTMEM16, fungal homologs of the ANOs, have broadened our 
understanding of the family even further and now suggests an evolutionary path from 
one function to the other (Brunner et al., 2014; Whitlock and Hartzell, 2016a).   
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Figure 1.2 Rooted phylogenetic tree of the anoctamin family. Figure taken from Whitlock and 
Hartzell (2016b). Below each anoctamin name is the percent identity and (similarity) to ANO1 
as well as any associated diseases. For each, both the anoctamin and TMEM16 nomenclature 
are given. The original authors used a subset of 1650 anoctamin sequences acquired from 
Uniprot to build the tree. A subset was used to remove duplicates and splice variants.   
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1.5 Development of ANO5 knockout mouse models and improved understanding 
of anoctamins as scramblases 
There were no mouse models, cell lines or reliable antibodies available for anoctamin 5 
prior to the start of this project. As such, investigation of ANO5 specific antibodies and 
development of model knockdown cell lines formed an integral part of this project. 
However, in the last two years of this project, three ANO5 knockout mice have been 
published by different labs (Gyobu et al., 2015; Xu et al., 2015; Griffin et al., 2016). As 
these mice were not available to this project they were not investigated, but the 
implications from the characterisation of these mice is discussed in greater detail in 
chapter 6 of this thesis. 
Additionally, in the last year a great deal has been learned about the scramblase ability 
of the anoctamin family members and their fungal homologs. This recent information 
has been included within this introduction to provide an up to date view of the current 
understanding of the anoctamins, though these details were unpublished or speculative 
at the start of this project.   
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1.6 Anoctamins as calcium activated chloride channels 
CaCCs are known to be important in several physiological functions including 
amplification of olfactory transduction (Matthews and Reisert, 2003), stabilization of 
membrane potential in photoreceptors (Lalonde et al., 2008), fluid secretion in glands 
and airway epithelia (Kunzelmann et al., 2009), neuron action potential waveform and 
both firing and regulation of smooth muscle contraction (Hartzell et al., 2009). However, 
until the discovery of anoctamin 1 and its closest related family member anoctamin 2 
(MIM# 610109), the identity of the genes coding for CaCCs remained unknown. 
Homologues of anoctamin 1 prepared from both Xenopus oocytes and mice have been 
show to produce the same CaCC currents as native Axolotl oocyte CaCC when injected 
with Xenopus oocytes and mouse mRNA (Schroeder et al., 2008).  
Since their discovery, anoctamins 1 and 2 have been confirmed to function in the same 
processes and tissues as other recorded CaCCs. They have been identified as regulators 
of airway smooth muscle contraction (Huang et al., 2012), in the rod photoreceptor 
terminals of mice retina (Stohr et al., 2009; Dauner et al., 2013) and in murine taste 
(Cherkashin et al., 2015) and olfactory tissues (Dauner et al., 2012). However, several 
studies have also expanded on their tissue specific functions, identifying them as CaCCs 
responsible for insulin secretion in mouse β-cells (Crutzen et al., 2015) and microvilli 
length and surface area in frog oocytes (Courjaret et al., 2016). Anoctamin 1 
specifically has been found to play an important role in cancer development. It has been 
identified as a potential biomarker in esophageal cancer (Shang et al., 2016) and that 
tumour cell proliferation an migration are promoted by its overexpression (Guan et al., 
2016). 
Due to the high sequence homology within the anoctamin family, the other anoctamins 
were also thought to act as CaCCs, although confirmation of this was difficult  to 
establish (Duran and Hartzell, 2011). Several studies claimed to have identified chloride 
conductance induced by expression of other anoctamins. For example, anoctamins 6, 7 
and 10 have been recorded producing chloride channels of various intensities. However 
the intensity of the ion flux recorded for these three anoctamins was less than 10% that 
of the flux recorded for anoctamin 1. Additionally, while a short form of anoctamin 7 
has also been identified without any transmembrane domains making it an unlikely ion 
channel, it still produces an ion flux of the same intensity as the full form of anoctamin 
7 (Schreiber et al., 2010). The suggestion was made that due the presence of at least one 
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anoctamin in any one cell line, expression experiments of anoctamin conductance have 
the potential to be contaminated by endogenous anoctamins (Kunzelmann et al., 2009; 
Schreiber et al., 2010).  
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1.7 Asymmetry, pathways and essential components of the plasma membrane 
All cell membranes are built from a complex amalgam of lipids and proteins, relying on 
the amphipathic nature of lipids to arrange into two symmetrical monolayers (van Meer 
et al., 2008). The hydrophilic head groups of the lipids face the aqueous outer 
environment, while their attached hydrophobic hydrocarbon chains point towards one 
another at the centre of the bilayer (van Meer et al., 2008; Whitlock and Hartzell, 
2016a).  
Ordinarily phosphatidylcholine, sphingomyelin and glycolipids are maintained on the 
exoplasmic leaflet of the membrane while phosphatidylserine, 
phosphatidylethanolamine and phosphatidylinosital are retained on the cytoplasmic 
leaflet (Zachowski, 1993; Daleke, 2007). Maintaining plasma membrane asymmetry is 
an essential part of proper cell function as movement of lipids from one membrane 
leaflet to another are required for membrane stability, cell signalling, blood coagulation, 
apoptosis and membrane protein regulation (Andersen et al., 2016). The redistribution 
of phospholipids between bilayers, for example the movement of 
phosphatidylethanolamine into phosphatidylcholine rich areas of the membrane (van 
Meer et al., 2008), is also required for initiating curvature of the plasma membrane 
which is further required for vesicle budding and fusion (Pomorski and Menon, 2006). 
The structure of the membrane bilayer is such that transition from one monolayer to 
another is highly energy demanding (Pomorski and Menon, 2006; Andersen et al., 
2016), with spontaneous diffusion of a single lipid taking 24 hours on average (Nakano 
et al., 2009). Three groups of transmembrane lipid transporter protein are involved in 
maintaining and redistributing the plasma membrane, depending on the stimulus or 
required function. The heterogeneous distribution of lipids is maintained by ATP 
dependant flippases and floppases working in counter balance to one another (Daleke, 
2003). Flippases preferentially transport lipids, most notably phosphatidylserine (PS), 
from the exoplasmic to the cytoplasmic leaflet (Pomorski and Menon, 2006) while 
floppases work in the reverse (Borst et al., 2000). There are several types of both 
transporter types as each have different specificities and cell types. For example ATP-
binding cassette (ABC) transporters as floppases (van Helvoort et al., 1996) and the P4 
subtype of P-type ATPases and aminophospholipids as flippases (Daleke and Lyles, 
2000; Lopez-Marques et al., 2014). 
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1.7.1 Phospholipid Scramblases and Phosphatidylserine exposure 
Scramblases are the third group of transmembrane lipid transporter proteins. They act 
during specific cellular processes to rapidly disrupt lipid asymmetry and non-selectively 
expose lipids to the outer surface of the plasma membrane (Bevers et al., 1983; 
Williamson et al., 1992; Williamson et al., 1995). Phospholipid scramblases are 
activated by increases to cytosolic calcium concentration (Zwaal and Schroit, 1997; 
Williamson et al., 2001), which simultaneously inhibits flippase activity (Bitbol et al., 
1987) and lower the energy requirement for transition across the bilayer (Whitlock and 
Hartzell, 2016a). Current research carried out using computer models of nhTMEM16, 
suggests that scramblases reduce the energy demand by bending the plasma membrane 
and reducing the distance between the two leaflets of the membrane. Distortion of the 
membrane is greatest around the hydrophilic groove where the distance between 
membranes reduces from 28.5 Å to 18.3 Å. Furthermore, the presence of water within 
the hydrophilic groove of the scramblase and collections of lipid head groups at either 
end of this groove appear to facilitate the moment of lipids from one membrane to the 
other. Dipole stacks grow halfway into the groove from a high density lipid head group 
on the cytoplasmic leaflet of the membrane (termed the SC region). The dipole stacks 
provide a scaffold for lipids to move along by forming dipole-dipole interactions as they 
pass through (Bethel and Grabe, 2016). Binding sites lining a channel pore, acting as a 
stepping stone mechanism, have also been observed in ion channels (Doyle et al., 1998).  
PS is a key lipid often exposed to the extracellular leaflet during scrambling events, 
where it acts as a marker to other cells. PS is exposed by scramblases during blood 
coagulation (Lhermusier et al., 2011), apoptosis (Fadok et al., 1992; Schlegel and 
Williamson, 2001), differentiation and microvesicle formation (Sessions and Horwitz, 
1983; Schlegel and Williamson, 2001; van den Eijnde et al., 2001). It is also becoming 
increasingly clear that PS plays a key role in sarcolemma wound healing (Middel et al., 
2016), a pathway also associated with dysferlin function.  
1.7.2 Dysferlin, membrane repair and phosphatidylserine 
Dysferlin is homologous with the FER-1 gene in Caenorhabditis elegans (Bashir et al., 
1998; Liu et al., 1998; Bansal et al., 2003), which is responsible for the fusion of large 
vesicles called membranous organelles to the plasma membrane (Achanzar and Ward, 
1997). Studies of dysferlin have indicated that in wild type mouse muscle, dysferlin 
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enriched vesicles seal sites of muscle cell damage by fusing to the sarcolemma (muscle 
cell membrane). However, dysferlin-deficient mouse muscle shows vesicle 
accumulation at the site of damage, but a lack of vesicle fusion to the sarcolemma 
(Bansal et al., 2003). In all muscle, sarcolemmal damage is caused by mechanical stress 
from regular muscle function (McNeil and Khakee, 1992; Cohn and Campbell, 2000). 
In dystrophic muscle mechanical stress has also been shown to lead to necrosis with 
membrane damage occurring in the initial stages (Straub et al., 1997). Ineffective cell 
repair following damage has therefore been suggested as causative for LGMD2B and 
MMD1 (Liu et al., 1998; Bansal et al., 2003). 
Very recently, the role of dysferlin in membrane repair has been more fully investigated 
furthering the understanding of the extent of the complexity of membrane repair. 
Demonbreun et al. (2016b) identified two structures which rapidly form following 
plasma membrane wounding. They term these structures the “repair cap” and the 
“shoulder” proteins. The authors define the “shoulder” as the region adjacent to the 
“repair cap” which its self lies above the area of damage. They identify dysferlin as a 
key “shoulder” protein as it is rapidly recruited immediately following laser injury and 
because they identified significant delay in membrane resealing in dysferlin-deficient 
myofibers. They also suggest that there is a level of safe-guarding in these shoulder 
proteins as they also investigated the related protein myoferlin. Myoferlin and dysferlin-
deficient myofibers showed similar delay in membrane resealing while myofibers 
deficient for both proteins showed the greatest delay in repair. Demonbreun et al. 
(2016b) suggest that lateral membrane recruitment, that is recruitment of proteins from 
the surrounding plasma membrane rather than from cytoplasmic stores, leads to the 
accumulation of these proteins within the shoulder region.  
The “repair cap” is comprised of aggregated annexin A6 (ANXA6) and also forms 
rapidly following membrane wounding. The aggregation of other annexins including 
annexin A1 and A2 follow soon after. Dysferlin is known to bind annexin A1 and A2 
proteins (Lennon et al., 2003; Cagliani et al., 2005) and they have also been suggested 
as important in membrane repair (Boye and Nylandsted, 2016). Demonbreun et al. 
(2016b) also locate PS within the shoulder region during repair though after the 
recruitment of both the shoulder proteins and the repair cap. This highly ordered 
recruitment of dysferlin, annexin A6 then annexin A1 and A2 following membrane 
damage has also been recorded in zebrafish (Roostalu and Strahle, 2012) 
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1.7.3 The Annexins 
Annexins are a group of calcium-dependant membrane-binding proteins, which form a 
superfamily of over 100 different proteins found throughout the animal kingdom (Moss 
and Morgan, 2004). As such they are divided into separate groups (labelled A-E); 
human annexins and orthologs (ANXA), invertebrates (ANXB), plants (ANXC), fungi 
(ANXD) and protists (ANXD) (Gerke and Moss, 2002; Moss and Morgan, 2004). 
Twelve annexins have been identified in humans, ANX1-11 and ANX13 (there is no 
protein currently assigned to ANXA12) (Gerke and Moss, 2002; Mirsaeidi et al., 2016).  
Annexins are intracellular proteins which bind with phospholipids found preferentially 
in the cytoplasmic leaflet of the plasma membrane and so localise either to the cytosol 
or plasma membrane, depending on the presence of calcium (Gerke and Moss, 1997). 
They are found in a diverse range of cells and tissues (Moss and Morgan, 2004). 
Annexins play a part in multiple cellular pathways such as regulation of membrane 
trafficking (Gerke et al., 2005), ion channel regulation (Gerke and Moss, 2002), calcium 
homeostasis and adaptation during cellular stress (Monastyrskaya et al., 2009), 
anticoagulation, phospholipase A2 inhibition (Raynal and Pollard, 1994), vesicle 
aggregation (Bitto and Cho, 1998; Spenneberg et al., 1998), endocytosis (Creutz and 
Snyder, 2005), interactions with the cytoskeleton (Oliferenko et al., 1999) and the 
aforementioned plasma membrane repair pathway (Roostalu and Strahle, 2012; 
Demonbreun et al., 2016a; Demonbreun et al., 2016b). 
Each annexin is formed of a NH2-terminal “head” domain and a conserved COOH-
terminal protein core domain itself formed of four homologous repeats (Geisow et al., 
1986; Moss and Morgan, 2004), though annexin A6 has eight repeats (Avila-Sakar et al., 
2000). Each repeat contains five α-helices (Huber et al., 1990), a calcium binding site 
(Geisow et al., 1986) and are all highly conserved both between annexin family 
members and between the repeats themselves (Moss and Morgan, 2004). 
1.7.4 Apoptosis and phosphatidylserine exposure 
Exposure of PS to the cell surface is also required during apoptosis, the programmed 
and controlled death of a cell (Li et al., 2003). Apoptosis is a critical and evolutionary 
conserved process, involved in killing infected or malignant cells (Hochreiter-Hufford 
and Ravichandran, 2013) but also as a counter processes to cell proliferation, removing 
excess cells during development and growth (Kerr et al., 1972). For example, 
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incomplete or disturbed apoptosis can lead to several developmental disorders including 
malformation of limbs (Guha et al., 2002), congenital brain malformation and 
respiratory distress syndromes (Li et al., 2003).  
It is the programmed and ordered nature of apoptosis which distinguishes it from 
necrosis and other types of cell death (Kerr et al., 1972). Apoptosis of mammalian cells 
can be initiated either through extracellular proteins binding to death-receptors on the 
cell surface (extrinsic pathway), or through the release of intracellular proteins 
following stress to the cell (intrinsic pathway) (Putcha et al., 2002). Both pathways 
ultimately lead to the release of mitochondrial proteins such as cytochrome c, activation 
of caspases and ultimately cell death involving cell shrinkage, DNA fragmentation, 
condensation of chromatin, membrane blebbing and formation of apoptotic bodies 
(Thornberry and Lazebnik, 1998; Towomey and McCarthy, 2005).  
The caspases are a family of highly specific proteases which are key proteins in 
apoptosis. There are thirteen caspase family members in mammals, though caspases 11 
and 12 are murine homologs and do not exist in humans (Thornberry and Lazebnik, 
1998). The three key roles of caspases in apoptosis are inhibition of apoptosis inhibitors 
like ICAD and Bcl-2 (Cheng et al., 1997; Enari et al., 1998), destruction of cell structure 
(leading to cell shrinkage) and interruption of protein activity (Thornberry and Lazebnik, 
1998). Caspase independent apoptosis has also been recorded in several cells however. 
This process also involves the release of mitochondrial proteins (AIF, EndoG and Omi), 
though these proteins activate apoptotic characteristics such as chromatin condensation 
and endonuclease activity without involvement from caspases (Towomey and McCarthy, 
2005). 
The final stages of apoptosis are the removal and final destruction of the dying cell by 
phagocytes, which is necessary to stop the leakage of cellular components into the 
extracellular space and initiation of the inflammatory response (Kerr et al., 1972). PS 
exposure is one of the most ubiquitous “eat me” signals used to signal to phagocytes 
(Fadok et al., 2001) and an early indicator of an apoptotic cell (Kurosaka et al., 2003) 
though other proteins have been identified as exposed on the cell surface during 
apoptosis (Dini et al., 1996; Taylor et al., 2000). For example annexin A1 has been 
shown to co-localise with PS on the plasma membrane where its presence has been 
suggested to enhance uptake by phagocytes (Arur et al. 2003; Gardai et al. 2005).  
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Increases in intracellular calcium are required for exposure of PS in apoptotic cells. 
Research has shown that apoptotic cells lacking intracellular calcium experience normal 
cell shrinkage, membrane blebbing and protein cleavage but reduced PS exposure. Re-
addition of calcium to these deprived cells rescued PS exposure (Hampton et al., 1996). 
Similarly, phagocytes derived from PS receptor deficient mice display a 50% reduction 
in phagocytotic ability (Li et al., 2003). Finally PS expressing liposomes have also been 
observed as reducing mouse forepaw oedema in a dose dependant manor (Ramos et al., 
2007).  
Timely exposure of PS identifies the cell for phagocytosis which in turn release anti-
inflammatory signals thereby avoiding activation of the inflammatory pathway 
(Kurosaka et al., 2002). While inflammation is a vital process in keeping the site of 
injury or infection clear of further damage (Rock and Kono, 2008), failure to remove 
accumulated lysed or infected cells will lead to an inflammatory response in turn 
leading to delayed repair or recovery and other complications including muscular 
dystrophy as is the case with the dysferlinopathies (Tidball, 2005; Rawat et al., 2010).   
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1.8 Anoctamins as phospholipid scramblases 
1.8.1 Development of an ion transporter from a phospholipid scramblase  
Despite the initial assumption that all anoctamins are CaCCs, very recent investigation 
of the anoctamin family and related fungal homologs, nhTMEM16 and afTMEM16, 
now suggests that the anoctamins originated as scramblases with ANO1 and ANO2 
developing into CaCC, rather than the other way round (Whitlock and Hartzell, 2016a). 
It was the observation of phospholipid scrambling following purification and 
reconstitution into liposomes of fungal ANO homologs that finally indicated that 
anoctamins were historically scramblases (Brunner et al., 2014). However the structural 
differences between common ion transporters and the anoctamin scramblases seem to 
be incompatible.  
The conventional ion channel is a funnel, with the protein surrounding the entire 
channel and providing a selective path for specific ions (MacKinnon, 2004). The 
anoctamins however appear to better fit the predicted model for scramblases with a 
hydrophilic “furrow” on one side of their surface, specifically formed of membrane 
helices 4 and 6 (Pomorski and Menon, 2006; Brunner et al., 2014; Whitlock and 
Hartzell, 2016b). In ANO6, the furrow also contains the scramblase domain that has 
been recently identified (Yu et al., 2015). The hydrophilic environment within this 
furrow is essential as it allows the hydrophilic lipid head groups to transition from one 
bilayer to the other while the hydrophobic acyl tails remains within the internal phase of 
the lipid bilayer.  
This structural arrangement would be incompatible for ion transport as the ion would be 
permanently exposed to the bilayer on one side. Transition from scramblase to ion 
transporter however is supported by mutagenesis studies which show that the ion 
selection and conduction residues are homologous to the scramblase regions of the rest 
of the family (Whitlock and Hartzell, 2016b). Two hypotheses have been proposed to 
rectify this conflict. First, Whitlock and Hartzell (2016b) suggest that the pore of ANO1 
and ANO2 is adjacent to a non-bilayer with the lipid head groups of this bilayer 
orientated towards the furrow of the anoctamin. Chloride ions would then transition 
along the furrow between the lipid head groups. Alternatively Brunner et al. (2014) 
suggest that the anoctamins form dimers, with the dimer structure of ANO1 and ANO2 
differing from that of the scramblase anoctamins. In this model the furrows of ANO1 
and ANO2 dimers are orientated towards each other, forming a funnel structure similar 
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to the conventional ion channel. The scramblase anoctamins meanwhile, form dimers 
with furrows orientated away from each other, in effect creating dimers that each have 
two furrows with which to facilitate scramblase function. 
1.8.2 Anoctamin 6 is a phospholipid scramblase 
Anoctamin 6 is the closest related family member to anoctamin 5 (Hartzell et al., 2009) 
and has been found to play a role in the extremely rare bleeding disorder Scott 
Syndrome (Suzuki et al., 2010; Castoldi et al., 2011). Patients with Scott Syndrome 
present with moderately mild bleeding episodes due to ineffective phospholipid 
scramblase action in thrombocytes and related blood cells (Lhermusier et al., 2011). 
Very few Scott syndrome patients have so far been identified (Weiss et al., 1979; Toti et 
al., 1996; Munnix et al., 2003; Suzuki et al., 2010; Castoldi et al., 2011) which has led 
to the suggestion that Scott Syndrome is underdiagnosed due to the mildness of the 
bleeding episodes and because phospholipid scrambling assays are not routine 
investigative tools (Solari et al., 2016). Platelets from ANO6-deficient mice have also 
been found to be defective for phospholipid scramblase activity (Fujii et al., 2015; 
Mattheij et al., 2015). Specifically, the exposure of PS on platelet surfaces following 
calcium treatment as well as microparticle shedding and thrombin production are 
impaired in platelets from ANO6-deficient mice (Fujii et al., 2015). These mouse 
models also show unaffected clot retraction and normal bleeding times which closely 
replicates the patient phenotype (Fujii et al., 2015).  
During normal blood coagulation, scramblases redistribute the phospholipid bilayer of 
thrombocytes and expose PS which in turn triggers the blood clotting cascade (Spronk 
et al., 2014). The identification of mutations in ANO6 in Scott Syndrome patients led to 
the suggestion that anoctamin 6 either interacts with vital molecules in the pathway, 
such as scramblases or calcium detecting molecules, or is itself the scramblase, actively 
binding to calcium and activating the cascade (Suzuki et al., 2010).  
While similarity of structure does not always equal similarity of function, the very high 
sequence homology between anoctamin 5 and 6 suggests that both are involved with 
phospholipid scrambling and exposure of PS. Inhibition or distortion of anoctamin 5, 
which is most highly expressed in muscle cells, may lead to ineffective cellular function 
and eventual muscle weakness.  
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1.9 Hypotheses of anoctamin 5 function 
Improvements in the genetic diagnosis of LGMD2L and the identification of more 
anoctaminopathy patients reinforces the need to identify the function of anoctamin 5. A 
number of hypotheses on anoctamin 5 function have been formed based on the similar 
LGMD2L and 2B pathologies and the confirmed functions of some of the other 
anoctamin family members. 
Initially, the most common assumption was that the whole anoctamin family were 
CaCCs as anoctamin 1 and 2 had been shown to be robust CaCCs, in different tissues 
(Hartzell et al., 2009). Despite extensive testing though, no robust CaCC activity has yet 
been demonstrated for anoctamin 5 (Schreiber et al., 2010; Duran and Hartzell, 2011). 
At the outset of this project, the anoctamins were still strongly suspected of being a 
family of CaCCs, though current research now suggests that this function has evolved 
from their initial function as scramblases. However calcium is the trigger mechanism in 
several important cellular functions such as membrane repair (Bansal et al., 2003) and 
phospholipid scrambling (Mirnikjoo et al., 2009a). Therefore if anoctamin5 is a CaCC, 
mutations in ANO5 leading to a non-functioning protein could lead to disturbed calcium 
signalling and downstream alterations to these other cellular processes. 
Membrane repair is also often hypothesised as one of the potential cellular roles for 
both anoctamin 5 and dysferlin. Faulty cell repair has been observed in non-dysferlin 
deficient fibroblasts from MMD3 patients despite the presence of lysosomes and 
enlargeosomes, compartments thought to aid in repair, at the wound site (Jaiswal et al., 
2007). Coupled with the observations of similarities in phenotype between 
LGMD2L/MMD3 and LGMD2B/MMD1, the hypothesis suggested was that anoctamin 
5 may act upstream of dysferlin in the cell repair pathway. The role of anoctamin 5 in 
this pathway has yet to be fully characterised and so far, no other anoctamin has been 
recorded as being involved in a similar pathway. 
An alternative hypothesis formulated from the functions of the other non-CaCC 
anoctamins, is that anoctamin 5 acts as a phospholipid scramblase, specifically in the 
exposure of PS on the outer plasma membrane. As an apoptotic marker normally 
located on the internal leaflet of the plasma membrane, exposure of PS on the outer 
leaflet marks the cell for destruction by phagocytes (Verhoven et al., 1995). Removal of 
damaged or dead cells is an essential part of the inflammatory process after tissue 
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damage and maintains healthy tissue function (Hochreiter-Hufford and Ravichandran, 
2013). 
If ANO5 has a similar function to ANO6 and is either interacting with or is itself a 
phospholipid scramblase, mutations would lead to a loss of this function. Effective 
phospholipid scrambling would therefore not take place, PS would not be exposed at the 
cell surface and apoptotic signalling would not occur. Loss of apoptotic signalling may 
then delay or inhibit recruitment of phagocytes and the removal of damaged cells.  
PS is also required for fusion of cell membranes and is exposed at the cell-to-cell 
contact points during differentiation of C2C12 (van den Eijnde et al., 2001). An 
alternative hypothesis is therefore that impaired PS exposure in ANO5 deficient cells 
leads to impaired myoblast differentiation or fusion of satellite cells to areas of muscle 
damage. Ultimately, impaired PS exposure may lead to impaired muscle regeneration 
and potential onset of the anoctaminopathy phenotype.  
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1.10 PhD Aims 
This PhD aims to discover the subcellular location and function of ANO5. A better 
understanding of these aspects of anoctamin 5 would be invaluable in understanding 
how anoctamin 5 mutations cause three different musculoskeletal diseases. This 
information could then potentially lead to a better understanding of the other muscular 
dystrophies with similarly dichotic presentations, e.g. mutations in DYSF leading to 
MMD1 and LGMD2B. Additionally, identifying the subcellular location and function 
of anoctamin 5 will improve the current understanding of anoctamin biology.  
Identification of anoctamin 5 localisation will be accomplished through transfection of 
various tagged ANO5 constructs into several cell lines. Immunofluorescence and co-
localisation with cell compartment markers will then allow for identification of 
localisation in these transfected cell lines. These constructs will then be used to 
investigate in vivo localisation of overexpressed ANO5.  
Identifying the function of anoctamin 5 will be accomplished in two ways, both using 
ANO5 knock down C2C12 cell lines (a mouse myoblast line) developed during this 
project. The first route of investigation will be unbiased characterisation of the knock 
down cells, achieved using 2-dimenstional gel investigation. Proteins with altered 
expression levels in ANO5 knock down C2C12 compared to Control knock down and 
wild type C2C12 will be identified by spot differences in 2-dimensional gels and 
MALDI-MS/MS analysis. Inferences about these proteins relationship to ANO5 will 
then be made.  
The second route of investigation will be a biased, specific examination of phospholipid 
scramblase activity in the knock down C2C12, investigated using functional assays for 
scramblase activity. FITC conjugated annexin V, which preferentially binds to PS, will 
be used to visualise the exposure of PS during differentiation and induced apoptosis. 
Quantitative differences between ANO5 knock down and Control knock down C2C12 
will then be made. Finally, this assay will then be used to investigate the scramblase 
activity of ANO5 patient primary myoblasts.  
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Chapter 2 Materials and Methods 
2.1 Tissue Culture 
Cell lines were cultured in a Hera Cell 240 incubator set to 37°C in 5% CO2 and all 
work was carried out in a Hera Safe Cabinet. HeLa, HEK, MIN6, NIH 3T3 and wild 
type C2C12 cell lines were cultured in growth media while ANO5 knock down and 
Control knock down C2C12 were cultured in selection media. Primary patient cells 
were cultured in Skeletal Muscle Cell Growth Media and were kindly donated by the 
Muscle Tissue Culture Collection in Munich (LGMD2L and LGMD2B patient cells) 
and from the John Walton Muscular Dystrophy Research Centre Biobank (control 
patient cells).  
Cultures were maintained by cycles of 0.05% trypsin dissociation from the culture 
vessel, centrifugation in an Eppendorf 5804 R centrifuge to remove the trypsin and 
reseeded at lower densities onto clean plasticware. Details of the specific plasticware 
used are indicated in the corresponding techniques below. Stocks of each cell line were 
made using the same trypsin dissociation steps described above but with the cell pellet 
resuspended in either commercially sourced Recovery Cell Culture Freezing Media or 
freezing media made in house. 1ml aliquots of resuspended cells were placed in 
cryogenic vials and were frozen overnight in a Mr Frosty Cryo 1°C Freezing Container 
in a -80°C freezer. Aliquots were then moved to plastic box racks in the same -80°C 
freezer or to liquid nitrogen storage for long term storage. 
2.1.1 C2C12 Differentiation 
C2C12 myoblasts were differentiated into myotubes by replacing growth media with 
differentiation media. Upon reaching ~50-60% confluence, cells were washed once with 
2ml differentiation media and then treated with 4ml differentiation media. This was the 
D0 time point. Differentiation media was then replaced and refreshed one day (D1 
timepoint), three days (D3) and five days (D5) following this. If D5 was the 
experimental end time point then cells were fixed in 4% PFA in PBS rather than having 
differentiation media refreshed.  
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2.2 ANO5 knock down C2C12 production 
2.2.1 ANO5 and Control shRNA 
Control and ANO5 specific Short Hairpin RNAs (shRNA) were purchased from Santa 
Cruz Biotechnology. The ANO5 shRNA consisted of a pool of three different shRNA 
plasmids, each with a different sense and antisense sequence. The Control shRNA 
consisted of a scrambled sequence which would therefore not target any gene for knock 
down, but still produce antibiotic resistant cells. Both shRNA’s conferred puromycin 
resistance to successfully transfected cells. 
2.2.2 shRNA Transfection 
C2C12 cells were seeded into twelve 100mm tissue culture petri dishes and cultured in 
growth media until 50-70% confluent. Individual solutions for shRNA constructs, GFP 
construct and plasmid transfection reagent were made (Table 2.1). 3000μl of shRNA 
Plasmid Transfection Reagent solution was added to each of the other solutions. Mixed 
solutions were gently mixed by pipetting and incubated for 45 minutes at room 
temperature. 
 Control shRNA ANO5 shRNA GFP plasmid shRNA PTR 
Reagent Volume 60μl 60μl 12μl 432μl 
DMEM 2940μl 2940μl 1188μl 6768μl 
Table 2.1 Solution components for shRNA transfections. Total volumes of each component are 
given. Plasmid and shRNA solutions were prepared at a concentration 6μg per 100mm dish, 
diluted 0.5μg/μl (Control and ANO5 shRNA) and 1μg/μl (GFP). shRNA Plasmid Transfection 
Reagent (shRNA PTR) was prepared at a concentration of 36μl per 100mm dish. 
Each culture dish was washed twice with 4000μl of DMEM before 8800μl DMEM was 
added to each dish. 1200μl of combined solutions were added drop wise to individual 
100mm culture dishes (Control to five dishes, ANO5 to five dishes, GFP to two dishes) 
and were mixed by gentle pipetting. Dishes were incubated overnight in standard tissue 
culture conditions before 5000μl of DMEM plus 20% FBS was added to each dish. 
Cells were then incubated for an additional day under standard tissue culture conditions 
before the medium was aspirated from each dish and replaced with 10ml fresh selection 
media. Dishes were checked daily for clone formation and the replacement of selection 
media. 
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2.2.3 Clone selection, proliferation and differentiation 
Once stable clones were of a sufficient size, cloning cylinders and trypsin cell 
dissociation media were used to pick clones and transfer them to an individual well of a 
24 well plate. Cells continued to be cultured in selection media, using PBS washes, 
trypsin dissociation, centrifugation and reseeding cycles to transfer cells to larger tissue 
culture plates until a clone occupied all wells of a 6 well plates. At this stage all wells 
were washed with PBS, trypsinised, divided into two separate 15ml falcon tubes and 
centrifuged. The cell pellet from one falcon was resuspended in 2ml of Cell Recovery 
Freezing Medium and aliquoted into two cryotubes for storage at -80 and later use. The 
other cell pellet was seeded into another 6 well plate for differentiation. 
Upon reaching ~70-80% confluency all wells were imaged using an Eclipse TS100 
using NIS Elements (D 3.2) image acquisition software. Three wells were then washed 
with PBS, trypsinised, centrifuged at 4000rpm for 5 minutes and stored at -80 for later 
extraction of Day 0 RNA. The remaining 3 wells were differentiated using the protocol 
given in section 2.1.1. Images were taken at D0, D3, D5 and D7 time points to track 
differentiation progression. At the D7 time point cells were stored at -80 for RNA 
extraction.  
2.2.4 RNA Extraction 
D0 and D7 time point cell pellets were resuspended in 1ml of Trizol and transferred to 
an RNase free eppendorf tube. To each sample, 200µl of RNase free chloroform was 
added and inverted to produce an emulsion. Eppendorf’s were spun at 14000rpm for 10 
minutes in an Eppendorf 5810 R centrifuge and the clear fraction of the resulting 
solution pipetted into new eppendorf tubes. 2μl of Pellet Paint and 0.5ml of isopropanol 
were added to the solution and the eppendorf inverted before being spun again at 
14000rpm for 10 minutes. The isopropanol was removed and 200µl of 75% ethanol in 
nuclease free water was added without disturbing the pellet, followed by brief spinning. 
The ethanol was removed with residual ethanol removed by brief centrifugation and 
careful pipetting and gentle warming in a heat block. The pellet was then resuspended in 
30µl nuclease free water before quantification using a Nanodrop 8000 UV-Vis 
Spectrophotometer.  
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2.2.5 cDNA Preparation 
RNA was then converted to cDNA using Superscript III RT. 1μl of random primers, 6μl 
of sample RNA (100ng/μl) and 1μl of 10mM dNTP mix (10mM each dATP, dGTP, 
dCTP and dTTP at neutral pH) were added to one well of a 96 well PCR plate, covered 
by 8 well domed strip caps. The plate was then heated to 65˚C for 5 minutes in a 
Labcycler PCR machine and incubated on ice for 1 minute immediately afterwards. 4μl 
of 5X First-Strand Buffer, 1μl 0.1M DTT, 1μl RNaseOUT Recombinant RNase 
Inhibitor (40units/μl) and 1μl Superscript III RT (200units/μl) were then added to each 
well. Each mixture was mixed by gentle pipetting and the plate placed back in PCR 
machine. The plate was incubated at 50˚C for 1 hour, then 70˚C for 15 minutes and 
stored at +4˚C (short term) or -20˚C (long term).  
2.2.6 Reverse transcription PCR 
The resulting cDNA was then used in a standard PCR reaction to confirm the presence 
or absence of ANO5 in C2C12. Two 96 well plates were run to test ANO5 knock down 
cDNA with ANO5 and GAPDH primers (Table 2.2). Two master mixes were also 
prepared, each with a different primer pair. Both master mixes contained 70µl 10nM 
dNTPS, 175µl 10xPCR Buffer, 140µl PCR Enhancer, 70µl Moltaq, 70µl of each of the 
corresponding forward and reverse primers and dH2O up to a final volume of seventy 
25µl reactions. For the ANO5 primer plate 3µl of each ANO5 knock down cDNA 
sample was put into 66 wells, while only 1µl of ANO5 knock down cDNA were put 
into the corresponding 66 wells of the GAPDH primer plate. Both plates were then run 
simultaneously on Labcycler PCR machines (SensoQuest) using the same PCR 
programme (Table 2.3). 5µl of each PCR product was mixed with 2µl of loading dye 
and loaded, with a 1kbp reference ladder, on a 1% (w/V) agarose gel in TAE buffer 
prepared with 5µl of SafeView stain. Samples were separated by molecular weight with 
application of an electrical current at a constant 100v for 1 hour.  
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Gene Target Forward Primer Sequence Reverse Primer Sequence 
ANO5 CAAGAACTGGGCTCGATTTT AGGTCACTGTGGTCCCTGAC 
GAPDH GGGTGTGAACCACGAGAAAT GCCATGTAGGCCATGAGGT 
Table 2.2 Forward and reverse ANO5 and GAPDH primer sequences. Both primers were 
designed to amplify a 500bp region of the gene targets. 
Step Temp (°C) Time (s) Passes Notes 
1 94 120 1  
2 94 10 19  
3 55 30 19  
4 72 150 19  
5 94 10 19 plus 20s on each pass 
6 55 30 19 plus 20s on each pass 
7 72 120 19 plus 20s on each pass 
8 4 - -  
Table 2.3 PCR programme for amplification of shRNA transfected C2C12 cDNA. Steps 2-4 and 
5-7 were repeated for the number of passes indicated before proceeding to the subsequent step. 
Samples were held at step 8 at 4°C until removed from the Labcycler.  
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2.3 Cell Transfection 
2.3.1 Lipofectamin 2000 
Lipofectamin 2000 was used to transiently transfect MIN6, NIH3T3 and HeLa cell lines. 
All cell lines were cultured to ~90% confluence on glass 8 well chamber slides under 
normal tissue culture conditions. For each experiment separate solutions were made for 
Lipofectamine 2000 and each construct transfection condition. 1µl of Lipofectamine 
2000 was used for each transfected well, diluted 1:10 in DMEM. Constructs were 
prepared at a total concentration of 1µg per well, diluted 1:50 in DMEM. Co-
transfections therefore used 0.5µg of each construct. Complexes were left to incubate 
for 5 minutes at room temperature before 10µl of construct solution and 10µl of 
Lipofectamine 2000 solution were gently mixed together in new eppendorf tubes. 
Combined solutions were left to incubate for a further 20-40 minutes at room temp. 
20µl of the combined solutions were then added to the corresponding wells of the 8 well 
chamber slide, mixed by gently pipetting. Slides were incubated overnight under 
standard tissue culture conditions before fixation in 4% PFA in PBS.  
2.3.2 FuGene 
FuGene was used to transfect wild type undifferentiated C2C12 cells prior to 
differentiation into myotubes. C2C12 were cultured to ~50-60% confluence on 
slideflasks under standard tissue culture conditions. For each slideflask, 4ml of fresh 
growth media was replaced prior to addition of 100µl of transfection solution consisting 
of 5µl FuGene transfection reagent, 10µl total plasmid construct (5µl of each plasmid in 
co-transfections) and 85µl DMEM. Slides were incubated overnight in standard tissue 
culture conditions, before fixation in 4% PFA in PBS.  
2.3.3 Amaxa 
Amaxa was used to transfect wild type undifferentiated C2C12 cells prior to 
differentiation into myotubes. Cells were removed from culture vessels using standard 
trypsin methods and the cell density calculated using a haemocytometer. 1 x 106 cells 
were resuspended in 100μl Cell Line Nucleofector Solution V and combined with 2μg 
of plasmid. The entire suspension was then transferred into a cuvette, with the sample 
covering the bottom with no air bubbles, and sealed with a cap. Each cuvette was then 
inserted into the holder of a Nucleofector® I Device and the programme B-32 used to 
 39 
treat the cells. Immediately after the programme had completed (<60 seconds), the 
cuvette was taken out of the holder and 500μl of culture medium was added to the 
cuvette. 500μl of the solution was then transferred to a single well of a 6-well plate pre-
treated with 1ml of growth media (final volume 1.5ml media per well). Cells were then 
incubated overnight in standard tissue culture conditions, before fixation in 4% PFA in 
PBS. 
2.3.4 GeneJuice 
GeneJuice was used to transfect wild type undifferentiated C2C12 with tagged ANO5 
constructs, prior to apoptosis treatment. 36µl of GeneJuice was mixed with 600µl 
DMEM minus serum, vortexed briefly and left to stand for five mins. 350µl of this 
solution was mixed with 14µl ANO5-Myc, 250µl was mixed with 5µl GFP and 
incubated at room temperature for 15 mins. 50µl of the appropriate mixture was then 
added to the corresponding wells and incubated overnight under normal tissue culture 
conditions, before fixation in 4% PFA in PBS.  
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2.4 Electroporation and Cryosectioning of Mouse Muscle 
All animal work was conducted following Home Office guidelines under Professor 
Volker Straub’s project licence 60/4137. As such I merely observed the actually 
electroporation conducted by Dr Mojgan Reza, but assisted with weighing the mice and 
conducted the dissections of the tibialis anterior (TA) muscle myself. C57BL/10 (BL10) 
and C57BL/10ScSn-Dmdmdx (mdx) mice stocks were maintained by Elizabeth Greally 
(personal licence number 60/10222).  
For each electroporation, age and gender matched mice were weighed and administered 
with isoflurane. The corresponding volume of pain relief was then administered 
subcutaneously (carprofen at 50mg/kg). After shaving the animals legs, 25µl of 
hyaluronidase (0.4U/µl), an enzyme which helps to increase tissue permeability, was 
then administered directly to the TA muscle of each leg. The final injection of 50µl of 
construct (~1µg/µl) was then administered to the central portion of the TA muscle. In 
the fourth round of electroporation GFP and ANO5 constructs were mixed with the 
mini-dysferlin construct before injection and a total volume of 50µl was administered. 
Immediately following injection each leg was electroporated with 8x20ms pulses of 
200V/cm at intervals of 250ms. After suitable recovery time mice were sacrificed by 
cervical dislocation and their TA muscles dissected and mounted in OCT on cork disks 
and snap frozen in isopentane for storage at -80.  
A Microm HM 560 cryostat was used to cut 8 nm thick serial sections from embedded 
TA muscle, which were then serially mounted on sets of 10 permafrost slides (6-7 
sections per slide). Sections were stored wrapped in cling film at -80°C until the day of 
staining.  
 41 
2.5 Immunocytochemistry, Immunohistochemistry and Haematoxylin and Eosin 
Staining 
2.5.1 Immunofluorescence (IF) staining 
HeLa, MIN6 and NIH 3T3 cell lines were cultured on glass eight well chamber slides. 
Undifferentiated and differentiated C2C12 were cultured on permanox 4 well chamber 
slides and slide flasks. Relative reagent volumes for each culture vessel are given in 
Table 2.4. All cell lines were fixed in 4% paraformaldehyde in PBS (4% PFA/PBS) for 
10 minutes at room temperature in the dark. Slides were then washed once with 1xPBS 
before addition of blocking solution to each well of multi-well chamber slides or the 
entire surface of chamber slides. Slides were incubated for 1 hour at room temperature 
in the dark. Blocking solution was replaced in the corresponding wells/slideflask with 
primary antibody diluted in blocking solution and incubated for another hour in the dark. 
Primary antibody negative conditions were treated with the same volume of 
1xPBS.Slides were washed three times in 1xPBS for 20 minutes in the dark, before 
replacement with secondary antibody diluted in blocking solution for an hour in the 
dark. Slides were washed again three times in 1xPBS for 20 minutes in the dark before 
chamber gaskets were removed.  
For eight well chamber slides this was achieved by applying 100µl of ice cold methanol 
to each well, incubating for 7 minutes at room temperature and levering the chamber 
gasket from the slide. For 4 well chamber slides and slideflasks, gasket chambers were 
levered from the slide. Slides were briefly washed in PBS, air dried in the dark, 
mounted using a few drops of Vectashield plus DAPI and covered with a cover slip. 
Slides were stored at +4°C in the dark until imaging. 
Solution 8 wells 4 wells Slideflask 
4% PFA/PBS 100µl 300µl 500µl 
Blocking solution 100µl 300µl 500µl 
Antibodies 100µl 300µl 500µl 
Washes 500µl 500µl 1000µl 
Table 2.4 Adjusted immunofluorescence staining reagent volumes for each culture vessel used.  
Volumes given are per well of the culture vessel except for chamber slides where volumes refer 
to the entire surface area of the slide. 
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2.5.2 Haematoxylin & Eosin staining 
Selected slides were defrosted and air dried on the bench for 30 minutes and then 
submerged in Haematoxylin stain for seven minutes, before being washed in water for 
two minutes. Slides were then dipped in 1% hydrochloric acid in 70% ethanol, washed 
in water for 30 seconds submerged in eosin for 30 seconds and then washed in water 
again for 30 seconds. All wash steps were under a constantly flowing tap. The slides 
were then immediately submerged in increasing concentrations of ethanol solution; 5 
seconds in 70% ethanol, 5 seconds in 90% ethanol and then 1 minutes in 100% ethanol. 
Slides were then immediately submerged in histoclear (National Diagnostics) for 3 
minutes and then in another container of fresh histoclear for an additional 3 minutes. 
Finally, slides were then mounted with coverslips using hard setting DPX. Slides were 
kept in histoclear solution until mounting to ensure that the stained muscle sections did 
not dry out before mounting. 
2.5.3 Immunohistochemistry staining 
Slides were removed from -80°C freezer storage and thawed for 30 minutes at room 
temperature wrapped in cling film. Slides were unwrapped and laid out on a square 
plastic tray (humidified with damp towels) for a further 30 minutes. During this warm 
up period, an ImmEdge Pen was used to encircle each muscle section with a waterproof 
wax boundary. After the warm up period and wax boundaries had dried, the slides were 
placed in a Hellendahl jar and immersed in 0.1% Triton X-100 in PBS for 15 minutes. 
Slides were then washed in PBS for 5 minutes before being removed from the jars, 
excess buffer blotted from the slides and arranged on the same humidified square plastic 
tray. Slides to be treated with non-mouse derived primary antibodies were then blocked 
in 2 drops of Odyssey protein block. However slides to be treated with mouse derived 
antibodies were blocked in M.O.M mouse Ig Blocking Reagent (2 drops of stock 
solution in 2.5ml PBS). Slides were then covered and blocked for 30 minutes at room 
temperature. Protein block was then flicked off and the slides washed in PBS for 15 
minutes in Hellendahl jars.  
Anti-GFP and Anti-Dystrophin primary antibodies were diluted in Odyssey protein 
block while Anti-Myc was diluted in M.O.M diluent. Slides treated with M.O.M mouse 
Ig Blocking Reagent were incubated in M.O.M diluent for 5 minutes at room 
temperature, while 50µl of appropriate primary antibody was added to each section of 
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the non-M.O.M treated sections. 50µl of Anti-Myc was then applied to M.O.M treated 
sections, the tray covered with the tray lid and all sections were left at +4˚C overnight. 
The following morning, slides were left to warm for 1 hour on the bench. Slides were 
the rinsed in 1x PBS solution applied from a plastic squeeze bottle before slides were 
washed for 30 minutes in 1xPBS in Hellendahl jars. 1xPBS was refreshed after the first 
7 minutes. Secondary antibody Donkey anti-Rabbit 594 (Abmart) diluted in Odyssey 
protein block was prepared for anti-GFP and anti-Dystrophin slides, while secondary 
antibody Goat anti-Mouse 488 (Abmart) diluted in M.O.M diluent was prepared for 
anti-Myc slides. 50µl of secondary antibody was then applied to the corresponding 
muscle sections and incubated at room temperature for 90 minutes, covered by the tray 
lid. Slides were washed in 1xPBS for 30 minutes, with the 1xPBS again replaced after 7 
minutes. Slides were then dried a few at a time (to avoid sections from drying out), 
before a few drops of vectashield+DAPI were added and the sections covered by a glass 
coverslip. Slides were then stored at +4˚C until imaging. 
2.5.4 Lysosome staining 
To optimise LysoTracker staining of lysosomes, ~90% confluent wild type C2C12 on 
two 8 well chamber slides were stained with 50nM, 60nM and 70nM concentrations of 
LysoTracker for 1 hour and 30 minutes. 70nM solution was made from 0.7µl 
lysotracker in 10ml Growth media and subsequently diluted to 60nM (1371.4µl in 
228.6µl Growth media) and 50nM solutions (1142.9µl in 457.1µl Growth media). 
Slides were then fixed, washed in PBS and mounted using Vectorshield + DAPI and 
coverslips.  
Tandem LysoTracker and IF staining was achieved using the above LysoTracker 
method followed by standard fixation and IF staining protocols (1:100 9E10 primary 
antibody, 1:3000 goat anti-mouse 488 secondary antibody) described in Section 2.5.1. 
Cells were transiently transfected using the GeneJuice method (Section 2.3.4) the day 
before staining.  
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2.6 Phosphatidylserine exposure detected using FITC conjugated Annexin V 
staining 
2.6.1 Phosphatidylserine exposure during differentiation 
Wild type C2C12 cells were cultured on slideflasks and differentiated to day 1 (D1), 
day 3 (D3) and day 5 (D5) time points, using established tissue culture techniques 
(Section 2.1). Upon reaching the required time point slide flasks were washed with 1ml 
ice cold 1xPBS and immediately incubated in 900µl FITC-AV solution in the dark for 
15 minutes as per manufacturer instructions. Slides were then washed twice in 1ml of 
1x binding buffer (1ml 10x binding buffer + 9ml dH2O) and fixed in 500µl of 4% 
PFA/PBS for 10 mins. Slides were stored in PBS at +4° overnight or blocked for 1 hour 
at room temperature in 1ml blocking solution.  
To track differentiation of the cells, immediately following blocking, slides were 
incubated in 900µl phalloidin 594 (diluted 1:300 in IF blocking solution) at room 
temperature for 1 hour. Finally, slides were washed in 1ml of 1xPBS three times, for 20 
minutes before the chamber was removed, the slide air dried and mounted with 
Vectashield + DAPI and a coverslip. Slides were stored at +4° before imaging. 
2.6.2 Phosphatidylserine exposure during apoptosis 
Cells were cultured on permanox 8 well chamber slides until ~90% confluent. 
Apoptosis was induced in six wells using combinations of 50µM staurosporine (a PK 
inhibitor) and 3mM EGTA (a calcium chelator) in growth media (Table 2.5). Two wells 
were left untreated (growth media only) as negative controls. Slides were incubated for 
four hours at 37° and 5% CO2. Media was removed following incubation and all wells 
washed in 400µl of 1xPBS. Each well was then incubated in 100µl of FITC-AV 
solution for 15 minutes at room temperature in the dark. Wells were then washed twice 
in 200µl of 1x binding buffer before fixation in 100µl of 4% PFA/PBS per well for 10 
minutes and mounting with Vectashield + DAPI and a coverslip.  
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Solution ID Solution Components Expected Observation 
A. 50µM staurosporine + 3mM EGTA in 
100µl DMEM + 10% FBS 
Apoptosis, but with less annexin V 
positivity compared to solution B 
B. 50µM staurosporine in 100µl DMEM 
+ 10% FBS 
Apoptosis with high annexin V 
positivity 
C. 3mM EGTA in 100µl DMEM + 10% 
FBS 
No induced apoptosis and therefore 
very little annexin V positivity 
Table 2.5 Composition of experimental and control solutions used to induce apoptosis. 
Solutions A and C were control solutions as the EGTA would chelate intracellular calcium and 
reduce the apoptotic effect caused by the staurosporine. Solution B was the experimental 
solution as the staurosporine would inhibit protein kinase, triggering apoptosis. 
2.6.3 Phosphatidylserine exposure potential of knock down C2C12 investigated using 
FITC-AV staining and anti-activated caspase 3 staining 
The initial FITC-AV staining was modified to include an additional anti-active caspase 
3 stain. Apoptosis induction remained the same but following this only half of the wells 
were treated with Annexin V assay solution (Figure 2.1 Layout of FITC-Annexin V + 
active Caspase 3 assay eight well chamber slides.Figure 2.1). The other wells were kept 
in 1xPBS until fixation in 4% PFA/PBS. Following fixation, 100µl of blocking solution 
was added to each well and the slide incubated at room temperature for 1 hour in the 
dark. After incubation, 100µl of anti-active caspase-3 antibody (Abcam, ab2302), 
diluted 1:100 in blocking solution was added to all wells and incubated in the dark at +4° 
overnight. 
The following morning, slides were washed three times for 20 minutes in 400µl 1x PBS 
in the dark. 100µl of anti-Rabbit alexa fluor 594 secondary antibody diluted 1:3000 in 
blocking solution was applied to each well and left to incubate in the dark for 1 hour at 
room temperature. All wells were again washed three times for 20 minutes in 400µl 1x 
PBS in the dark. The chamber gasket was removed from the slide, excess PBS gently 
removed, slides air dried in the dark and mounted with Vecta Shield + DAPI and a glass 
coverslip. All slides were stored at +4° until imaging, blinding and cell counting. 
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Figure 2.1 Layout of FITC-Annexin V + active Caspase 3 assay eight well chamber slides. 
Squares filled half red and green indicate wells treated with both FITC-AV and aC3 primary 
antibody + alexa fluor 594 secondary. Red filled squares indicate wells only stained with aC3 
and alexa fluor 594 secondary. Reagents used to induce apoptosis are given in each well. 
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2.7 Lysate Preparation 
2.7.1 Western Blot Lysate Preparation 
Lysates were made from GFP-ANO5-MycHis transfected HeLa cells (transfected using 
the Lipofectamin 2000 protocol in section 2.3.1) and untransfected HEK cells, cultured 
in 6 well plates. Media was removed, plates placed on ice and each well washed with 
1ml of ice cold PBS. PBS was removed, 150μl of ice cold lysis buffer applied to each 
well, cells scraped from each well using a plastic scraper and the suspension transferred 
to a 1.5ml Eppendorf tube on ice. Suspensions were constantly agitated for 30 minutes 
at 4°C then centrifuged at 12000rpm for 20 minutes at 4°C. The supernatant from each 
tube was then transferred to a fresh Eppendorf on ice, quantified using a Qubit 
fluorometer as per the manufacturer’s instructions and stored at -20°C. 
2.7.2 Subcellular fractionation by differential centrifugation and 2D gel lysate 
preparation 
The subcellular fractionation protocol used was taken from Dimauro et al. (2012) 
(Figure 2.2). C2C12 cells were grown to 90% confluence in either four T75’s or two 
T150’s. Flasks were washed once with ice cold PBS (each T75 with 3ml; each T150 
with 6ml) and then immediately treated with STM buffer (each T75 with 0.5ml; each 
T150 with 1.5ml). Cells were then manually removed using a plastic cell scrapper and 
collected into one 15ml falcon tube per cell line. Cells were pelleted by centrifugation in 
an Eppendorf 5804 R centrifuge for the first step and then in an Eppendorf 5810 R 
centrifuge for all subsequent steps. Where stated, cell pellets were resuspended in 500µl 
of STM buffer, 100µl of NET buffer and 300µl of solubilisation solution. Where stated, 
cell suspensions were mixed with 2.5ml of 100% acetone (five volumes of cell 
suspension) and 800µl of solubilising solution (eight volumes of cell suspension). P5 
was further lysed by being passed sequentially through a 19G and 21G Microlance 3 
needle on Micro-Fine 0.5ml syringes. All steps were carried out over ice. 
For use in 2D gels, wild type and knockdown C2C12 subcellular fractionations were 
either mixed with 800µl or resuspended in 300µl of solubilisation solution.  
 48 
 
Figure 2.2 Subcellular fractionation work flow adapted from Dimauro et al (2014).“S” denotes 
supernatant fraction, “P” denotes pellet fraction. Green boxes indicate treatment (if any) of 
pellets or supernatants that were further fractionated. Blue boxes represent final experimental 
pellet and supernatants. Red boxes indicate discarded pellets or supernatants. White boxes 
indicate centrifuge speeds and times for each step. 
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2.8 Protein Quantification 
2.8.1 Quantification by Qubit Protein Assay 
The protein concentration of all transfected HeLa and untransfected HEK lysates were 
measured using the Qubit Protein Assay on a Qubit 2.0 fluorometer. The Qubit 
fluorometer was calibrated for each protein quantification run, so an additional three 
0.5mL PCR tubes were prepared each time for the required standards (identified as 1, 2 
and 3). Tubes were labelled and enough Qubit working solution prepared for each 
sample and standard to be run (1µl Qubit Protein Reagent in 200µl Qubit Protein Buffer 
for each sample). 190µl and 199µl of Qubit working solution was added to 10µl of 
standards and 1µl of samples respectively. Tubes were vortexed for 2 to 3 seconds 
before being incubated at room temperature for 15 minutes in the dark. The three 
standards were then read on the Qubit in sequential order to calibrate the machine 
before samples were run and the protein concentration recorded for each.  
2.8.2 Quantification by MiniBrandfrod Assay 
All fractionated lysates were treated the same no matter which buffer was used for 
preparation. A standard curve was first prepared using six samples of Bovine Serum 
Alubumin (BSA, 1mg/ml) in increasing concentrations plus Protein Assay Dye Reagent 
Concentrate and dH2O (Table 2.6). Initial volumes of 1µl were used for each lysate 
sample. All samples were mixed together in disposable semi-micro polystyrene cuvettes 
(340-900nm range), run on a BioPhotometer and the A595 fluorescence values recorded. 
If lysate sample fluorescence was lower than the value recorded for the 1µl standard 
curve sample, the lysate sample was re-run with 10µl of lysate to ensure the 
fluorescence value fell within the curve.  
The A595 fluorescence values were inputted into Microsoft Excel (fluorescence values 
on the y axis and BSA concentrations on the x axis) to plot the standard curve. y 
equation values from the resulting curve generated by Excel were inputted into Equation 
2.1 to calculate the concentration (mg/ml) of lysates. Concentration values were divided 
by ten for lysates which used 10µl of sample rather than 1µl.   
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BSA Protein Assay Dye dH2O 
1 799 200 
3 797 200 
5 795 200 
10 790 200 
15 785 200 
20 780 200 
Table 2.6 Sample components for creation of BSA standard curve. All values are given in µl. 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = (𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 − 𝑦𝑏)/𝑦𝑎 
Equation 2.1. Calculation of lysate concentrations. ‘Absorbance’ is the A595 value obtained 
from the BioPhotometer readout. ‘ya’ is the first value given in the y equation and ‘yb’ is the 
second value, i.e. y= ya + yb  
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2.9 2D gel electrophoresis 
Mitochondrial, nuclear and cytoplasmic subcellular fractionations were run out using 2 
dimensional (2D) electrophoresis using the ZOOM runner IPG system. For each 3-
10NL ZOOM IPG strip to be run (to a maximum of eight per cassette), 140μl of 
subcellular fraction lysate was loaded into the individual sample loading well of a 
ZOOM IPGRunner Cassette. Each strip was loaded into the cassette with the positive 
end orientated at the bottom of the cassette. Strips were sealed into the cassette using 
sealing tape and rehydrated for an hour at room temperature. The Sealing Tape and 
Sample Loading Devices were removed from the cassette, and an electrode wick 
attached to the now exposed adhesive at each end of the cassette. 600μl of deionised 
water was applied to each wick. The cassette was sandwiched against one side of a 
ZOOM IPGRunner Core with the electrode wicks touching the electrodes of the core. A 
second cassette or a buffer dam was placed on the other side of the runner core and the 
assembled sandwich placed into a Mini-Cell Chamber, secured in place with a Gel 
Tension Wedge. The outer chamber was filled with 600ml of deionised water, with 
extra care taken to ensure none got into the inner chamber. The lid of the chamber was 
secured with the correct electrodes connected to the corresponding power pack ports. 
Isoelectric focusing (IEF) was performed on the IPG strips using a three step set 
programme on a Bio-Rad PowerPac HC; 175 volts for 1 hour, slow ramping up to 2000 
volts for 45 minutes and held at 2000 volts for a further 45 minutes. 
Following IEF, the rig was carefully disassembled, taking extra care not to get water on 
the cassette surface. IPG strips were then either wrapped in cling film and stored at -
80°C for future running of the second dimension or immediately run through the 
equilibration step. For equilibration, each IPG strip was submerged in 5mL of sample 
reducing buffer for 15 minutes and 5mL of 125mM Alkylating solution for an 
additional 15 minutes. Frozen IPG strips were defrosted for ~15 minutes before the 
equilibration step and resumption of the protocol. 
SDS page was performed on equilibrated IPG strips using 4-12% Bis-Tris ZOOM 
protein gels. The IPG strip was inserted into the well of the gel with the negative end of 
the strip closest to the ladder lane. A scalpel was used to push the IPG strip so it touched 
the gel and removed any trapped air bubbles which would distort the SDS page run. The 
gel was inserted into the XCell SureLock® Mini-Cell with either another gel or a buffer 
dam on the opposite side of the core. Approximately 350µl of 0.5% agarose, dissolved 
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in MES running buffer, was used to seal in the IPG strip. The inner and outer chambers 
were filled with MES running buffer and 0.5ml of NuPAGE® antioxidant was added to 
the inner chamber. 10µl of Chameleon Duo Pre-stained Protein Ladder was loaded into 
the ladder well and the lid attached to the Mini-Cell. Gels were then run for 45 minutes 
at 200v on a Bio-Rad PowerPac HC. 
2.9.1 Coomassie Staining 
Proteins present in 2D gels were visualised by Coomassie staining using SimplyBlue 
SafeStain. Gels were removed from the Mini-Cell chambers, carefully removed from 
their plastic cassette containers and transferred to large weight boats. Gels were washed 
with 100mL dH2O three times for 5 minutes with continuous shaking. Gels were stained 
with approximately 15ml SimplyBlue SafeStain for 1 hour at room temperature with 
gentle shaking. SimpleBlue SafeStain was discarded and gels were washed in 100ml 
dH2O over night before being imaged on an Odyssey CLx. 
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2.10 Western Blotting 
2.10.1 Stacking and Resolving gel preparation 
Hand cast gels (15%) were made to western blot for S100-A4 protein. 0.75mm glass 
moulds were assembled on an Mini-PROTEAN Tetra Cell Casting Module. 5ml of 
resolving gel solution was assembled  and poured into the glass moulds (Ammonium 
persulphate and TEMED were added immediately before pouring as these cause the 
solution to solidify). Solutions were topped with 100% isopropanol to level the 
resolving gel. Isopropanol was poured off after the resolving gel had set, the gel was 
washed with dH2O and briefly dried. 3ml of the stacking gel solution was then 
assembled (Ammonium persulphate and TEMED again added immediately before 
pouring) and poured on top of the resolving gel. A 10 well comb was then inserted into 
the mould. Gel was then left to dry before either immediately used for SDS page or 
wrapped in cling film in an excess of dH2O and stored at 4°C for later use. 
Commercially sourced NuPage Bis-Tris gels were used for all other proteins. 
2.10.2 SDS PAGE 
Western blots were run fresh for each experiment. 25µg of protein were prepared in a 
final volume of 20µl of running buffer in an eppendorf tube. 7.5µl NuPage LDS sample 
buffer x4 and 3µl NuPage reducing agent 10 x were added to prepared lysates and 
denatured at 90-100 °C for 5 mins. Commercially sourced gels were assembled gel with 
the front of the gel facing the inner chamber of a Mini-Cell chamber. Hand poured gels 
were assembled into Mini-PROTEAN Tetra Electrode Assembly. If only running one 
gel a buffer dam was placed on the opposite side before the entire sandwich is clamped 
in place inside the chamber. The inner chamber was filled with running buffer and 
checked for leaks before the outer chamber is filled with the remaining running buffer. 
The wells were then flushes with a syringe before loading with 20µl (HeLa and HEK 
lysates) or 30µl (C2C12) of samples and 10µl of SeeBlue Plus2 ladder (ECL detection) 
or chameleon duo ladder (Li-Cor detection). Gels were then run at 200V for 
approximately 50 minutes or until the yellow loading buffer tide line reached the bottom 
of the gel  
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2.10.3 Protein Transfer 
Gels were removed from the Mini-Cell chambers, carefully removed from their plastic 
cassette containers or glass moulds and placed on top of Immobilon-FL PVDF 
membrane, cut to size. The membrane had been pre-wet in 100% methanol and rinsed in 
chilled transfer buffer. Together they were placed between four squares of cut to size 
blotting paper and two sponges, all soaked in chilled transfer buffer. This “sandwich” 
was placed in a transfer cassette and placed in a transfer tank, with the membrane 
orientated closest to the positive electrodes. Two gels were run in the same tank, if 
required, which was filled with chilled transfer buffer. Proteins were transferred for 90 
minutes at 350mA using a Bio-Rad PowerPac HC. Protein transfer to the membrane 
was confirmed using Ponceau staining (Sigma) of the membrane for 5 minutes.  
2.10.4 Antibody probing and washing 
Two different protocols were used depending on the method of eventual visualisation to 
be used.  
For ECL detection, following ponceau staining, the membrane was destained in dH2O, 
blocked for 1 hour at room temperature in 5% milk in TBST on a shaker, cut into strips 
so that it could be probed by different primary antibodies and then incubated overnight 
at +4° in primary antibody prepared in 5% milk in TBST. The following morning 
primary antibody was removed, the membrane washed in TBST three times for 10 
minutes, incubated for 90minutes in horseradish peroxidase (HRP) conjugated 
secondary antibody prepared in 5% milk in TBST and washed again three times for 10 
minutes in TBST before ECL detection. 
For Li-Cor Odyssey detection, following ponceau staining, the membrane was pre-wet 
for 1 minute in 100% methanol, rinsed with ultrapure water, wet in 1x TBS for 2 
minutes and incubated for one hour in TBS Odyssey Blocking Buffer with gentle 
shaking. During this time primary antibodies were prepared to a final dilution of 5ml in 
TBS-Ta Blocking solution. Membranes were blotted in primary antibody overnight at 
4°C with gentle shaking. 
The following morning membranes were washed three times in ~10ml TBS-T Wash 
buffer with vigorous shaking for 5 minutes. During the washes the IRDye secondary 
antibodies were diluted in TBS-Tb to a final volume of 5ml. Blots were incubated in 
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secondary antibody for one hour at room temperature, protected from light with gentle 
shaking. Following incubation, blots were again washed three times for 5 minutes with 
vigorous shaking in ~10ml TBS-T Wash buffer, whilst also being protected from light. 
Membranes were rinsed a final time in 1x TBS to remove residual Tween 20 and stored 
in 1x TBS in the dark at 4 °C or imaged immediately with the Odyssey CLx. 
2.11 Visualisation of Western blot and Coomassie stains 
2.11.1 ECL Detection and development 
Standard Western blot membranes of HeLa and HEK cell lysates were visualised in a 
dark room on using SuperSignal West Dura Chemiluminescent Substrate kit. Each 
section of membrane was incubated for 5 minutes at room temperature in 1ml of ECL 
substrate, prepared from equal parts solutions A and B provided in the kit. Photographic 
film was then exposed to the membrane for a determined amount of time in a sealed 
film cassette, separated by transparent plastic film, before development of the film and 
final visualisation of the blot. 
2.11.2 Odyssey CLx Gel Scanning 
All knockdown C2C12 lysate Coomassie stained gels and standard and 2D Western blot 
membranes were imaged using an Odyssey CLx and Image Studio Ver 4.0 software. 
Gels were placed on the scanning surface of the Odyssey CLx in an excess of dH2O or 
1x TBS, to ensure the gels and membrane didn’t dry out during scanning. Test images 
were taken to ensure the gel or membrane was fully within the scanning area of the 
Odyssey and then scanned only in the 700 nm spectrum (Coomassie gels) or 
simultaneously in the 700 nm and 800nm spectrums (western blots) at 21µm/pixel 
resolution and medium quality.  
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2.12 Microscopy and Image Analysis 
All immunofluorescent, immunohistochemical and Annexin V assay images were taken 
on the AxioImager (Zeiss) microscope using AxioVisions40 (V 4.8.2.0) image 
acquisition software. Heamotoxinalin and Eosin staining images were taken on the 
Axioplan (Zeiss) microscope using AxioVision (V 4.8.1.0) image acquisition software. 
Brightfield images of knock down C2C12 clone selection and differentiation were taken 
on an Eclipse TS100 (Nikon) using NIS Elements (D 3.2) image acquisition software. 
In experiments involving detection of fluorescent tags, initial values of laser exposure 
required to optimally detect each fluorophore at each magnification were maintained 
across all subsequent wells or slides containing the same experimental condition and 
their controls. 
2.12.1 Annexin V assay imaging and cell counting 
For each image, individual image files were created for each fluorescence channel and 
exported in a .tiff format. Each image folder containing these multiple files was blinded 
prior to cells counting using the Cell Counter plugin of Image J. Each fluorescence 
channel file was opened individually (DAPI only, FITC-AV+DAPI, Caspase 3+DAPI, 
all channels) and the number of positive cells recorded to an excel spreadsheet before 
un-blinding the images and statistical analysis. 
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2.13 Flow cytometry analysis using FACSCanto 
2.13.1 Cell sample preparation 
Three different experimental flow cytometry set ups were used, referred to as 1µM 
Time Series, 50µM Time Series and 50µM Apoptosis. In each, C2C12 and patient 
myoblasts were cultured in 6 well plates using standard tissue culture methods, as 
described in section 2.1.  
For 1µM and 50µM Time Series experiments, a master mix of 1µM or 50µM 
staurosporine in 2000µl growth media was prepared. Apoptosis was induced in ~95% 
confluent cells by replacing culture media in a single well with 500µl of the master mix 
and returning to normal tissue culture conditions for one hour. This process was 
repeated three times producing 4hour, 3hour, 2hour, 1hour and two 0hour time points. 
For 50µM Apoptosis, normal culture media was removed from two wells of ~95% 
confluent cells and replaced with 50µM staurosporine in 500ul growth media in one 
well and 50µM staurosporine and 3mM EGTA in 500ul growth media in the second 
well. Plates were incubated for 4 hours under normal tissue culture conditions.  
Collection of cell populations was consistent across experimental set ups. Following 
incubation, media from each well was transferred to individual 15ml falcon tubes and 
the wells were washed with 500µl of ice cold PBS, which was also added to the same 
15ml falcon tubes. Remaining adherent cells were removed by applying 300µl of 
TrypLE trypsin to each well and incubating for 5 minutes in normal tissue culture 
conditions. 500ml of ice cold PBS was added to each well to dilute the TrypLE and the 
total 800µl solution removed from each well and added to the corresponding 15ml 
falcon. Finally, the wells were washed again with 500µl of ice cold PBS, with washes 
again added to the corresponding falcon tube. Collected cells were pelleted by 
centrifuging at 1000rcf for 5 minutes in a Eppendorf 5804 R centrifuge. Cells were 
washed by resuspension in 500µl of ice cold PBS followed by centrifugation at 1000rcf 
for 5 minutes, discarding the PBS afterwards.  
Cell pellets were resuspended in different Annexin V assay solutions. For 1µM and 50 
µM Apoptosis set ups, three different solutions were prepared. Both populations of 
treated cells and one population of untreated cells were resuspended in 100µl of 
Solution 1, one population of untreated cells was resuspended in 100µl of Solution 2 
and another untreated population in Solution 3 (Table 2.7). For Time Series set up, all 
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populations of treated cells and one untreated population were resuspended in 100µl of 
Solution 1. The last population in each set up remained unstained as a negative control 
and was resuspended in 500µl of 1x Binding Buffer (1ml 10x Binding Buffer + 9ml 
dH2O).  
Resuspended cells were then transferred to clean FACS tubes (Corning) and left to 
incubate for 15 minutes at room temperature in the dark. Following incubation, 400µl of 
1x Binding Buffer was added to each FACS tube containing stained cell populations 
and all populations immediately analysed by Flow cytometry.  
Solution 1 Solution 2 Solution 3 
3µl FITC Annexin V 
conjugate 
1µl FITC Annexin V 
conjugate 
- 
30µl Propidium Iodide - 10µl Propidium Iodide 
30µl 10x Binding Buffer 10µl 10x Binding Buffer 10µl 10x Binding Buffer 
237µl dH2O 89µl dH2O 80µl dH2O 
Table 2.7 Composition of annexin V staining solutions for flow cytometry. Total volumes 
required to stain the number of samples for each condition. 
2.13.2 Flow Cytometry 
Fluorescence data of stained and unstained C2C12 and patient myoblast cell populations 
was collected using a FACSCantoII (BD) equipped with 2-488/530/30-A and 2-
488/585/42-A lasers to capture FITC-Annexin V (FITC-AV) and propidium iodide (PI) 
fluorescence signal respectively. Samples were interrogated and manually gated using 
FACSDiva (BD) software. While automated procedures are available and recommended 
for large datasets (Verschoor et al., 2015), manual gating analysis is still a valid and 
relatively fast method of analysis when dealing with smaller sample sizes (e.g. fewer 
than 40 samples). A total of 10,000 events (i.e. cells passing through the path of the 
lasers) were captured per sample.  
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2.14 Statistical Analysis 
All statistical analyses were carried out in Microsoft Excel. Chi2 calculations (Equation 
2.2) were used to test the difference in the number of positive cells between ANO5 and 
Control knock down C2C12 and between LGMD2L or LGMD2B and wildtype patient 
myoblasts in each treatment condition. Chi2 was used as the data was non-parametric 
and categorical (i.e. yes or no for positive staining). The null hypothesis tested was 
“ANO5 knock down does not affect PS exposure in C2C12 cells”. 
The Chi2 statistic is calculated using Equation 2.2. For the analysis of knock down 
C2C12 images, observed values in each treatment condition were the summed counts of 
the number of positive cells across the five images taken of each well. For analysis of 
patient myoblast flow cytometry data, the number of events recorded in each quadrant 
in each treatment condition for each cell line were used as the observed values. The 2x2 
table method was used to generate the expected values (Figure 2.3). These values were 
then used in Equation 2.2 to generate a Chi2 statistic with 1 degree of freedom.  
𝜒2 =
∑(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 − 𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑)2
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑
 
Equation 2.2 Chi2 equation used to calculate the association between positive count values. 
 
 
Control ANO5 
 
Number of 
Positive Cells 
A B A+B = AB 
Number of 
Negative Cells 
C D C+D = CD 
 
A+C = AC B+D = BD A+B+C+D 
Observed = B 
Expected = A/AC x BD 
Figure 2.3 Example of 2x2 table calculations used to generate expected values for the Chi2 
statistic. “Positive” and “Negative Cells” refer to either FITC-AV or aC3 depending on the 
condition being tested   
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2.15 Consumables and Equipment 
Item  Product Code  Supplier 
0.05% Trypsin 25300096 Gibco 
0.45µm PES membrane  89220-712 VWR 
1.5ml microfuge tube 211-2610 VWR 
1000μl pipette filter tips S1122-1830 Starlab 
100mm petri dishes 734-2321 VWR 
10ml serological pipettes 86.1254.001 Sarstedt 
10μl pipette filter tips S1121-3810 Starlab 
15ml centrifuge tubes 430766 Corning 
19G Microlance 3 needle ND500 BD 
1kb DNA ladder G571A Promega 
2.0ml Skirted Cryovial  E3090-0013 Star Labs 
200μl pipette filter tips S1120-8810 Starlab 
20μl pipette filter tips S1120-1810 Starlab 
21G Microlance 3 needle ND434 BD 
24-well plate 734-2325 VWR 
25ml serological pipettes 86.1685.001 Sarstedt 
2-mercaptoethanol 31350-010 Life Technologies 
30% Acrylamide/Bis Solution 161-0159 Bio-Rad 
50ml centrifuge tubes 430829 Corning 
50ml serological pipettes 86.1689.001 Sarstedt 
50ml syringes without needles SYR6212 SLS 
5ml serological pipettes 86.1689.001 Sarstedt 
6-well plate 734-2323 VWR 
8 well chamber slides 734-0089 VWR 
8-channel spectrophotometer ND-8000 NanoDrop 
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8-Strip PCR Caps, Domed I1400-0800 Star Labs 
96-well PCR plates E1403-5200 Starlab 
Acetic acid A6283-1L Sigma-Aldrich 
Acetone 20066.330 VWR 
Agarose NBS-AG500 NBS Biologicals 
Agarose gel electrophoresis tanks 1704405 Bio-Rad 
Alexa Fluor 488 goat anti-mouse IgG A11001 Invitrogen 
Alexa Fluor 594 goat anti- mouse IgG A11008 Invitrogen 
Alexa Fluor 594 goat anti- rabbit IgG A11005 Invitrogen 
Alexa Fluor 594 phalloidin A12381 Invitrogen 
Ammonium Persulfate (APS) 10 g 161-0700 Bio-Rad 
Ampicillin sodium salt A9518-5G Sigma-Aldrich 
Anti-Active Caspase-3 ab2302 Abcam 
Anti-Annexin A2 ab41803 Abcam 
Anti-c-Myc Antibody (9E10) sc-40 Santa Cruz Biotech 
Anti-c-Myc Antibody (ab39688) ab39688 Abcam 
Anti-dystrophin antibody ab15277 Abcam 
Anti-GFP ab290 Abcam 
Anti-Hsp27 ab2790 Abcam 
Anti-S100A4 ab93283 Abcam 
Autoclave RS232 Astell 
Autoclave tape 817-0118 VWR 
Bio-Lyte 3/10 Ampholyte 40% 10ml 163-1112 Bio-Rad 
BioPhotometer  - Eppendorf 
Blue/orange 6x loading dye G190A Promega 
Bovine Serum Albumin (BSA) A3294-50G Sigma 
Camera BW AxioCam HRc Zeiss 
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Camera RGB DS-Fi2 Nikon 
Carprofen 33975-100MG-R Sigma Aldrich 
cDNA reverse transcription kit 4368814 App’d Biosystems 
Cell Scraper, 320mm Long, pivoting blade CC7600-0320 Starlab 
Chameleon Duo Pre-stained Protein Ladder 928-60000 Li-Cor 
Chloroform C2432-1L Sigma 
Class 1 airflow cabinet Hera guard Heraeus 
Class 2 airflow cabinet Hera safe Heraeus 
Cloning cylinders, glass C1059-1EA Sigma-Aldrich 
Cover glasses, 22x50mm, 0.13mm thickness 631-0137 VWR 
Cryostat  Microm HM 560 
Thermo Fisher 
Scientific (TFS) 
DEPC-treated water AM9906 Ambion 
Dimethyl sulfoxide (DMSO) D-8779 Sigma-Aldrich 
Dulbecco's modified Eagle medium 41966052 Gibco 
EDTA E5134-500G Sigma-Aldrich 
EGTA E8145 Sigma-Aldrich 
EndoFree Plasmid Maxi Kit (10) 12362 QIAGEN 
Ethanol 20821.33 VWR 
FACS Tubes 352054 Corning 
Fine scales BD BH 110 Denver 
Flask tissue culture 150cm² 430825 Corning 
Flask tissue culture 75cm² 734-2313 VWR 
Flow Cytometer FACSCanto II BD 
Foetal bovine serum (FBS) EU-000-F SLI 
Freezer -80° U725 NB Scientific 
Fridge/freezer -20° KGV36VW32G Bosch 
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FuGENE HD Transfection Reagent E2311 Promega 
GAPDH (mouse) ab8245 Abcam 
GAPDH (rabbit) D16H11 Cell Signal Tech 
GelDoc-It Imaging System GelDoc-It310 UVP 
GeneJuice  70967-6 Merck Millipore 
Gentamicin 15750-037 Gibco 
Glucose G8270-100G Sigma-Aldrich 
Glycerol G5516-100ML Sigma-Aldrich 
Glycine G8898-1KG Sigma-Aldrich 
Haemocytometer 680030 Marienfeld 
Heater magnetic stir block 101N0052 Fisher 
HEPES H3375-100G Sigma-Aldrich 
Horse serum 26050088 Gibco 
Hyaluronidase H3506 Sigma-Aldrich 
Hybond PVDF membrane RPN303F GE Healthcare 
HCl, Hydrochloric acid 84436-1L Sigma-Aldrich 
IGEPAL CA-630 I7771-50ML Sigma-Aldrich 
ImmEdge Pen  H-4000 Vector Labs 
Immobilon-FL PVDF  IPFL00010 Merck Millipore 
Incubator Hera cell 240 Heraeus 
Insulin syringe with needle 613-4897 VWR 
Iodoacetamide I6125-5G Sigma Aldrich 
IRDye 680RD Goat anti-Rabbit 926-68071 Li-Cor 
IRDye 800CW Donkey anti-Mouse 926-32212 Li-Cor 
Isopentane M32631-2.5L Sigma-Aldrich 
Isopropanol 20842.33 VWR 
Lab Armor beads A1254301 Life Technologies 
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LDS sample buffer NP0007 Invitrogen 
Lens tissue 2105-841 Whatman 
L-Glutamine 35050-038 Gibco 
Lipofectamine® 2000  11668019 Life Technologies 
Lyostracker Red DND-99  L-7528 TFS 
MES SDS protein gel running buffer NP0002 Invitrogen 
Methanol 20846.326 VWR 
MgSO4, Magnesium sulphate 208094-500G-D Sigma-Aldrich 
Micro-Fine 2.5ml syringes SYR2LL Terumo 
Microfuge 5415D Eppendorf 
Microscope filter DAPI FS02 Zeiss 
Microscope filter GFP FS13 Zeiss 
Microscope filter Rhodamine FS15 Zeiss 
Microscope inverted fluorescence AxioVert200M Zeiss 
Microscope inverted light AE20 Motic 
Mini-PROTEAN Tetra Cell Casting Module 1658010 Bio-Rad 
Mini-PROTEAN Tetra Electrode Assembly  1658037 Bio-Rad 
Mounting medium with DAPI H-1200 Vectorlabs 
Mouse on Mouse (M.O.M.) Basic Kit BMK-2202 Vector Labs 
Mr Frosty Cryo 1°C Freezing Container  5100-0001 TSF 
NaCl, Sodium chloride S9888-5KG Sigma-Aldrich 
NaOH, Sodium hydroxide S5881-500G Sigma-Aldrich 
Nitrile gloves 112-2755 VWR 
Novex Mini-gel PAGE tanks 120801-2839 Invitrogen 
Nuclease-free water (NFW) AM9937 Ambion 
Nunc Lab Tek 8 Well Permanox Slides 177445K SLS Ltd 
Nunc Lab-Tek 4 Well Permanox Slides C6932-1PAK Sigma-Aldrich 
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Nunc Lab-Tek Chamber Slides C7182-1PAK Sigma-Aldrich 
NuPAGE antioxidant  NP0005 TFS 
NuPAGE MES SDS Running Buffer (20X) NP0002 Life Technologies 
NuPAGE MOPS SDS Running Buffer (20X) NP0001 Life Technologies 
NuPAGE Novex 4-12% Bis-Tris Protein Gels NP0321BOX Life Technologies 
Objective CFI Plan Apochromat 20x VC 20x/0.75 Nikon 
Objective CFI Plan Fluor 10x DL-10x F/0.3 Nikon 
Objective Plan Neofluar 10x 10x/0.3 Zeiss 
Objective Plan Neofluar 20x 20x/0.5 Zeiss 
OCT cryoembedding Matrix 12678646 TFS 
Odyssey Blocking Buffer (TBS) 927-50003 Li-Cor 
Odyssey Infrared Imaging System Odyssey CLx Li-Cor 
Paraformaldehyde P6148-1KG Sigma-Aldrich 
Pasteur pipettes 230mm 612-1702 VWR 
PBS tablets 18912-014 Gibco 
PCR plate adhesive sealing sheets AB-0558 TFS 
PCR thermocycler LabCycler Sensoquest 
Pellet Paint Co-Precipitant 69049-3 Merck Millipore 
Penicillin/Streptomycin 15070063 Gibco 
pH meter HI 2210 Hanna 
Phenol:chloroform:isoamyl alcohol 15593031 Ambion 
Phenylmethanesulfonyl fluoride P7626-1G Sigma-Aldrich 
Phosphate buffered saline solution 20012068 Gibco 
Ponceau P7170-1L Sigma 
PowerPac HC 1645052 Eppendorf 
Protein Assay Dye Reagent Concentrate  500-0002 Bio-Rad 
cOmplete protease inhibitor tablet 05892791001 Roche 
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QIAprep Spin Miniprep Kit 27106 Qiagen 
QIAquick Gel Extraction Kit 28706 Qiagen 
Qubit 2.0 flourometer Q32866 TFS 
Qubit Protein Assay Kit Q33212 TFS 
Recovery Cell Culture Freezing Medium 12648-010 Life Technologies 
Refrigerated centrifuge 5804R Eppendorf 
RNase Zap AM9780 Ambion 
RNaseOUT Recombinant RNase Inhibitor 10777-019 Invitrogen 
Rotor A-4-44 Eppendorf 
Rotor F45-30-11 Eppendorf 
Rotor A-4-62 Eppendorf 
SafeView nucleic acid stain NBS-SV1 NBS Biologicals 
Sample reducing agent NP0009 Invitrogen 
Scales HL-200i A&D 
Scalpels no.22 REF0508 Swann-Morton 
SDS L3771-500G Sigma-Aldrich 
SeeBlue Plus2 protein standards LC5925 Invitrogen 
Semi-micro Polystyrene Cuvettes 634-0676 VWR 
shRNA Plasmid Transfection Reagent  sc-108061 Santa Cruz Biotech 
SimplyBlue SafeStain LC6060 Invitrogen 
Skeletal Muscle Cell Growth (SMCG) Media  C-23060 Promo Cell 
SMCG Media Supplementary Mix C-39365 Promo Cell 
Sodium azide S2002-5G Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) L3771-500G Sigma-Aldrich 
Sodium deoxycholate D6750  Sigma-Aldrich 
Staurosporine from Streptomyces sp. S4400-.5MG Sigma-Aldrich 
Superfrost Plus Slides 631-0108 VWR 
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Superscript III Reverse Transcriptase  18080-044 Invitrogen 
TACS Annexin V-FITC Apoptosis Kit 4830-01-K R&D Systems 
TEMED 161-0800 Bio-Rad 
Triton X-100 T8787-50ML Sigma-Aldrich 
Trizma base T1503-1KG Sigma-Aldrich 
TRIzol 15596026 Ambion 
TrypLE Express Enzyme (1X) 12604013 Life Technologies 
Tween 20 P9416-100ML Sigma-Aldrich 
Ultrapure water system D11901 TFS 
Urea U5378-1KG Sigma-Aldrich 
Virkon A01302780 Dupont 
Water bath JB Aqua 18 Plus Grant 
Western blot transfer tanks 1703930 Bio-Rad 
ZOOM IPG Strips - pH 3-10NL ZM0011 Life Technologies 
ZOOM IPGRunner Cassettes ZM0003 Life Technologies 
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2.16 Solutions 
125mM Alkylating solution   
Iodoacetamide 232mg 
1X NuPAGE LDS Sample Buffer  10ml 
 
15% Resolving Gel Solution  
30% Acrylamide 2.5ml 
1.5M Tris, pH 8.8 1.25ml 
10% SDS 50µl 
10% Ammonium Persulfate 50µl 
TEMED 2µl 
dH2O 1.15ml 
 
15% Stacking Gel Solution  
30% Acrylamide 300µl 
1.5M Tris, pH 6.8 375µl 
10% SDS 30µl 
10% Ammonium Persulfate 30µl 
TEMED 3µl 
dH2O 2.26ml 
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4% (w/V) paraformaldehyde (PFA) in PBS 
dH2O  500ml 
PBS tablets  2 
NaOH  3 pellets 
PFA  40g 
pH adjusted with NaOH  7.4 
dH2O  to 1000ml 
 
Annexin V solution   
 Differentiation  Apoptosis 
FITC-Annexin V conjugate 9µl 1µl 
10x Binding Buffer 90 µl 10µl 
dH2O 801µl 79µl 
 
Apoptosis Solutions    
 Solution A Solution B Solution C 
Staurosporine 50µM 50µM - 
EGTA 3mM - 3mM 
DMEM + 10% FBS up to 100µl Up to 100µl up to 100µl 
 
Differentiation Media  
DMEM 48ml 
Horse Serum 1.5ml 
Penicillin/Streptomycin 500µl 
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Freezing media  
DMEM  70ml 
FBS  20ml 
DMSO  10ml 
filtered through a 0.45µm PES membrane  
 
Growth Media  
DMEM 500ml 
FBS 50ml 
 
IF Blocking Solution  
Triton X-100 50µl 
FBS 5ml 
10x PBS 5ml 
dH2O 40ml 
 
Lysis Buffer   
Radioimmunoprecipitation (RIPA) 
assay buffer 
150 mM sodium chloride 0.88g 
 1% Triton X-100 10µl 
 0.5% Sodium deoxycholate 0.5 µl 
 0.1% SDS 1µl 
 50 mM Tris at pH 8.0 0.61g 
 dH2O 100ml 
Protease inhibitor tablet  1 tablet/10ml 
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MES and MOPS SDS protein running buffer 
MES SDS protein running buffer (20x) or 
MOPS SDS protein running buffer (20x) 
35ml 
dH2O  700ml 
 
M.O.M diluent 
Protein Concentrate stock solution 600µl 
1x PBS 7.5ml 
 
NET Buffer  
1M HEPES pH 7.9 200µl 
1M MgCl2 15µl 
1M NaCl 5ml 
100mM EDTA 20µl 
Glycerol 2ml 
Triton X-100 100 µl 
200mM PMSF (serine protease inhibitor) 50 µl 
dH2O up to 10ml 
 
Phosphate buffered saline (PBS)  
PBS tablets  2 
dH2O  1000ml 
 
Tris buffered saline (TBS) 10x  
Trizma base  60.5g 
NaCl  87.6g 
dH2O Up to 1L 
pH adjusted with HCl  7.5 
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Reconstitution Buffer, for Abmart Antibodies 
1% BSA 1g 
0.01% Sodium Azide 0.01g 
50% Glycerol 50ml 
10mM HEPES at pH 7.5 0.23g 
dH2O 50ml 
 
Selection Media  
DMEM 500ml 
FBS 50ml 
10µg/ml Puromycin 500µl 
 
Skeletal Growth Media (SGM)  
Skeletal Muscle cell growth media 500ml 
FBS 50ml 
Skeletal Muscle Cell Growth Media 
Supplementary Mix 
25.9ml 
L-Glutamine 5ml 
Gentamicin 300µl 
 
STM Buffer  
1M Sucrose 12.5ml 
1M Tris-HCl, pH 7.4 2.5ml 
1M MgCl2 250µl 
200mM PMSF (serine protease inhibitor) 250µl 
dH2O up to 50ml 
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Solubilisation Solution   
1ml Buffer A 9M urea 20ml 
 2% (v/v) Nonidet P-40 400µl 
 0.8% (w/v) ampholine pH 3-10 400µl 
 2% (v/v) 2-mercaptoethanol 400µl 
100µl Buffer B PMSF 15.5mg 
 95% ethanol 1ml 
 
Sample Reducing Buffer  
NuPAGE® Sample Reducing Agent (10X) 0.5mL 
1x NuPAGE® LDS Sample Buffer 4.5mL 
 
Tris acetic acid EDTA (TAE) buffer  
Tris  400mM 
EDTA  10mM 
Acetic acid  11.4% (V/V) 
pH (with Trizma base and acetic acid)  7.6 
 
TBS-Ta Blocking Solution  
TBS Odyssey blocking buffer 30ml 
Tween 20 60µl 
 
TBS-Tb Blocking Solution  
TBS Odyssey blocking buffer 20ml 
Tween 20 40µl 
10% SDS 20µl 
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TBS-T Washing Buffer  
1x TBS 200ml 
Tween 20 200µl 
 
Western blotting protein transfer buffer (PTB) 
Trizma base  3.03g 
Glycine  14.4g 
dH2O  to 800ml 
Methanol  200ml 
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Chapter 3 In Vitro and In Vivo localisation of ANO5 
3.1 Introduction 
One key indicator of the physiological function of a protein is the subcellular 
localisation. Early localisation studies of mouse Ano5 (a homolog for human ANO5) in 
murine embryogenesis found evidence for anoctamin 5 localising to the plasma 
membrane as well as several subcellular compartments including Golgi apparatus, trans-
Golgi network, secretory vesicles, endoplasmic reticulum (ER) and endosomes (Mizuta 
et al., 2007). Similarly, HEK (Human Embryonic Kidney), HeLa and CHO (Chinese 
Hamster Ovary) cell lines transfected with Green Fluorescent Protein (GFP) tagged 
ANO7 have been shown to display characteristic ER-like expression when colocalised 
with the ER marker, mCherry-17. This has led to the suggestion that all intracellular 
anoctamins localise to the ER (Duran et al., 2012). Other early data has shown that 
ANO5 localises to the ER (Tsutsumi et al., 2004), but has not been confirmed in all 
studies.  
Indeed the precise localisation of anoctamin 5, other than to the cytoplasm, has yet to be 
determined (Duran et al., 2012). Gaining a better understanding of anoctamin 5 
localisation would allow inference of the functional pathways in which it is involved 
and other proteins with which it interacts. These pathways and interacting proteins can 
then be further investigated, confirming or rejecting hypotheses and adding to the 
overall picture of anoctamin 5 function. 
For example, observing co-expression of anoctamin 5 and dysferlin may suggest that 
these proteins are both involved in the same pathway. As dysferlin has already been 
suggested to be heavily involved in membrane fusion and repair pathways in muscle, 
specific investigation could then be conducted into a similar role for anoctamin 5 
(Bansal et al., 2003; Lennon et al., 2003). Investigation may then clarify the 
involvement of anoctamin 5 in these pathways and go a step towards reconciling the 
overlapping phenotypes of the anoctaminopathies and dysferlinopathies. 
In general, subcellular localisation of proteins is identified using antibody staining of 
tissue sections (Ohlendieck et al., 1991; Matos et al., 2010), cell cultures (Campbell et 
al., 1979; Mandinova et al., 1998) or biochemically fractionated material (Lee et al., 
2010). As no verified anoctamin 5 antibody is commercially available a validated 
antibody would be of considerable value to the research field. Therefore as a first step 
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for this project, validation of a pool of customized antibodies was carried out to identify 
an antibody suitable for further investigation. 
As an alternative approach to antibody staining, anoctamin 5 was tagged with either 
GFP or a small epitope (cMyc tag) to enable the exogenously expressed fusion protein 
to be tracked by fluorescence microscopy. In this chapter, tagged anoctamin 5 
constructs were used to investigate the localisation of anoctamin 5 in cell cultures and 
mouse muscle.   
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3.2 Custom anoctamin 5 antibody validation 
Nine custom mouse monoclonal antibodies were obtained from the company AbMart. 
This company uses a “library” approach termed SEAL (Surface Epitope Antibody 
Library) which targets multiple epitopes of the protein of interest and utilises multiple 
antigens, immunisations, fusions and clone selections to create a number of antibodies 
for the target protein. 
Antibodies were received as ascites and resuspended in 0.5ml of reconstitution buffer 
suggested by Abmart. Gentle heating in a heat block with brief vortexing was also 
applied to improve the resuspension of antibodies, though the first batch of antibodies 
remained very viscous and were difficult to work with. 
3.2.1 Validation by Western blotting 
Validation of both sets of nine Abmart ANO5 antibodies by western blotting was 
achieved by investigating protein extracts derived from transiently GFP-ANO5-MycHis 
transfected HeLa and untransfected HEK lysates on precast gels. As ANO5 has been 
shown to be unexpressed in HeLa cells and endogenously expressed at low levels in 
HEK cells, untransfected HEK lysates were used as endogenously expressing controls 
to overexpressing HeLa lysates (Kunzelmann et al., 2009). Following transfer, the 
membranes were cut vertically along the ladder so that the blot could be probed with 
multiple concentrations of Abmart antibodies as well a control GAPDH primary 
antibody. GAPDH was used as a control as a well-established loading control. Goat 
anti-mouse HRP and goat anti-rabbit HRP secondary antibodies were used against 
Abmart and GAPDH primary antibodies respectively.  
The first batch of nine antibodies, with the exception of Ab9A, had a very high level of 
background at very high dilutions (Figure 3.1). In each case, the entire blot is mostly 
black and in some blots is so over exposed that some potential bands appearing as white 
rather than black (Figure 3.1 Ab1A, 2A, 4A, 5A and 6A). Ab9A however, produced 
almost no background even at a lower concentration of 1:5000, but still failed to detect 
a band in either cell lysate. Due to time pressure to validate these antibodies, alternative 
blocking methods to reduce the background were not attempted. The high level of 
background strongly indicated that this batch of antibodies could not be optimised for 
ANO5 detection and so were excluded from further experimentation and a second batch 
of antibodies was requested from the Abmart.   
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Figure 3.1 Western blots probed with nine custom ANO5 antibodies (Batch A). Ab1A to Ab8A 
were used at a concentration of 1:10,000. Ab9A was used at a concentration of 1:5000. 
Exposure times for Ab1A-8A were 1m. Exposure times of 1m and 5m were investigated for 
Ab9A to ensure that a faint band was not missed at the shorter exposure time. The 
corresponding GAPDH control blots are given under each antibody. Biological N = 9. 
Technical N = 1.  
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To rapidly optimise the second batch of antibodies, several dilutions of Ab1B were run 
on a blot of only transfected HeLa lysates (Figure 3.2). This blot was then analysed on a 
GelDoc-It imaging system following ECL treatment. These results show that there is 
still a high degree of background with this antibody at lower antibody concentrations 
(1:500). Though at higher dilutions (1:5000 and 1:10,000) there is markedly reduced 
background compared against the same dilutions of the batch A antibodies. More 
importantly, there are also two bands present on the blot at ~38 and ~36kDa and that 
these bands are detectable up to a dilution of 1:5000. From this initial experimentation, 
dilutions of 1:1000 and 1:2500 were used for Ab2B, 3B, 4B and 5B on both HeLa and 
HEK lysates (Figure 3.3 A., B., C. and D.). Antibodies were tested sequentially, during 
which it became apparent that a dilution of 1:2500 was optimal for band detection with 
minimal background. Therefore HeLa and HEK lystates were probed with Ab6B, 7B, 
8B, and 9B at a dilution of 1:2500 only (Figure 3.3 E. and F.). These blots were all 
visualised using the standard X-ray developer method. 
These results show that the same two bands detected by Ab1B at ~38 and ~36kDa are 
detected by all of the subsequent batch B antibodies but only in the transfected HeLa 
lysates. Antibodies Ab2B, 4B, 5B, 6B, 7B, 8B and 9B also detected a small additional 
band at ~62kDa in both the transfected HeLa and untransfected HEK lysates. However 
the expected molecular weight of ANO5 is 102kDa well above any of these bands. 
Despite the lack of a band at the predicted molecular weight for ANO5, this batch of 
antibodies were further investigated using immunofluorescence staining.  
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Figure 3.2 Western blot probed with increasing dilutions of Ab1B. Arrows indicate double 
bands detected by Ab1B at ~40 and ~37kDa. Bands are clearly detected at 1:500 and 1:1000 
dilutions, faintly at 1:5000 and undetected at 1:10,000. GAPDH control, probed at a dilution of 
1:10,000 is detected at 38kDa. The full blot was reassembled prior to imaging and exposed for 
60 seconds. Biological N =1. Technical N = 1. 
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Figure 3.3 Western blots using the second received batch of custom ANO5 antibodies. A. 30 
second exposure of Ab2B blot. B. 1 minute exposure of Ab3B blot. C.30 second exposure of 
Ab4B blot. D.30 second exposure of Ab5B blot. E. 1minute exposure of Ab6B and Ab7B blot at 
1:2500. F. 1 minute exposure of Ab8B and Ab9B blot at 1:2500.The white arrows on A. C. D. E. 
and F. indicate the position of the 62kDa band detected by these antibodies in both lysates. 
GAPDH controls included on each blot are at 1:10,000. Biological N = 8. Technical N = 1.  
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3.2.2  Validation by immunofluorescence staining 
GFP-ANO5 and ANO5-MycHis were transfected into HeLa cells cultured on 8-well 
chamber slides using Lipofectamin 2000 methods and analysed by immunofluorescence 
staining to determine the sensitivity of Abmart antibodies. Both GFP and Myc-tagged 
constructs were used to corroborate the data of the other and confirm antibody detection 
sensitivity. 
Positive immunofluorescence staining showed successful transfection with an efficiency 
of approximately 5-7% for both constructs. However, where GFP or highly expressed 
Myc tag signals indicated transfection, an increase in cell staining above that seen in the 
surrounding cells was not detected by any Abmart antibody (Figure 3.4 and Figure 3.5). 
These data in concert with failure to detect of a band of the predicted molecular weight 
for ANO5 during western blotting indicated that no antibody could be selected as 
suitable for detecting ANO5.  
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Figure 3.4 Custom ANO5 antibody immunofluorescence stain of ANO5-MycHis transfected 
HeLa cells. Left hand images are micrographs of red fluorescence of each Abmart antibody 
(labelled) + alexa fluor 594 secondary antibody. Right hand images are micrographs of the red 
fluorescence signal merged with green fluorescence from anti-Myc (ab39688) antibody + alexa 
fluor 488 secondary antibody. Bottom right image Control images show secondary antibody 
only condition in transfected cells. All images are at x20 magnification (scale bars = 50µm). 
Biological N = 10. Technical N = 2. 
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Figure 3.5 Custom ANO5 antibody immunofluorescence stain of GFP-ANO5-MycHis 
transfected HeLa cells. Left hand images are micrographs of red fluorescence of each Abmart 
antibodies (labelled) + alexa fluor 594 secondary antibody. Right hand images show the 
merged images with GFP fluorescence from GFP tag. Bottom right image Control images show 
secondary antibody only condition in transfected cells. All images are at x20 magnification 
(scale bars = 50µm). Biological N = 10. Technical N = 2.  
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3.3 Creation of GFP and MycHis tagged anoctamin 5 constructs 
To better understand anoctamin 5 expression in vitro, GFP and YFP-tagged organelle 
markers were co-transfected with Myc-tagged anoctamin 5 constructs. GFP-ANO5-
MycHis, GFP-ANO5, ANO5-MycHis and ANO5 only constructs were developed by 
Catherine Jepson prior to this project using the synthetic Homo sapiens cDNA clone 
encoding the full length of human ANO5 transcript variant A (IMAGE: 100061756) 
(Figure 3.6 A.-D.). GFP only, GFP-DFL (a GFP-tagged dysferlin construct) and BIN-1 
constructs were developed by Dr Steve Laval (Figure 3.6 E.-G.). GFP-DFL and BIN-1 
constructs included the human cDNA of the respective genes cloned into an adapted 
pcDNA4/TO/Myc-HIS vector (Klinge et al., 2007). Fluorescent organelle constructs for 
Golgi, endoplasmic reticulum and endosomes (Figure 3.6 H.-J.) were commercially 
sourced (Takara) prior to the start of this project. 
GFP has an excitation peak of 509nm (Johnson et al., 1962; Morise et al., 1974) and 
due to its stable fluorescence in other organisms, has become a common photoprotein 
tag (Chalfie et al., 1994; Inouye and Tsuji, 1994). GFP expression has been used to 
confirm the transduction efficiency of plasmid and viral vectors (Smolina et al., 2015) 
as well as to detect the subcellular expression of tagged proteins in murine models of 
muscular dystrophy (Li et al., 2006). For example GFP tagged mini dystrophin 
constructs transduced into mdx mice have shown GFP positivity in the sarcolemma of 
skeletal myofibres (Li et al., 2006).  
Commercially sourced fluorescent organelle constructs (Golgi, ER and ENDO) 
contained enhanced YFP (eYFP) tags. The eYFP tag is a yellow fluorescence with an 
excitation maximum of 513nm. However it can also be efficiently excited at 488nm 
which is the standard laser emission for GFP detection. While the close spectra of these 
markers is an issue during simultaneous detection, for individual expression 
experiments they allow for detection of both GFP and eYFP using the same laser 
(Zimmermann, 2005; Dinant et al., 2008). 
Each commercial construct also contains sequences which specifically localise it to the 
organelle of interest. The Golgi construct contains 81 amino acids of human beta 1,4-
galactosyltransferase (Human–GT). This is a membrane anchoring signal peptide which 
localises the construct to trans-medial region of the Golgi apparatus (Watzele and 
Berger, 1990). The ER construct contains the protein sequence for calrecticulin which 
localises to the endoplasmic reticulum (Fliegel et al., 1989) and the ENDO construct 
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contains RhoB GTPase which localises the construct to the surface of endosomal 
pathway vesicles. The ENDO construct also contains a Myc tag which makes direct 
comparison between co-transfected ENDO and ANO5-Myc constructs impossible. This 
construct was still included in experiments however, as the literature suggests that 
ANO5 may localise to the endosome (Mizuta et al., 2007). Comparison was instead 
made between eYFP fluorescence of the ENDO construct and the Myc fluorescence of 
singly transfected ANO5-Myc.   
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Figure 3.6 Representative diagrams of essential components of constructs used for antibody 
validation, organelle localisation and electroporation localisation experimentation. A.-D. 
Anoctamin 5 constructs developed by Catherine Jenson. Locations of BamHI, EcoRI and NotI 
restriction sites are indicated. E.-G. GFP construct, GFP tagged Dysferlin (GFP-DFL) and 
BIN-1 constructs developed by Dr Steve Laval. Locations of BamHI, EcoRI and NotI restriction 
sites in GFP construct are indicated. H.-J. Fluorescent Organelle constructs purchased from 
Takara H. Golgi construct, Human–GT marked section localises construct to the Golgi, I. ER 
construct, Calrecticulin marked section localises construct to the endoplasmic reticulum, J. 
ENDO construct, RhoB marked section localises construct to the surface of endosomal pathway 
vesicles. Arrows indicate the direction of DNA translation. Amp and Kan/Neo indicate the 
antibiotic resistances (ampicillin or kanamycin/neomycin) of the particular construct. eYFP 
indicates constructs with enhanced Yellow Fluorescent Protein. For simplicity diagrams are not 
to scale. Breaks in the diagrams indicate large distances in the sequence of the construct.  
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3.4 Co-expression of ANO5-Myc with fluorescently tagged organelle markers in 
MIN6 and NIH3T3 cell lines 
The Myc tagged anoctamin 5 construct was transiently transfected into mouse 
pancreatic cell line MIN6 or mouse fibroblast cell line NIH 3T3 with fluorescent 
organelle constructs BIN-1, ENDO, ER and Golgi (Figure 3.7 and Figure 3.8). 
ANO5-Myc has a punctate pattern of expression throughout the cytoplasm of both 
transiently transfected cell lines. These structures become denser the closer they are to 
the nucleus. Populations of MIN6 and NIH 3T3 cells successfully co-transfected with 
both ANO5-MycHis and fluorescent organelle markers indicate that all constructs 
localise to the cytoplasm as expected.  
BIN-1, an endosomal marker in non-myoblast cell lines, shows a similar pattern of 
diffuse cytoplasmic distribution in NIH 3T3 cells which closely overlay with the 
ANO5-Myc fluorescence. BIN-1 cytoplasmic expression is denser in MIN6 cells and 
does not localise to the same parts of the cell so does not over lay with the ANO5-Myc 
pattern of expression. ENDO also has a punctate expression pattern in the cytoplasm 
though the spots of fluorescence are much larger than in the NIH 3T3 cells compared to 
the single ANO5-Myc fluorescence and so are unlikely to co-localise. Comparison of 
independent ENDO and ANO5-Myc fluorescence patterns in MIN6 cells is harder to 
distinguish as the ENDO fluorescence pattern is very similar to single ANO5-Myc 
fluorescence. Without co-expression images it is not possible to accurately determine 
co-localisation between ENDO and ANO5-Myc constructs.  
In MIN6 cells ER, the endoplasmic reticulum marker, has a punctate pattern throughout 
the cytoplasm, overlapping with ANO5-Myc fluorescence. In NIH 3T3 cells, ER 
localises very densely around the nucleus and does not overlap with ANO5-Myc 
fluorescence.  
ANO5 does not appear to localise to the Golgi apparatus in either MIN6 or NIH 3T3, 
though there is some overlap in localisation in Golgi signal in NIH 3T3 cells. 
Untransfected controls, stained with anti-Myc antibody were negative for fluorescence 
signal.  
These data suggest that fluorescently tagged ANO5 constructs partially co-localise with 
ER in MIN6 cells and BIN-1 in NIH 3T3 cells (Figure 3.7 and Figure 3.8). 
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Figure 3.7 Co-expression of ANO5-MycHis and fluorescent organelle markers in MIN6 cells. 
Left hand images are micrographs of green fluorescence signal (BIN-1 and ENDO localise to 
Endosomes, ER localises to endoplasmic reticulum, Golgi localises to Goligi apparatus). The 
ANO5 column shows red fluorescence of anti-Myc (9E10) antibody + alexa fluor 594 secondary 
detecting the ANO5-MycHis construct and the right hand images show the merged images. 
Untransfected control cells are shown in the bottom right image. All images are at x63 
magnification (scale bars = 20µm). Biological N = 6. Technical N = 2.  
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Figure 3.8 Co-expression of ANO5-MycHis and fluorescent organelle markers in NIH 3T3 cells. 
Left hand images are micrographs of green fluorescent organelle makers (BIN-1 and ENDO = 
Endosomes, ER = endoplasmic reticulum, Golgi = Goligi apparatus). The ANO5 column shows 
red fluorescence of anti-Myc (9E10) antibody + alexa fluor 594 secondary detecting the ANO5-
MycHis construct and the right hand images show the merged images. Untransfected control 
cells are shown in the bottom right image. All images are at x63 magnification (scale bars = 
20µm). Biological N = 6. Technical N = 2.  
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3.5 Co-expression of ANO5-Myc and fluorescently tagged organelle markers in 
undifferentiated and differentiated C2C12 
T-tubules are invaginations in the sarcolemma of muscle cells and part of the 
cytoskeleton, responsible for transmitting electrical signals across the full width of cells 
and myofibrils, ultimately resulting in synchronous contraction of the full muscle 
(Huxley and Taylor, 1958; Bastian and Nakajima, 1974). The t-tubules have also been 
identified as the site of dysferlin localisation during muscle development (Klinge et al., 
2007) and have also been suggested as dependant on dysferlin for correct formation 
(Demonbreun et al., 2014).  
To investigate the subcellular localisation of anoctamin 5 in a more biologically relevant 
model and to investigate potential ANO5-Myc localisation to the t-tubules, transient 
transfection of the same ANO5-Myc with BIN-1 and Golgi marker constructs was 
carried out in undifferentiated (D0) and differentiated (D5) C2C12 mouse myoblasts 
(Figure 3.10). In this system the BIN-1 construct is predicted to be targeted to the t-
tubules in differentiated myotubes (Lee et al., 2002). Golgi marker constructs were 
included as a negative control as ANO5 was not expected to co-localise with these 
organelles.  
3.5.1 Transfection optimisation 
Several attempts were made to optimise transient transfection of undifferentiated 
C2C12 prior to myotube differentiation (Figure 3.9). Lipofectamine 2000 and Amaxa 
transfection methods were attempted, but these either had low initial transfection 
efficiencies (Lipofectamin 2000) or killed too many cells during transfection to lead to 
viable differentiation (Amaxa). FuGene was selected for further transfection 
experiments as it yielded the highest transfection efficiency in undifferentiated C2C12 
and retained the GFP construct over five days of differentiation. 
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Figure 3.9 Comparison of Lipofectamin 2000, AMAXA and Fugene transfection efficiencies of 
GFP construct and retention during differentiation. D0 (Undifferentiated), D3 (fusing C2C12) 
and D5 (early myotubes) time points are shown. All images are at x10 magnification (scale bars 
= 100µm). Biological N = 3. Technical N = 2. 
3.5.2 Co-expression of ANO5-Myc and fluorescently tagged organelle markers in 
undifferentiated and differentiated C2C12 
D0 C2C12 successfully transfected with ANO5-Myc retain the same pattern of 
expression seen in MIN6 and NIH 3T3 cells. There is a punctate pattern throughout the 
cytoplasm with increased density in proximity to the nucleus. A similar pattern is also 
seen in D5 differentiated C2C12, though with the punctate pattern appearing to form 
slight striated patterns within the cell. This may be due to elongation of the cell and not 
represent actual structures within the cell. 
BIN-1 is expressed throughout the cytoplasm at both D0 and D5 time points. While 
ANO5-Myc also localises to similar areas of the cytoplasm at both time points, the 
signals do not completely overlap suggesting that ANO5 only partial co-localises with 
BIN-1 (Figure 3.10). ANO5 does not localise to the Golgi apparatus in either D0 
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myoblasts or D5 myotubes. The Golgi construct localises around the nuclei and to a few 
concentrated clusters in the cytoplasm. C2C12 stained with only secondary antibody or 
transfected only with FuGene were negative for any fluorescence other than DAPI. 
These results suggest that ANO5 partially localises to the t-tubules in both 
undifferentiated and differentiated C2C12.   
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Figure 3.10 Co-Expression of ANO5-MycHis and fluorescent organelle markers in 
undifferentiated and differentiated C2C12. A. Control C2C12 transfected with ANO5-MycHis 
only. B. BIN-1 marker identifying t-tubules in green. C. Golgi marker identifying Golgi 
apparatus. Left hand images are micrographs of green fluorescent organelle makers, ANO5 
column of images show red fluorescence of anti-Myc (9E10) antibody + alexa fluor 594 
secondary antibody detecting the ANO5-MycHis construct and the right hand images show the 
merged images. All images taken at x63 magnification (scale bars = 20µm). Biological N = 3. 
Technical N =1.  
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3.6 Co-expression of ANO5-Myc with fluorescently tagged DYSF marker in 
undifferentiated and differentiated C2C12 
The anoctaminopathies and dysferlinopathies share a number of clinical features 
including a late age of onset, infrequent cardiac or respiratory involvement and a similar 
rate of progression and pattern of muscle involvement (Jarry et al., 2007). Anoctamin 5 
co-localisation with dysferlin was investigated in undifferentiated and differentiated 
C2C12 cells. 
Partial co-localisation of ANO5-Myc and GFP-DFL is seen in undifferentiated C2C12 
cells (Figure 3.11). Anoctamin 5 is visible with the punctate pattern of expression across 
the cytoplasm with some clustering near the nucleus, which had been previously 
observed, while dysferlin has a more filamentous pattern of expression throughout the 
cytoplasm. 
These staining patterns remain when the myoblasts fuse to become myotubes at day 5, 
but the dysferlin pattern is more pronounced, becoming more obviously filamentous 
across the length of the myotube. At both day 0 and day 5, the punctate pattern of 
anoctamin 5 lines up with the filamentous pattern of dysferlin, seen in the yellow signal 
in the merged channel. Slides stained with only secondary antibody or transfected only 
with FuGene were negative for fluorescence other than DAPI.  
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Figure 3.11 Co-Expression of ANO5-MycHis and DYSF in undifferentiated and differentiated 
C2C12. Top row of images are micrographs of green fluorescent GFP-tagged dysferlin (DYSF) 
maker, middle row of images are micrographs of red fluorescence of anti-Myc (9E10) antibody 
detecting the ANO5-MycHis construct and the bottom row of images are micrographs of the 
merged images. All images taken at x63 magnification (scale bars = 20µm). Biological N = 1. 
Technical N = 1.  
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3.7 In vivo localisation of anoctamin 5 using electroporation of mdx mouse muscle 
3.7.1 Construct validation 
To understand ANO5 localisation in a more biologically relevant model, electroporation 
was used to introduce expression constructs into the tibialis anterior muscle of male 
mdx mice in order to identify the in vivo localisation of ANO5 constructs. 
Electroporation experimentation were carried out using GFP, GFP-ANO5, ANO5-
MycHis and mini-dystrophin constructs, either singly or in combination. 
All constructs were first validated using restriction digest and expression in HeLa cells. 
Restriction digest products visualised on 1% (w/V) agarose gel confirmed that the 
constructs each contained inserts of the expected sizes (Figure 3.12). Similarly, 
immunofluorescent staining of GFP and Myc expression in transiently transfected HeLa 
cells indicate that the constructs were functionally viable and that staining methods were 
sufficient (Figure 3.13). 
The ANO5-Myc construct shows the expected punctate pattern of expression within the 
cytoplasm of the cell seen in previous experiments. Both the GFP control and GFP-
ANO5 constructs appear to be uniformly expressed throughout the cytoplasm, though 
the GFP-ANO5 construct has a comparatively lower level of fluorescence. 
Immunofluorescent staining with anti-GFP (ab290) appears to detect GFP only at the 
plasma membrane. Though as untransfected cells within the same wells did not display 
positive immunofluorescent staining, it was decided that this antibody was still useful as 
a second stain for confirming positive GFP expression.  
The transfection efficiency varied between constructs with the GFP control construct 
having the highest (~40-50% of cells with detectable fluorescence). Of the two tagged 
ANO5 constructs, GFP-ANO5 had the highest transfection efficiency (~15-20%) and 
ANO5-MycHis the lowest (~5-10%). Mini-dystrophin construct C1 was not tested in 
HeLa cells as it had been used successfully by another member of the group in a 
previous electroporation experiment.  
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Figure 3.12 Electrophoresis gel of whole and restriction digested dystrophin and ANO5 
expression constructs. C1-RD lane shows restriction digest product of C1 construct, insert 
present at ~4.5 kb. GFP-RD lane shows restriction digest product of GFP construct, insert 
present at ~0.8 kb. GFP lane shows undigested GFP construct. 2c1-RD lane shows restriction 
digest product of GFP-ANO5 construct, insert present at ~2.8 kb. 2c1 lane shows undigested 
GFP-Myc construct. 3d1-RD lane shows restriction digest product of ANO5-Myc construct, 
insert present at ~3 kb. 3d1 lane shows undigested ANO5-Myc construct. 1kbp ladder used with 
3000 and 1000bp markers indicated. Biological N = 7. Technical N = 1.  
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Figure 3.13 GFP and ANO5-tagged construct functionality examination by immunofluorescent 
staining of transfected HeLa cells. Left hand images are micrographs of transfected constructs 
+ indicated primary and secondary antibodies. Middle images are micrographs of transfected 
constructs + secondary antibody only. Alexa fluor 594 secondary antibody was used for anti-
GFP and secondary antibody only conditions. Alexa fluor 488 secondary antibody was used for 
anti-Myc (9E10) and secondary antibody only conditions. Right hand images are micrographs 
of Untransfected + primary and secondary antibodies conditions. All images are taken at x20 
magnification (scale bars = 50µm). Biological N = 4. Technical N = 1.  
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3.7.2 Electroporation of mdx and C57BL/10 mice 
Following validation, constructs were used in electroporation experiments utilising both 
C57BL/10ScSn-Dmdmdx (mdx, a mouse model of Duchene muscular dystrophy), and 
C57BL/10 control mice (BL10). The mdx mouse model has weaker plasma membranes 
(Straub et al., 1997) and it was hoped this would improve uptake of constructs into the 
muscle tissue following electroporation and improve localisation detection since GFP 
was not visualised in the initial electroporation attempts in BL10.  
Three initial attempts of electroporation experimentation used only GFP and GFP-
ANO5, as it was hoped the GFP marker would be sufficient to detect successfully 
electroporated fibres. However successfully electroporated fibres could not be 
distinguished from normal fibres as the level and non-specific pattern of fluorescence 
was unchanged across the muscle sections. Additionally, the same non-specific pattern 
was observed in non-electroporated control muscle. Immunofluorescent staining for the 
GFP marker using an anti-GFP antibody was attempted, to improve detection of GFP-
positive fibres but this yielded the same non-specific patterns of fluorescence as 
previous attempts. Additional controls were therefore included in the fourth round of 
electroporation. 
ANO5-MycHis was included in an attempt to use the Myc tag as a second method of 
identifying ANO5 localisation. Additionally, GFP and ANO5-tagged constructs were 
co-electroporated with mini-dystrophin constructs (Meng et al., 2016; Reza et al., 2016), 
which had been detectable following immunofluorescent staining in previous 
electroporation experiments (Mojgan Reza, unpublished data). Dystrophin is absent 
from the cytoskeleton of muscle fibres of mdx mice (Hoffman et al., 1987). 
Successfully electroporated mini-dystrophin constructs restore dystrophin to muscle 
fibres and were therefore used in these experiments as an indicator of successfully 
electroporated muscle fibres. Comparison of serially sectioned haematoxylin and eosin 
stained electroporated mdx muscle were used to identify the injection site in each 
condition (Figure 3.14). The site of injection was approximated by identifying signs of 
muscle repair from morphological features. 
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Figure 3.14 Haematoxylin and eosin staining of electroporated mdx mouse muscle sections. 
Electroporated constructs and unelectroporated control are indicated. miniDMD indicates 
mini-dystrophin electroporated tissue. Squares indicate the areas of further investigation 
displayed in Figure 3.15 and Figure 3.16 (White = identified injection site in electroporated 
muscle; Orange = chosen area of comparison in unelectroporated control). All images taken at 
x5 magnification (scale bar = 200µm). Biological N = 4. Technical N = 1. 
3.7.3 IHC Staining of electroporated mouse muscle 
Fluorescent Immunohistochemistry (IHC) staining was used to identify clusters of 
dystrophin-positive fibres near these sites of injection. The corresponding locations in 
the serial sections immediately following positively identified sections were then 
investigated for GFP or Myc fluorescence using additional IHC staining. 
Unelectroporated controls were also investigated in this way, using dystrophin-positive 
revertant fibres as controls to compare GFP and Myc tag detection against. Revertant 
fibres are fibres in which the loss of dystrophin has been naturally overcome and 
dystrophin is therefore visible following staining (Hoffman et al., 1990). 
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At x20 magnification there was no detectable difference in the green fluorescence 
between dystrophin-positive and dystrophin-negative fibres in either GFP-ANO5 or 
GFP-electroporated muscle (Figure 3.15). However, there appeared to be co-localisation 
of GFP and anti-GFP stain fluorescence in GFP electroporated muscle when viewed at 
x63 magnification. In GFP-ANO5 muscle a very faint fluorescence was observable but 
was not different to that seen in the surrounding dystrophin negative fibres. Furthermore 
this same fluorescence was also present in unelectroporated mdx muscle in fibres 
identified as dystrophin-positive (Figure 3.15). 
Similarly, at x20 magnification in ANO5-MycHis electroporated muscle no obvious 
fluorescence was observed in dystrophin-positive fibres above that of surrounding 
dystrophin negative fibres. But at x63 magnification, a fluorescence pattern of internal 
localisation was observed, which is consistent with that expected from endoplasmic 
reticulum localisation. In secondary only controls this patterning is not seen (Figure 
3.16). However the same pattern of fluorescence is also seen in dystrophin-positive 
fibres of unelectroporated muscle stained for the Myc tag. This pattern of fluorescence 
is not seen in dystrophin negative fibres or in secondary antibody only stained sections 
of unelectroporated muscle (Figure 3.16).  
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Figure 3.15 Immunofluorescent images of mdx mouse TA muscle electroporated with GFP and 
GFP-ANO5. Row headings indicate electroporated constructs and unelectroporated controls, 
column heading indicate primary antibodies and secondary only conditions. miniDMD 
indicates mini-dystrophin electroporated tissue. Alexa fluor 594 secondary antibody was used 
for both anti-GFP and anti-DMD primary antibodies. Arrows indicate the dystrophin-positive 
fibres of interest in each condition. All images are taken at x20 magnification, (scale bars = 
50µm) except where indicated as taken at x63 magnification (scale bars = 20µm). Biological N 
= 3. Technical N = 1.  
 104 
 
Figure 3.16 Immunofluorescent images of mdx mouse TA muscle electroporated with ANO5-
MycHis. Row headings indicate electroporated constructs and unelectroporated controls, 
column heading indicate primary antibodies and secondary antibody  only conditions. 
miniDMD indicates mini-dystrophin electroporated tissue. Alexa fluor 594 secondary was used 
for anti-DMD primary antibody, while alexa fluor 488 secondary antibody was used for anti-
Myc primary antibody. Arrows indicate the dystrophin-positive fibres of interest in each 
condition. All images are taken at x20 magnification, (scale bars = 50µm) except where 
indicated as taken at x63 magnification (scale bars = 20µm). Biological N = 2. Technical N = 1.  
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3.8 Discussion 
None of the Abmart ANO5 antibodies detected overexpressed anoctamin 5 in either 
Western Blot or IF experiments and as such were deemed sub-optimal for further 
experimentation. High background produced by Western Blotting of the first batch of 
antibodies, even highly diluted, was most likely due to the method of production and 
insufficient filtering and clean-up of the antibodies. Additional cleaning and filtering of 
the antibodies was not attempted as the high viscosity of this batch of antibodies made 
them very difficult to work with and it was hoped a second batch of antibodies would be 
more reliable.  
The second batch of antibodies was easier to work with and had reduced background 
allowing for detection of the same multiple bands by several of the antibodies. However 
all of these bands were smaller than the predicted molecular weight of ANO5 
(~107kDa), suggesting that these antibodies could be unspecifically binding, especially 
the small ~62kDa band detected in both HeLa and HEK lysates. However, as the two 
bands at ~40 and 37kDa were only detected in transfected HeLa cell lysates, an 
alternative explanation for these bands may be that they are remnants of overexpressed 
ANO5 constructs being broken down and removed from the cell. Failure to detect 
overexpressed ANO5 by IF is likely due to the antibodies failing to detect the correct 
epitope tag, as the fluorescence of positively transfected cells, indicated by GFP and 
Myc fluorescence, was no higher than that of the surrounding untransfected cells.  
The failure to identify a workable ANO5 antibody is not unexpected as the 
identification of a suitable anoctamin 5 antibody has eluded the research and clinical 
fields for several years. An explanation for this may be that while anoctamin 5 is the 
most highly expressed anoctamin in skeletal muscle its expression at the cellular level 
may be highly dependent on specific stimuli acting on the cell, for example induction of 
scramblase activity (Suzuki et al., 2013). Alternatively, it may be that identification of a 
suitable specific epitope for anoctamin 5 is hindered due to cross reactivity with the 
closely related anoctamin 6 also present in the same tissues.  
In vitro results using Myc-tagged ANO5 suggest that anoctamin 5 localises to the 
endoplasmic reticulum in MIN6 cells and the endosomes in NIH 3T3 cells, indicated by 
positive BIN-1 staining. These findings are consistent with reports of ANO5 
localisation in the literature (Tsutsumi et al., 2004; Mizuta et al., 2007). Anoctamin 5 
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also partially localises to the t-tubules in both undifferentiated and differentiated 
myoblasts, a finding not previously described.  
This finding is of interest given that the related anoctamins ANO1 and 2, have been 
described as calcium activated chloride channels and that proper action potential 
generation in the t-tubules are vital for correct muscle contraction. However anoctamin 
5 has not yet been found to produce an action potential in the presence of calcium, even 
when modified to include the current forming loop present in ANO1 (Duran et al., 
2012). Similarly, robust chloride conductance has not been recorded in the other 
anoctamin family members other than ANO1 and 2, though some have been found to 
function as other ion transporters (Schreiber et al., 2010; Yang et al., 2012; 
Kunzelmann et al., 2014). Therefore anoctamin 5 may be functioning as a channel for 
another ion in the t-tubules. 
Finally, it was hoped that in vivo investigation of electroporated mdx muscle would 
characterise anoctamin 5 localisation in whole tissue, complementing the previous in 
vitro localisation results. From this work, further routes of investigation of the function 
of anoctamin 5 could be conducted. Unfortunately due to the poor signal to noise ratio 
of the stained muscle sections, it was not possible to accurately distinguish true signal of 
tagged ANO5 constructs from background and thereby definitively determine ANO5 
localisation.  
While electroporation experimentation has worked well for other members of this 
research team before, in this instance it was unsuccessful. Due to these previous 
successes, it is therefore unlikely to have been the technique which was at fault. A 
possible explanation is that while the tagged constructs work well in vitro, it may be 
that in vivo these constructs are rapidly broken down and their signal lost amongst the 
autofluorescence of the muscle. While there is no direct evidence in the literature to 
support this exact notion, electroporation success and construct retention time within 
mouse muscle have been found to be affected by factors such as the size of the construct, 
the co-injection of chemicals to increase membrane permeability (such as hyaluronidase) 
and even the strain of the mouse (Molnar et al., 2004).  
Furthermore, Scudieri et al. (2015) suggest that adding tags to constructs can alter their 
localisation. In their paper investigating ANO6 function, the authors suggest this is as 
an explanation for the conflicting reports of ANO6 localisation. It is therefore possible 
that the Myc tag has affected ANO5 expression, changing its localisation in culture, 
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altering its electroporation efficiency and potentially reducing the retention of the 
constructs within mouse muscle. Further optimisation of this experimentation may yet 
yield positive identification of anoctamin 5 localisation. As localisation was only one 
facet of this project, other routes of investigation were instead followed. 
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Chapter 4 Investigation of proteins affected by the knockdown of 
ANO5 in C2C12 cells using 2-Dimensional gel electrophoresis 
4.1 Introduction 
Identifying that anoctamin 5 localises to the endoplasmic reticulum, and possibly to the 
t-tubules, in the previous chapter suggests that anoctamin 5 may be involved with 
calcium homeostasis (Doutheil et al., 2000) and proper protein folding (Hebert and 
Molinari, 2007). However, precise identification of the function of ANO5 at either the 
cellular or biochemical level is limited by the lack of an antibody and an ANO5 
deficient model system. Despite concerted efforts, the former deficiency has not been 
remedied. 
Lacking access to an animal model of anoctaminopathy, an anoctamin 5 deficient 
cellular model is required. Knockdown of anoctamin 5 was achieved in C2C12 cells 
(mouse myoblasts) using a pool of short hairpin RNAs (shRNAs) and validated by 
reverse transcription PCR (rtPCR). A Control knockdown line was generated in tandem 
using scrambled shRNAs to confer the same antibiotic resistances and experimental 
pressures but without affecting gene expression. The anoctamin 5 model was then 
characterised using 2D gel electrophoresis to better understand what effect, if any, 
removing anoctamin 5 has on other proteins.  
In this chapter the results of the stable knockdown C2C12 generation are presented. The 
differences in protein expression between the generated clones were subsequently 
explored using 2D gel electrophoresis, the identified proteins confirmed by Matrix 
Assisted Laser Desorption/Ionisation tandem Mass Spectrometry (MALDI MS/MS) and 
western blotting and then investigation of the identified proteins carried out with 
reference to what their change implies about anoctamin 5 function. 
4.1.1 MALDI-MS/MS analysis and identification of proteins 
Mass spectrometry (MS) has long been a robust method of identifying and quantifying 
the isotopic signature, mass and molecular structure of a sample by analysing the mass-
to-charge ratio of ions excited from that sample (Wolff and Stephens, 1953). Matrix 
assisted laser desorption/ionisation (MALDI) mass spectrometry is one variety of mass 
spectrometry commonly used to identify biomolecules such as proteins (Karas et al., 
1987).  
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In MALDI MS, the “matrix” is typically a crystallised acid which is mixed with the 
sample and solubilised in water and an organic solvent (to solubilise the hydrophobic 
elements of the sample). This solution is then applied to a metal plate where the water 
and organic solvent are evaporated to leave a thin, optically homogenous, crystallised 
layer containing both the matrix and the sample to be analysed (Karas et al., 1987). This 
thin layer of the matrix/sample is then irradiated with a pulsed laser causing ablation of 
the matrix from the plate and formation of a gas in which the sample molecules are 
ionised (Karas et al., 1987). The ionised molecules can then be accelerated and analysed 
using the chosen method of MS.  
Typically, MALDI MS measures the time of flight (TOF) of excited ions in an electric 
field of known strength over a given distance (e.g. from the point of excitation to the 
detector) (Figure 4.1). These measurements are used to calculate the ion’s mass-to-
charge ratio (Wolff and Stephens, 1953). The accuracy of MS analysis to identify any 
particular protein from a complex mixture can be increased, whilst also retaining the 
same level of sensitivity and speed, by using MS machines in series. This process is 
known as tandem mass spectrometry (MS/MS) and involves using a second round of 
MS to generate a subpopulation of ions from each of the initial ions excited from the 
sample (McLafferty and Bockhoff, 1978; McLafferty, 1981).  
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Figure 4.1 Simplified diagram of MALDI MS/MS process. Representations of different 
molecules contained within the matrix are shown as variously coloured shapes. Following 
excitation by laser pulses and acceleration from the field generators, the molecules move at 
different speeds towards the first and second detectors, which then indicates their relative mass 
to charge ratios. 
Samples prepared as part of this project, as well as the internal controls serotransferrin 
and bovine serum albumin, were analysed by MALDI-MS/MS by the contract research 
organisation Alphalyse in Denmark. Alphalyse reduced the provided 2D gel 
electrophoresis spots into individual peptide sequences, concentrated them on a ZipTip 
micropurification column and deposited onto an anchorship target for analysis using a 
Bruker Autoflex Speed MALDI TOF/TOF instrument. Partial sequencing was carried 
out using 15 peptides obtained from the initial reduction of the provided protein 
material. The mass spectrometry analysis software, Mascot, was then used to compare 
the resulting data against in house Alphalyse databases compiled from UniProt and 
NCBI sources. A probability scoring algorithm was then used to identify the most 
significant non-homologous corresponding protein. The results reported and discussed 
in this chapter are from their analysis using this process.  
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4.2 ANO5 knockdown C2C12 generation 
In this chapter, a stable ANO5 knockdown C2C12 line was established using ANO5 
targeting shRNAs and the effects of ANO5 deficiency at the cellular level characterised 
using 2D electrophoresis, MALDI MS/MS and western blotting. In the following 
chapter, results from investigation of ANO5 function as a phospholipid scramblase will 
be reported using the same generated ANO5 knockdown C2C12 clones.  
4.2.1 Cell culture, shRNA transfection and selection 
ANO5 specific short hairpin RNAs (shRNA) consisting of a pool of three plasmids, 
each with different complementary sense and antisense sequences (Table 4.1), were 
transfected into C2C12 cells to generate an ANO5 knockdown line. Two other separate 
cultures of C2C12 cells were also transfected with Control shRNA, containing a 
scrambled sequence, or the GFP construct described in the previous chapter. C2C12 
cells were seeded into twelve 100mm tissue culture dishes (5 plates treated with ANO5 
shRNA, 5 plates with Control shRNA, 2 plates with GFP) and transfected with shRNA 
Plasmid Transfection Reagent (sc-108061). 
All shRNA plasmids contained puromycin resistance, allowing for selection of 
transfected clones after 10-12 days treatment with selection media. Selection media was 
replaced daily and tissue culture dishes were checked for clone formation. GFP cells 
lacked puromycin resistance and so were used as a selection control. All GFP cells were 
dead within approximately 3 days post transfection.  
Cloning cylinders and trypsin cell dissociation media were used to pick stable clones 
and transfer them to individual wells of a 24 well plate. A total of 49 clones were picked 
from dishes (23 clones from ANO5 plates, 26 clones from Control plates). Cells 
continued to be cultured in selection media, using PBS washes, trypsin dissociation, 
centrifugation and reseeding cycles to transfer cells to larger tissue culture plates, until 
cells occupied all wells of 6 well plates. Twenty four clones survived to this stage (14 
ANO5 clones, 10 Control clones). Half of the cells of each clone were then resuspended 
in Cell Recovery Freezing Medium and stored at -80°C, while the other half were 
seeded into a new 6 well plate for differentiation and RNA extraction. All 24 clones 
survived selection to the differentiation and RNA extraction phase. 
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shRNA Name Hairpin Sense Antisense 
sc-154403-SHA GATCCCTGATATGCCA
GTTAGTAATTCAAGAG
ATTACTAACTGGCATA
TCAGTTTTT 
CUGAUAUGCCAG
UUAGUAAtt 
UUACUAACUGGC
AUAUCAGtt 
sc-154403-SHB GATCCGAACTATCGTG
TTACTGTTTTCAAGAG
AAACAGTAACACGATA
GTTCTTTTT 
GAACUAUCGUGU
UACUGUUtt 
AACAGUAACACG
AUAGUUCtt 
sc-154403-SHC GATCCCATCTGGAGTA
GACATATATTCAAGAG
ATATATGTCTACTCCA
GATGTTTTT 
CAUCUGGAGUAG
ACAUAUAtt 
UAUAUGUCUACU
CCAGAUGtt 
Table 4.1 Sequences of pooled shRNA used to knockdown ANO5 in C2C12. The “Hairpin” 
column indicates the sequences of each of the three shRNA’s used to knockdown ANO5. The 
“Sense” and “Antisense” columns indicate the specific sequences used to form the hairpin. 
4.2.2 Knockdown validation using differentiation and rt-PCR of selected C2C12 clones 
ANO5 expression is upregulated in C2C12 following myogenic differentiation into 
myotubes but is lowly expressed in undifferentiated C2C12 (Tsutsumi et al., 2005). 
Therefore to validate the knockdown of the C2C12 cells, RNA was extracted from both 
Day 0 myoblasts and Day 7 differentiated myotubes for each clone. Upon reaching ~70-
80% confluency in each well of a 6 well plate, clones were imaged and half the cells 
trypsinised, pelleted and stored at -80°C for later Day 0 (D0) time point RNA extraction. 
The remaining cells were differentiated and imaged at D3, D5 and D7 time points to 
track differentiation progression. These results show that a total of eight clones from 
both the ANO5 and Control knockdown C2C12 (four clones in each shRNA condition) 
form myotubes following 7 days of differentiation (Figure 4.2).   
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Figure 4.2 D7 time point differentiation of all ANO5 knockdown, Control knockdown and 
wildtype C2C12 clones. Four clones from each knockdown condition successfully produce 
myotubes following differentiation, indicated by white underlined labels; Control knockdown 
clones CON-2C, CON-2E, CON-5B and CON-5C; ANO5 knockdown clones ANO5-1A, ANO5-
1C, ANO5-4A and ANO5-5C. All images are taken at x10 magnification (scale bars = 100 um). 
Biological N = 25. Technical N = 1.  
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Figure 4.3 Electrophoresis gels of PCR products from undifferentiated and differentiated ANO5 
and Control knockdown C2C12 clones. Clone IDs are indicated above each pair of PCR 
product; D0 samples in the first lane of each pair and D7 samples in the second lane. Bold and 
italicised clone IDs indicate ANO5 and Control knockdown clones chosen for future 
experimentation. Due to primer design, all bands are ~500bp in size. Biological N = 25. 
Technical N = 1. 
At the D7 time point, cells were trypsinised, pelleted and stored at -80°C for RNA 
extraction using Trizol. Paint Pellet was used to assist in recovery of the RNA pellet 
during isopropanol precipitation. The RNA pellet was resuspended in 30 µl nuclease 
free water before quantification using a Nanodrop and cDNA synthesis in a LabCycler 
PCR machine. Generated cDNA was then amplified using ANO5 and GAPDH primers 
in a standard PCR reaction and visualised on 1% agarose gel under a BioSpectrum Gel 
Doc-It (Figure 4.3).  
GAPDH controls run for each cDNA produced bands of the expected size (~500bp) in 
each clone and at each time point (Figure 4.3). This confirms that the cDNA for each 
time point sample had not been degraded and that the reverse transcription reaction was 
successful. PCR of the cDNA generated from the RNA of the D0 time point showed 
that, as expected, no bands appeared at this time point in any clone for either ANO5 or 
Control shRNA treatment. The D7 time point of three Control clones produced bands of 
the expected size (~500bp) suggesting that these were stable clones with no knockdown 
(Figure 4.3). These clones have therefore been selected as controls for future 
experimentation. Apart from a single clone (designated ANO5-1A), no bands were 
visible for the D7 time points for the ANO5 knockdown clones. This suggests that these 
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clones were successful stable ANO5 knockdown clones. The very faint band at the D7 
time point for ANO5-1A suggests that it is a potential partial knockdown clone (Figure 
4.3).  
However, during differentiation series both ANO5 and Control myoblasts differentiated 
poorly, forming very few myotubes or none at all (Figure 4.4). This is either due to the 
effects of prolonged selection pressure on the myoblasts or due to a loss of 
differentiation ability in the initial stock of C2C12 myoblasts before the knockdown 
process began. In either case, the three ANO5 knockdown C2C12 clones which showed 
the best differentiation were chosen for further functional experimentation (Figure 4.4). 
As a result ANO5-1A was also included in later experimentation.  
The aim of this process was to generate a cellular knockdown model which closely 
replicated anoctaminopathy patient myoblasts as much as possible. However, the 
inconsistencies in differentiation ability of the generated myoblasts meant that further 
organelle fractionation, proteomics and functional experimentation would be carried out 
on undifferentiated myoblasts rather than myotubes. By doing so though, inherent 
differences seen between differentiating, proliferating and repair committed muscle cell 
populations can be avoided (Meola et al., 1991; Gross and Rotwein, 2013). For example, 
it has been shown that the terminal function of satellite cells (Mauro, 1961), muscle 
specific stem cells which assist in repairing damaged tissue (Partridge et al., 1978), are 
strongly influenced by factors influencing the parent population (Gross and Rotwein, 
2013). While the clones generated as part of this project will not exactly replicate 
patient systems, the shared linage and consistent treatment of the clones should increase 
the validity of observed results.  
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Figure 4.4 Differentiation series of selected ANO5 knockdown, Control knockdown and wild 
type C2C12. Columns from left to right show representative micrographs of C2C12 
differentiation progression (undifferentiated, D3, D5 and D7 time points). All images are taken 
at x10 magnification (scale bars = 100 um). Biological N = 7. Technical N = 1.  
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4.3 Subcellular fractionation by differential centrifugation of ANO5 and Control 
knockdown C2C12 
To reduce the complexity of the protein extracts when comparing spots between gels, 
crude subcellular fractionation was first applied to C2C12 lysates to separate the cellular 
components into nuclear, mitochondrial and cytoplasmic fractions. The subcellular 
fractionation protocol developed by Dimauro et al. (2012) (Section 2.7.2, Figure 2.2) 
was used for these experiments. This protocol relies on the differential sedimentation 
times of the various compartments during ultra-centrifugation in density media to 
separate proteins into nuclear, mitochondrial and cytoplasmic subcellular fractions. 
STM buffer was used throughout the protocol rather than detergent based lysis buffers, 
to reduce degradation to the proteins. For simplicity, ANO5-4A and CON-2C 
knockdown clones were chosen for 2D gel analysis comparison as these clones grew 
well in culture, differentiated well and were confirmed to be ANO5 negative and 
positive by rt-PCR respectively. 
  
 119 
4.3.1 2D gel electrophoresis 
The three fractionated lysates made using this crude subcellular fractionation 
(mitochondrial, nuclear and cytoplasmic) were run out using 2 dimensional (2D) 
electrophoresis using the ZOOM runner IPG system. To minimise experimental 
variability, each first dimension IPG strip was run at the same time, while second 
dimension ZOOM gels were prepared and run in pairs of one knockdown and one 
control sample before subsequent Coomassie staining and visualisation. 
4.3.2 Visualisation of protein spots 
Coomassie stained 2D gels were imaged using an Odyssey CLx. Test images were 
taken to ensure the gels were fully within the scanning area of the Odyssey before 
scanning in the 700 nm spectrum. This spectrum was used at it would accurately detect 
the blue dye of the Coomassie staining.  
The results of these gels show that the subcellular fractionation protocol does reduce the 
complexity of the proteins present in each lysate (Figure 4.5). The mitochondrial 
fraction shows the fewest protein spots, with just over ten spots visible on the scanned 
image of the gel. The majority of these spots are between 36.5 and 97.4 kDa in weight 
but are spread across the pH gradient of the IPG strip. Both the nuclear and the 
cytocolic fractions show more protein spots, across a much wider range of molecular 
weights. Interestingly though, in the nuclear fraction, a clear stopping point for the 
proteins appears just over halfway across the IPG strip, visible as protein spots all 
congregating at roughly the same place vertically in the gel at all molecular weights. 
While the precise pH of the strip at this point is not known, as each IPG strip was 
always orientated in the same direction in the ZOOM gel, this is the end that moved 
towards the cathode and is therefore the more acidic end of the IPG strip (pH 8-10). No 
protein spots are found past this line suggesting that either no proteins in this fraction 
are found at high pH or that more likely, that none are able to pass the proteins that have 
migrated to this point. It is possible a barrier of, for example, DNA or polysaccharides 
has formed at this particular pH. Both can clog the gel pores and effect the overall 
success of IEF at the acidic end of the gel (Berkelman, 2008). 
Of the three lysates the cytoplasmic fraction retains the majority of protein spots. These 
spots are clearly distinguishable from one another though there are a range of intensities 
among the spots indicating that some proteins differ in their expression levels within the 
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cytoplasmic fraction of wild type C2C12. Furthermore there are several examples of 
bright spots located very close to one another along a horizontal axis, appearing almost 
like a string. These spots all have very similar molecular weights but have different 
isoelectric points. These spots are likely phosphorylated forms of the same protein or 
isoforms of the same protein. The molecular differences between phosphorylated 
proteins mean that on a 2D gel they might appear with the same molecular weight but 
different isoelectric points, such as those seen in these gels. 
As anoctamin 5 has been suggested to localise to the ER in the literature (Tsutsumi et 
al., 2004; Mizuta et al., 2007) as well as ER and t-tubules in earlier localisation 
experiments, only the cytosolic fraction was used to investigate spot differences 
between ANO5 knockdown and Control knockdown C2C12 lysates.   
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Figure 4.5 Coomassie stained 2D gels of nuclear, mitochondrial and cytosolic subcellular 
fractions of wild type C2C12. The streaking of spots seen on the right hand side of the cytosolic 
fraction were caused by an air bubble between the IPG strip and the gel and are not replicated 
on subsequent gels run with the same lysate fraction. Gels were Coomassie stained and then 
imaged in the 700nm fluorescence range on a Li-Cor Odyssey CLx infrared imaging system. 
Biological N = 3. Technical N = 1.  
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4.4 2D gel electrophoresis of ANO5 knockdown, Control knockdown and wild type 
C2C12 cytosolic fractions 
Triplicate 2DE gels of ANO5-4A and CON-2C lysates were run to accurately confirm 
differences in the spot populations of gels. Biological, experimental and analytical 
variability inherently exist within 2DE experimentation and several steps were taken to 
limit the effect of this variability in these experiments (Choe and Lee, 2003; Zhan and 
Desiderio, 2003; Bland et al., 2006; Bland et al., 2010). For example, to reduce 
biological variability enough lysate was fractionated and prepared at the same time to 
run multiple gels from each lysate. To reduce experimental variability, IEF of IPG strips, 
SDS PAGE runs of the second dimension and staining steps were run concurrently on 
samples.  
No spot identification software was used to identify spot differences; instead gels were 
compared side by side and differences in the gels noticed by eye. Comparison by eye 
was achieved by comparing “constellations” of spots for similarities in patterns. For this, 
spots with consistent locations across all the replicate gels were used as points from 
which to check the other spot locations in each gel. 
Four spot differences were consistently identified in all three gel replicates (Figure 4.6). 
Spots labelled as A, B and C, were identified as having increased intensity on the ANO5 
knockdown C2C12 lysate while spot D was absent from the ANO5 knockdown gel. 
These spot differences were found at different molecular weights and pH ranges, though 
three of them (indicated by arrows A, B and D) were located on the side of the gel 
nearest the ladder, indicating that they were within the more acidic pH range of the IPG 
strip. Spot A is ~37 kDa, spot B is 2~3 kDa, spot C is ~56 kDa and spot D is ~7kDa. 
Spot C is present as several spots along the horizontal axis suggesting that this protein 
may be phosphorylated or post-translationally modified in some way. It is the only 
identified spot to show this patterning.  
A fourth gel was then run for each cell line for excision of the corresponding spots for 
MALDI MS/MS. The three spots consistently identified as present or absent on the 
ANO5 knockdown C2C12 gels (spots A, B and D), along with an additional control 
spot consistently present on both gels (spot E), were excised from 2-D gels and sent to 
Alphalyse in Denmark for MALDI MS/MS analysis.  
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However the fourth spot identified in the triplicate gels (spot C) was not present on the 
fourth ANO5 knockdown lysate gel and so could not be sent for mass spectrometry 
analysis and identification. An error in experimental reproducibility may be an 
explanation for the disappearance of this spot. While the first triplicate gels were all 
prepared at the same time (i.e. the IPG strips all run through IEF first dimension at the 
same time) the fourth set of gels were prepared separately. It is unlikely to be an error in 
biological reproducibility as for each cell line, the fourth gel was from the same 
biological replicate as the third gel.   
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Figure 4.6 Coomassie stained 2D gels of cytosolic fractions of ANO5 and Control knockdown 
C2C12. Lettered arrows indicate protein spots consistently identified as differentially expressed 
between replicate gels, except for E which is a control spot which was consistently unchanged 
across replicates. Both gels shown are the third replicates of triplicate gels run for each 
knockdown C2C12 line. Gels were Coomassie stained and then imaged in the 700nm 
fluorescence range on a Li-Cor Odyssey CLx infrared imaging system. Biological N = 2. 
Technical N = 4.  
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4.5 MALDI-MS/MS identification and western blot validation of protein spot 
differences 
4.5.1 Alphalyse MALDI MS/MS analysis 
Spots identified with consistent differences in intensity between Control and ANO5 
knockdown gels were excised from Coomassie stained 2DE gels run using the method 
described in Section 2.9, only with the addition of being carried out in a Safelab 
Systems class 1 fume hood, to reduce the collection of contaminants on the gel. Spots 
excised from these gels were collected into separate Eppendorf tubes and treated with 
500µl of distilled deionised water to keep the samples hydrated during shipping. 
Samples were then sent to the contract research organisation Alphalyse in Denmark for 
MALDI MS/MS analysis. 
Alphalyse identified the spots as Annexin A2 (ANXA2, spot A), Heat shock protein 
beta 1 (Hsp27 spot B) and S100-A4 protein (S100-A4, spot D) (Table 4.2). The control 
spot from both gels also sent for analysis was identified as Galectin-1 in both cases 
(spot E). The majority of the molecular weights of these identified proteins are 
consistent with the sizes of the spots from the gels (ANXA2 = 38 kDa, Hsp27 = 23 kDa, 
S100-A4 = 7 kDa), though Galectin-1 has a larger predicted molecular weight than that 
observed on the gel (predicted molecular weight = 15 kDa, observed molecular weight 
~14 kDa).  
Additionally, there is a range in the sequence coverage (“Seq.cov”) and “Scores” values 
between each of the identified proteins. The “Seq.cov” values are the percentage of 
coverage achieved by the sample sequence when compared against the identified 
protein in the databases. These values are not used to confirm protein identity but rather 
are used as internal controls. The “Scores” value, or Mascot Score, for a protein is the 
logarithmic, statistically significant score for how well the peptides identified in the 
supplied protein spot match with the peptides in the comparison database. A mascot 
score of more than 90 indicates that, when compared to the nrbd protein database from 
NCBI, the confidence that the protein has been positively identified is above 95% 
significance and so can be positively identified as that protein. 
The protein with the lowest significance score is S100-A4 (Score = 188). However as 
the percentage sequence coverage (Seq. cov. = 25%) is greater than the sequence 
coverage of BSA (Seq. cov. = 24%), one of the internal control samples, and as the 
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significance score is still well above the level of significance allowed by Alphalyse, it 
can still be assumed that S100-A4 is the most likely protein identity for spot 3. 
The protein with highest significance score and the highest sequence coverage is 
ANXA2 (Score = 570, Seq. cov = 57%) and so this spot is assumed to be the identified 
protein.  
Hsp27 has a fairly high percentage sequence coverage (Seq. cov. = 53%) but has the 
second lowest significance score of all the identified proteins (Score = 252). Again 
though, this is well above the significance scores allowed by Alphalyse and so is the 
most likely protein identifiable using this identification method. 
Sample Name 
Protein found in 
Database Gene Name Calculated MW Score Seq. cov. 
AB2-A Annexin A2 Anxa2 38937 570 57% 
AB2-B 
Heat shock protein 
beta-1 
Hspb1 23057 252 53% 
AB2-E Galectin-1 Lgals1 15198 473 55% 
CB2-D Protein S100-A4 S100a4 11942 188 25% 
CB2-E Galectin-1 Lgals1 15198 327 55% 
1pmol 
transferrin 
Serotransferrin TF 79294 929 51% 
62 fmol BSA Serum albumin ALB 71244 479 24% 
Table 4.2 Proteins identified by MALDI MS/MS analysis by Alphalyse. “Sample name” refers to 
the name of sample provided to Alphalyse; AB2 or CB2 refers to the gel while the final letter 
indicates the specific excised spot. “Protein found in database” refers to the details of protein 
in SwissProt database identified by MALDI MS/MS. “Gene Name” refers to the name of the 
gene for the protein as found entered on the SwissProt database. “Calculated MW” refers to 
the molecular weight. “Score” refers to the Mascot Score, the logarithmic, statistically 
significant score for how well the peptides identified in the supplied protein spot match with the 
peptides in the comparison database. A mascot score of more than 90 indicates that, when 
compared to the nrbd protein database from NCBI, the confidence that the protein has been 
positively identified is above 95% significance. “Seq. cov.” refers to the percentage of peptide 
sequence which matches to sequence found in SwissProt database.  
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4.5.2 2D gel western blot confirmation of MS/MS identified proteins 
To confirm that spots A, B and D were the proteins identified by MALDI MS/MS, 
triplicate 2D western blots were carried out using the standard 2D Gel Electrophoresis 
protocol described in Section 2.9 with the addition of protein transfer and 
immunoblotting (Sections 2.10.3 and 2.10.4) following SDS PAGE. Antibodies specific 
for ANXA2 (ab41803), Hsp27 (ab2790) and S100-A4 (ab93283) were used to probe 
western blots of 2D gels run with the same ANO5 knockdown and Control knockdown 
cytosolic fraction lysates (Figure 4.7, Figure 4.8 and Figure 4.9). Anti-GAPDH 
antibodies (D16H11 and ab8245) were used as positive loading controls in these 
experiments. 
ANO5 knockdown and Control knockdown blots probed with Hsp27 and S100-A4 are 
negative for both proteins (Figure 4.7 and Figure 4.8 respectively). Initially this was 
thought to be because of a low abundance of the proteins on the gel and so the images 
were overexposed in an attempt to visualise any lowly expressed spots. However, no 
other spots could be visualised on these blots in this fluorescence channel. Positive 
detection of GAPDH on Hsp27 and S100-A4 blots confirmed that it was the Hsp27 and 
S100-A4 antibodies that were failing to detect the specific proteins rather than 
degradation of the lysates or failure of the transfer during the blotting procedure. 
Western blotting using the ANXA2 antibody was successful as several spots are 
visualised with this antibody (Figure 4.9). Furthermore there is a difference in the spot 
patterns between the blots for the ANO5 knockdown and Control knockdown lysates. In 
both knockdown and Control blots there is a spot with a molecular weight of 
approximately 38 kDa (arrow 1), consistent with the molecular weight of ANXA2 and 
the position of the spot sent to Alphalyse for identification. In the ANO5 knockdown 
lysate blot this spot has an increased intensity compared to the corresponding spot in the 
Control knockdown blot (Figure 4.9). 
Probing both knockdown and Control blots with the ANXA2 antibody revealed two 
additional spots; one at approximately 50kDa (arrow 2) and the other at approximately 
16 kDa (arrow 3). However both of these spots have a much smaller expression in the 
ANO5 knockdown blots than the corresponding spots in the control knockdown blot. In 
the case of the heavier spot (arrow 2) on the ANO5 knockdown blot, it is very faint (and 
on one of the triplicate blots, it was completely absent). The lighter spot (arrow 3) on 
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the Control knockdown covers a wide pH range while it occupies a restricted range on 
the ANO5 knockdown blot. 
These differences in spot intensities were consistently observed across triplicate blots. 
The precise identities of these additional spots are not known, but given that they are 
detected by the ANXA2 antibody, they may potentially be modified versions of 
ANXA2. These results ultimately suggest though that the knockdown of anoctamin 5 in 
C2C12 affects the expression of annexin A2.   
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Figure 4.7 2D gel western blots of ANO5 and Control knockdown C2C12 probed with Hsp27 
and GAPDH antibodies. No green fluorescence is observed in either blot suggesting that the 
Hsp27 antibody is unable to detect the protein in these blots. Red fluorescence across the gel 
between 30-38 kDa indicates positive GAPDH staining. Blots were imaged in both the 700nm 
and 800nm fluorescence range on a Li-Cor Odyssey CLx infrared imaging system. Biological N 
= 2. Technical N = 1.
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Figure 4.8 2D gel western blots of ANO5 and Control knockdown C2C12 probed with S100-A4 
and GAPDH antibodies. No green fluorescence is observed in either blot suggesting that the 
S100-A4 antibody is unable to detect the protein in these blots. Red fluorescence across the gel 
between 30-38 kDa indicates positive GAPDH staining. Blots were imaged in both the 700nm 
and 800nm fluorescence range on a Li-Cor Odyssey CLx infrared imaging system. Biological N 
= 2. Technical N = 1.  
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Figure 4.9 2D gel western blots of ANO5 and Control knockdown C2C12 probed with ANXA2 
and GAPDH antibodies. Arrow 1 indicates the ANXA2 spot previously identified by MALDI 
MS/MS. Arrows 2&3 are unidentified spots consistently stained by the ANXA2 antibody across 
triplicate 2D gel western blots. Both spots are either diminished in intensity or entirely absent 
from ANO5 blots compared to the Controls. Green fluorescence across the gel between 30-38 
kDa indicates positive GAPDH staining. Blots were imaged in both the 700nm and 800nm 
fluorescence range on a Li-Cor Odyssey CLx infrared imaging system. Biological N = 2. 
Technical N = 3. 
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4.6 Western Blot investigation of identified spot proteins 
To further investigate the absence of Hsp27 and S100-A4 spots from the 2D gel western 
blots, SDS-PAGE western blotting was performed using lysates prepared in different 
buffers. The mini Bradford assay was used to first quantify protein concentration of 
lysates used for western blots. This protein quantification method was chosen to account 
for the high concentrations of urea in the solubilisation solution used to prepare the 
lysates for 2D electrophoresis. 
4.6.1 SDS-PAGE 
Hand poured, 15% gels (Section 2.10.1) were used to detect S100-A4 as the low 
molecular weight of the protein makes detection difficult on standard Bis-Tris gels. 
Hsp27 and Anti-GAPDH, again used as a positive loading control, were run on precast 
4-12% Bis-Tris gels. These western blots show that the antibodies do detect bands but 
that these bands are either the wrong molecular weight (Hsp27) or are only detected in 
specific lysis buffers (S100-A4) (Figure 4.10).  
The Hsp27 antibody detects a single band in all lysates of approximately 62 kDa, 
though the predicted size of Hsp27 is 23 kDa. The S100-A4 antibody detects bands of 
the correct size (12 kDa) but only in cytosolic fraction lysates suspended in STM buffer. 
Lysates prepared in Buffer A, an essential requirement for successful IEF in 2D gels, do 
not show bands. This suggests that the failure to detect spots using the S100-A4 
antibody may be due to the protein being altered by Buffer A during lysis in such a way 
as to make it undetectable. 
 133 
 
Figure 4.10 Western blot of cytosolic and whole cell knockdown and wild type C2C12 lysates 
probed with Hsp27, S100-A4 and GAPDH antibodies. The arrow indicates approximately 25 
kDa, the predicted size of Hsp27 and where bands were expected to be detected. To resolve the 
smaller S100-A4 protein the lower image displaying the S100-A4 bands are from a 15% gel. 
Blots were imaged in both the 700nm (red) and 800nm (green) fluorescence range on a Li-Cor 
Odyssey CLx infrared imaging system. Biological N = 8. Technical N = 1. 
Conversely, SDS-PAGE investigation of ANXA2 showed that differences in lysate 
preparation did not hinder this antibodies ability to detect the expected 38 kDa band in 
any lysate sample (Figure 4.11). Rather, the antibody detected multiple bands in all 
lysate preparations. The majority of these bands are not found on the 2D gels suggesting 
that these forms of ANXA2 do not migrate on the IPG during IEF. The spots that are 
present on the 2D gels are found in the bands of this western blot, though the intensities 
of the bands do not replicate the differences of the spot intensities seen in the 2D gels.  
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Figure 4.11 Western Blot of cytosolic and whole cell knockdown and wild type C2C12 lysates 
probed with ANXA2 antibody. A band at ~38 kDa, the expected molecular weight of ANXA2, is 
observed in all samples. Multiple other bands are also detected by the antibody though these 
are consistent between samples. Blot imaged in the 700nm (red) fluorescence range on a Li-Cor 
Odyssey CLx infrared imaging system. Biological N = 9. Technical N = 1.  
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4.7 Further investigation of identified proteins affected by ANO5 knockdown 
ANXA2 is expressed in several tissues and is known to form a heterotetrameric 
structure with S100-A10 (Bharadwaj et al., 2013). In this structure, two ANXA2 
proteins link to opposite sides of two S100-A10 proteins bound around a calcium 
molecule (Lewit-Bentley et al., 2000). One of the proposed functions of this 
heterotetramer is membrane fusion. It has been suggested that monomeric ANXA2 
proteins which are located within plasma membranes of opposing cellular vesicles or 
organelles are brought together via two S100-A10 proteins as a central anchor point 
(Rety et al., 1999). An additional feature of the resulting heterotetrameric structure is 
that it also increases the stability of S100-A10, preventing it from being disposed of via 
ubiquitin-mediated degradation (He et al., 2008). 
Several other annexins are also closely linked to other S100 proteins, for example 
ANXA1 and S100-A11 (Rety et al., 2000). Given the apparent relationship between 
annexins and S100 proteins, it is intriguing that two of these proteins are potentially 
altered in the cytosol of C2C12 cells when ANO5 is knocked down. 
4.7.1 Investigation of ANXA2 and S100-A4 colocalisation in wild type C2C12 
Colocalisation of ANXA2 and S100-A4 was investigated in wild type C2C12 using 
immunofluorescence staining to identify any potential link between the two proteins 
(Figure 4.12).  
These staining data show that the antibody directed against ANXA2 detects filamentous 
like structures running through the centre of C2C12 cells, including running through the 
nucleus of the cell (Figure 4.12 A., B. and E.). Other C2C12 which don't show these 
filamentous structures do still show some potential ANXA2 positivity in their nucleus, 
observed as purple signal in merged images of red (ANXA2) and blue (DAPI) 
fluorescence channels. This signal is however much fainter and may potentially be 
background produced by unspecific binding of the antibody.  
Very few C2C12 cells appear to be S100-A4-positive and only because “positive” cells 
had a marginally brighter green fluorescence than surrounding C2C12 (Figure 4.12). 
The pattern of staining is diffuse throughout the entire cytoplasm of the cell, with no 
clearly identifiable structures or organelle populations. From this pattern of staining it 
was concluded that this was background staining due to unspecific binding and that this 
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antibody could not sufficiently detect S100-A4 in immunofluorescence experiments. 
Furthermore, due to this insufficient detection, accurate co-localisation with ANXA2 
was not possible.  
The possibility of additional background due to co-staining with both antibodies was 
ruled out by running conditions which used both secondary antibodies but only one of 
the primary antibodies.  
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Figure 4.12 Co-localisation of S100-A4 and ANXA2 in wild type C2C12. “ANXA2” stained with 
anti-ANXA2 + alexa fluor 594 secondary antibody. “S100A4” stained with anti-S100A4 
primary antibody + alexa fluor 488 secondary antibody. “ANXA2+S100A4” co-stained with 
anti-S100A4 and anti-ANXA2 + alexa fluor 488 and 594 secondary antibody. “ANXA2+2nd” 
and “S100A4+2nd” stained with indicated primary antibody and both 594 and 488 secondary 
antibodies. “2nd” stained with both 594 and 488 secondary antibodies only. All images are 
taken at x20 magnification (scale bars = 50µm). Biological N = 4. Technical N = 1.  
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4.7.2 Investigation of ANXA2 localisation in undifferentiated and differentiated wild 
type, Control knockdown and ANO5 knockdown C2C12 
The previous immunofluorescence and subcellular fractionation experimentation 
confirm reports from the literature that while ANXA2 is found throughout the cell, as 
well as secreted into the extracellular space, it is predominantly located in the 
cytoskeleton and organelles associated with the plasma membrane, the early endosomes 
for example (Gerke and Moss, 1997). To better understand the role of ANXA2 in 
C2C12 and what its interaction with ANO5 might be, the localisation of ANXA2 during 
C2C12 differentiation was investigated. To this end immunofluorescence staining of 
differentiated C2C12 was carried out to identify ANXA2 localisation during 
differentiation and to identify any changes to this localisation when ANO5 is knocked 
down.  
Initial investigation of differentiating wild type C2C12 was made using 
immunofluorescent staining of D1, D3 and D5 time points to track ANXA2 localisation 
(Figure 4.13). These data show that throughout differentiation from myoblasts to 
myotubes, the same filamentous structures stained by the ANXA2 antibody as seen in 
previous experiments (Figure 4.12) are retained throughout the 5 day time series, 
appearing in approximately 10% of cells.  
Specifically, in D1 cells positive for ANXA2, single long spindle like structures are 
found running the length of the cell. Within each cell, all of these structures run in the 
same direction, but the direction varies between cells. While this staining pattern was at 
first thought to just be background, the persistence of this staining pattern in the D3 and 
D5 time point images suggests that this is a genuine structure within the cells, though 
similar structures have not been reported in the literature. At the D3 time point these 
spindle structure become more defined. As with the D1 time point, in the majority of the 
cells the spindles appears to cross over the nucleus and extend to cover the length of the 
cell. Finally at D5 a single spindle structure runs the length of formed myotube, again 
appearing to cross over the multiple nuclei of the myotube.  
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Figure 4.13 ANXA2 localisation in differentiating wild type C2C12. All micrographs show anti-
ANXA2 + alexa fluor 594 secondary antibody. Images in the left column are taken at x20 
magnification (scale bars = 50µm), the right column of images are taken at x40 magnification 
(scale bars = 20µm). Biological N = 1. Technical N = 1.  
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This experimental set up and immunofluorescence staining was repeated on the ANO5-
4A and CON-2C knockdown C2C12 clones (Figure 4.14). These data are less 
informative than the wildtype C2C12 data as these C2C12 do not differentiate as well as 
the wild type C2C12. They fail to produce multinucleated myotubes even by the D5 
time point. They do however line up and elongate, attempting to fuse to form myotubes.  
These data show that the spindle like structures are not seen in either cell line. Instead, 
the pattern of staining seen in these cell lines localises more to the nucleus, evidenced 
by the purple signal from the overlapping red (ANXA2) and blue (DAPI) staining. 
There is evidence of cytoplasmic staining in some cells both ANO5 knockdowns and 
controls, though this is a very diffuse pattern and may just be concentrations of antibody 
rather than true signal. Considered with the fact that these C2C12 do not differentiate 
well, ultimately it is not possible to accurately identify ANXA2 localisation in either of 
these knockdown C2C12 clones and understand how this localisation changes with the 
knockdown of ANO5.  
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Figure 4.14 Comparison of ANXA2 expression in differentiating ANO5 knockdown and Control 
knockdown C2C12. All micrographs show anti-ANXA2 and alexa fluor 594 secondary antibody. 
In both “ANO5 KD” and “Control KD” the top row of images are taken at x20 magnification 
(scale bars = 50µm), bottom row of images are taken at x40 magnification (scale bars = 20µm). 
Biological N = 2. Technical N = 1.  
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4.8 Discussion 
Crude subcellular fractionation by differential centrifugation was used to separate 
C2C12 lysates into nuclear, mitochondrial and cytosolic fractions, reducing the number 
of protein spots to compare between each gel. Differential centrifugation was used to 
fractionate lysates as it was the simplest method available to achieve the desired results. 
More sophisticated methods of subcellular fractionation such as density gradient 
centrifugation would produce purer fractions for further experimentation (Anderson, 
1955). However, as the aim of the fractionation was to reduce the number of spots for 
subsequent analysis, this method of fractionation was adequate. Additionally this 
fractionation method was specifically tailored for use with C2C12 cells to maximise the 
yield and purity of the fractions, using the simplest method possible (Dimauro et al., 
2012). 
To streamline 2D gel experimentation, but to cover as wide a pH range as possible, only 
IPG strips with a pH gradient of 3-10 were tested. This means that potentially altered 
proteins remained undetected because their isoelectric points fall outside of the pH 
range of the IPG strips used. This is unlikely however as most proteins have isoelectric 
points within the pH range tested (Schwartz et al., 2001; Weiller et al., 2004). A more 
likely scenario is that proteins distorted by the lysis and solubilisation process do not 
enter the gel at all during IEF. For example lipids can bind to proteins and alter their 
isoelectric point and solubility (Rabilloud, 1999). There are protocols which can be 
included during lysis to reduce such interference and produce cleaner lysates, but it has 
been suggested that reducing the handling of protein lysates produces a more 
informative gel, especially in the first instance (Berkelman, 2008).  
Furthermore, a number of proteins may be hidden in lipid rafts. Lipid rafts are found in 
both external and internal plasma membranes such as the Golgi apparatus and 
lysosomes, where they are thought to function as organising centres for other proteins 
involved in cell signalling (Pike, 2003). They are insoluble in non-ionic detergents 
compared to other parts of the membrane due to the presence of cholesterol, 
sphingolipids (Moldovan et al., 1995; Brown and London, 1997; Galbiati et al., 2001) 
and proteins such as caveolin (Perez-Verdaguer et al., 2016). It is likely that other 
proteins may be undetected because they are contained within these free floating, highly 
ordered and relatively insoluble regions of the plasma membrane  
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Conversely, investigating narrower pH ranges would in effect “zoom in” on a portion of 
the IPG strips already tested and allow for resolution of spots that are very close 
together and elucidate further potential differences between the knockdown clones. This 
would be particularly helpful if investigating strings of phosphorylated or post 
translationally modified proteins. 
Only one cell line from each shRNA knockdown condition was used. ANO5-4A and 
CON-2C gels were run in triplicate for both the initial Coomassie stained gels and the 
ANXA2 2D western blot investigation with consistent results obtained each time. 
Therefore the observed differences are likely to be correct for these clones. But to 
confirm that the observed differences in ANXA2, S100-A4 and Hspb27 are true in all 
ANO5 deficient C2C12, comparison of other ANO5 deficient cell lines should be 
investigated.  
Spot patterns on triplicate 2D gel western blots of ANXA2 suggest that knocking down 
ANO5 in C2C12 alters the intensity of the detectable ANXA2. Two other spots, one 
heavier (spot 2) and one lighter (spot 3), are also present on CON-2C blots which have a 
reduced expression level on ANO5-4A blots. The identities of these additional spots are 
not known, but suggestions about its identity can be made using the difference in 
molecular weights between the ANXA2 spot and spot 2. ANXA2 is subject to several 
post translational modifications including polyubiquitination (Lauvrak et al., 2005; 
Bharadwaj et al., 2013), acetylation, glutathionylation and serine and tyrosine 
phosphorylation (Bharadwaj et al., 2013). Glutathionylation and polyubiquitination are 
unlikely modifications as the addition of either glutathione (25 kDa) or polyubiquitin 
(minimum of 17 kDa) would make any potentially modified ANXA2 much larger than 
the identified spot. Monoubiquitination is a more likely modification as ubiquitin is only 
8.5 kDa.  
However, there is little direct evidence in the literature to suggest that ANXA2 is 
monoubiquitinated. Lauvrak et al. (2005) have noted however that ANXA2 is involved 
in endocytosis (Gerke and Moss, 2002) while monoubiquitination is implicated in 
tagging proteins for the endosomal pathway (Schnell and Hicke, 2003), therefore 
suggesting that monoubiquitination of ANXA2 is a possibility. If ANXA2 is 
monoubiquitinated then the absence of spot 2 from the ANO5-4A blots could suggest 
that the knockdown of ANO5 inhibits the monoubiquitination of ANXA2, potentially 
removing it from the endosomal pathway. 
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Finally ANXA2 localisation results show positive staining for filamentous structures 
within wild type C2C12. This structure persists throughout C2C12 differentiation. The 
same structure is seen in both ANO5-4A and CON-2C C2C12 myoblasts. However, as 
both knockdown C2C12 clones differentiate very poorly it is not possible to identify the 
same structure in differentiated knockdown C2C12. The identity of this structure is not 
known though this pattern of ANXA2 staining is atypical. The literature reports that 
ANXA2 can have a diffuse cytosolic localisation (Scharf et al., 2012; Dziduszko and 
Ozbun, 2013) suggesting either that ANXA2 localises only to this structure in C2C12 
cells or that these structures are artefacts. 
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Chapter 5 Investigation of ANO5 function as a phospholipid 
scramblase 
5.1 Introduction 
Anoctamins 1 and 2 have been well established as calcium activated chloride channels 
(CaCCs) (Caputo et al., 2008; Schroeder et al., 2008; Yang et al., 2008; Stohr et al., 
2009). Due to the close sequence homology between anoctamin family members, it was 
assumed that all anoctamins were CaCCs (Hartzell et al., 2009; Schreiber et al., 2010). 
However, extensive investigation of the other anoctamins has shown that while 
anoctamins 6, 7 and 10 produce currents when overexpressed in fisher rat thyroid cells, 
the current is less than 10% of that produced by anoctamins 1 and 2 in the same cell 
lines (Schreiber et al., 2010; Duran and Hartzell, 2011). Along with anoctamin 5, 
several other anoctamins have also been implicated in disease. Mutations in anoctamin 
10 have been implicated in brain angiogenesis (Vermeer et al., 2010) and mutations in 
anoctamin 6 are causative in Scott syndrome (Suzuki et al., 2010; Castoldi et al., 2011), 
a rare bleeding disorder (Rosing et al., 1985). 
The erythrocytes of patients with Scott syndrome fail to undergo coagulation during 
bleeding because they do not expose phosphatidylserine (PS) at the plasma membrane 
(Rosing et al., 1985). PS is a key component of the blood coagulation cascade (Spronk 
et al., 2014) where it is translocated from the inner to the outer leaflet of the plasma 
membrane by phospholipid scramblases in a calcium dependent manner (Bevers et al., 
1982; Bevers et al., 1983). Investigation of ANO6 has confirmed that it is involved in 
phospholipid scrambling (Suzuki et al., 2010; Scudieri et al., 2015). Furthermore, 
research suggests that the other non-CaCC anoctamins may also function as 
phospholipid scramblases (Suzuki et al., 2013). 
As well as signalling blood coagulation, PS exposure is also essential for apoptosis 
(Fadok et al., 1992; Schlegel and Williamson, 2001) and other cellular processes, such 
as differentiation (Sessions and Horwitz, 1983; Schlegel and Williamson, 2001; van den 
Eijnde et al., 2001) and wound healing (Middel et al., 2016). In both cases, PS exposure 
marks the cell as ready for the next step within the relative pathway; fusion with other 
differentiating cells (Jeong and Conboy, 2011) or accumulation of (Middel et al., 2016) 
and destruction by phagocytes (Fadok et al., 1992). As ANO6 and ANO5 are the most 
closely related anoctamins within the family (Duran and Hartzell, 2011) and as 
differentiation and apoptosis are of high biological importance for correct muscle 
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maintenance and repair (Hawke and Garry, 2001; Adhihetty and Hood, 2003), one 
hypothesis is that ANO5 functions as a phospholipid scramblase in the apoptosis of 
muscle tissue. This chapter reports on the investigation of the phospholipid scramblase 
ability of ANO5 knockdown C2C12 and patient myoblasts. 
5.1.1 Flow cytometry analysis of knockdown C2C12 and patient myoblasts 
Flow cytometry is a powerful analysis method capable of recording multiple parameters 
simultaneously from cell populations (Hulett et al., 1969; Hulett et al., 1973). The 
technology first appeared in 1965 as a cell sorter, able to discriminate cells on 
differences in their volume when passed through an electronic field (Fulwyler, 1965). 
This was then taken a step further in 1969 with the introduction of fluorescence assisted 
cell sorting (FACS). Here, sub-populations are identified by staining heterogeneous 
samples with fluorescent markers specific for proteins unique to the desired sub-
populations prior to sorting (Hulett et al., 1969). This early technology could only 
detect one or two colours from stained cells, but current generation cytometers are able 
to detect more than 20 different colours simultaneously (Bendall et al., 2012). Flow 
cytometry analysis is now so well established that it is routinely used for a range of 
diagnostic needs, from vaccine development and transplantation (Lanier, 2014) to 
screening various patient fluid samples for infection (Bignardi, 2015) and phenotyping 
blood samples (Maecker, 2009; Hensley-McBain et al., 2014).  
Typical fluorescent flow cytometry involves stained cell suspensions being passed 
through the path of a laser as a single stream. Light emitted from the cells is then picked 
up by a series of detectors (Figure 5.1 A.). Additional lasers and detectors aligned along 
the path of flow record multiple fluorescent parameters from each cell. As each cell is 
recorded as a single event and multiple fluorescent parameters can be gathered from 
each event, this technology allows for the generation of thousands of data points per cell 
population. Flow cytometry data must therefore be filtered following acquisition, to 
identify the populations of interest and discard uninformative data. This can be achieved 
using appropriate analysis software to select specific population sub-sets, termed “gates” 
(Figure 5.1 B.). By choosing gates from across several fluorescence channels it is 
possible to focus on specific cellular sub-populations of interest (Verschoor et al., 2015). 
For example, while the setup of flow cytometer technology should mean that each event 
is the analysis of a single cell, it is possible for cells to adhere to one another and for 
two cells to be analysed as a single event. By plotting the Forward Scatter Height (FSC-
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H) and Forward Scatter Area (FSC-A) data on the same graph, these doublets can be 
identified as events which are “taller” than they are wide and ignored (Figure 5.1 C.). 
 
Figure 5.1 Representation of flow cytometry workflow. A. is a simplified diagram of the process 
occurring within flow cytometry technology. Coloured circles indicate stained cells moving as a 
single stream in the direction of flow. Only one laser is shown though additional lasers with 
different emission spectra can then be positioned in the path of the cells for collection of more 
dye colours. The lower box shows the graphical output of data on FACSDiva software and the 
order of gating used in these experiments. B. is used to exclude debris (Forward Scatter Area 
[FSC-A] against Side Scatter Area [SSC-A]); C. is used to exclude doublet cells (FSA against 
Forward Scatter Height [FSC-H]); D. is the final gated population data collected from each 
sample, displayed as scatter plot of FITC-AV fluorescence (Axis labelled 2-488/530/30-A) 
against PI (Axis labelled 2-488/585/42-A). This final plot allows for visualisation of the 
movement of cell populations following apoptosis treatment.  
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5.2 Phosphatidylserine exposure during C2C12 differentiation 
The exposure of PS on wild type C2C12 during differentiation was investigated by 
staining cells with FITC conjugated Annexin V (FITC-AV). AV binds to exposed PS in 
a calcium dependant reaction (Tait and Gibson, 1992; Meers and Mealy, 1993), while 
differentiation progression was tracked using Alexa Fluor 594 phalloidin which stains 
the actin filaments, a marker of differentiation (Faulstich et al., 1988; Huang et al., 
1992). The aim of this investigation was to confirm that this assay would accurately 
identify PS exposure in differentiating C2C12. The assay would then be used to 
characterise differences in PS exposure between ANO5 and Control knockdown C2C12. 
Results show that at D1 only one or two C2C12 cells show any FITC-AV positivity and 
no phalloidin positivity can be observed (Figure 5.2). In the few FITC-AV-positive cells, 
x63 magnification reveals that FITC-AV appears to have a punctate pattern of staining 
within the cytoplasm of the cells.  
By D3, both FITC-AV and phalloidin positivity are observable, indicating 
differentiation of myoblasts into myotubes. Detectable FITC-AV fluorescence is seen 
external to the plasma membrane of cells in clusters of variable size; described as an 
aggregate staining pattern. External aggregation of FITC-AV is as expected (Jeong and 
Conboy, 2011), but the location of the FITC-AV staining pattern is not what is expected 
from the literature (van den Eijnde et al., 2001; Jeong and Conboy, 2011). Rather than 
aggregating around the cell-cell contact areas, such as the leading ends of the forming 
myotubes, the aggregation appears to be mostly along the longitudinal plane of the cell. 
The majority of C2C12 show positive staining with phalloidin, identifiable by the 
striated pattern of fluorescence along the length of the elongated myoblasts. A few 
multinucleated myotubes are formed by this time point but are small and not as 
numerous as the elongated pre-fusion myoblasts.  
These staining patterns are also observed in D5 C2C12 though with differences in the 
levels of fluorescence. Phalloidin staining is now consistent across all myotubes. The 
level of FITC-AV staining however is reduced and only appears next to a few formed 
myotubes. Additionally the aggregate staining pattern of FITC-AV remains localised 
next to the cells but again not in the locations associated with myoblast fusion. 
From these data it appears that FITC-AV aggregates on the longitudinal axis of 
myotubes, an area not expected to show PS exposure. While it is possible that these 
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findings represent previously unreported localisation for PS, it may also be background 
or expression of PS not related to differentiation; likely as the localisation detected are 
not areas associated with myoblast fusion. As such, this assay was determined to be 
suboptimal for further experimentation and potential differences between ANO5 and 
Control knockdown C2C12 were not investigated. 
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Figure 5.2 FITC-AV and phalloidin staining of differentiating wild type C2C12. Red 
fluorescence indicates alexa fluor 594 phalloidin staining. Green fluorescence indicates FITC-
AV staining. The left column of images are taken at x20 magnification (scale bars = 50µm), 
right column of images are taken x63 magnification (scale bars = 20µm). Biological N = 1. 
Technical N = 3.  
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5.3 Phosphatidylserine exposure during apoptosis in ANO5 knockdown C2C12 
PS exposure during apoptosis was investigated using the three selected clones of ANO5 
and Control knockdown C2C12 cells generated using ANO5 targeting shRNAs 
(described in Section 2.2).  
The FITC-AV assay, used in the differentiation experimentation in the previous section, 
was used to detect resulting PS exposure (Figure 5.3). Five random images of each well 
were collected, the images blinded and the number of FITC-AV-positive cells counted 
to determine the proportion of FITC-AV-positive cells for each shRNA treatment. 
FITC-AV-positive cells were identified as any cells showing bright green fluorescence 
at the plasma membrane. No distinction was made between cells with fluorescence 
around the full circumference or around just a portion of the cell, all were counted as 
positive. 
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Figure 5.3 Example images of FITC-AV stained Control and ANO5 knockdown C2C12. Labels 
on right hand column images also apply to left hand column. Images are taken at x20 
magnification (scale bars indicate 50µm). Biological N = 4. Technical N = 3. 
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Chi2 was used to statistically analyse the difference in the number of positive cells 
between the ANO5 and Control knockdown C2C12 in each treatment condition 
(Section 2.14). The combined total of FITC-AV-positive C2C12 from all knockdown 
clones show that there was a significant difference between the number of FITC-AV-
positive cells in both staurosporine+EGTA and staurosporine only treated ANO5 
knockdown clones compared to Control knockdown clones (Figure 5.4). There was no 
significant difference between ANO5 and Control knockdown C2C12 in EGTA and 
Untreated conditions. This is unsurprising as the level of apoptosis, and consequently 
FITC-AV positivity, was expected to be very low in the EGTA and Untreated 
conditions.  
 
Figure 5.4 Bar graph of preliminary positive FITC-AV count data for each treatment condition. 
Blue bars represent combined ANO5 knockdown data for that condition. Red bars represent 
combined Control knockdown data for that condition. Significant differences calculated using 
Chi2 Statistic. ** = p < 0.001 at 1 degrees of freedom. NS indicates no significant difference 
between data. Lines indicate calculated standard error. Biological N = 4. Technical N = 2.  
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
Staurosporin+EGTA Staurosporin EGTA Untreated
P
o
si
ti
ve
 C
e
lls
 (
%
)
Treatment
ANO5 KD
CON KD
**
**
NS NS
 154 
5.4 Phosphatidylserine exposure potential of knockdown C2C12 investigated using 
FITC-AV staining and anti-activated caspase 3 staining 
To validate the significant difference in PS exposure between ANO5 knockdown and 
Control knockdown C2C12, the experiment was modified and repeated to include a 
second immunofluorescent stain for active Caspase 3 (aC3). Activated by binding of the 
FasL receptors, aC3 is a key part of the apoptotic pathway (Porter and Janicke, 1999), 
activating other proteins which lead to membrane blebbing (Coleman et al., 2001), 
DNA fragmentation (Janicke et al., 1998) and chromatin condensation (Sahara et al., 
1999). This experiment aimed to test whether the levels of aC3 remained consistent 
between ANO5 and Control knockdown clones. This would then confirm that ANO5 
knockdown has a specific effect on the exposure of PS and was not altering apoptosis 
pathways in general.  
FITC-AV-positive cells were identified by bright green staining of the plasma 
membrane (Figure 5.5). This staining appears to localise around the nucleus, though this 
is due to the cell shrinkage during apoptosis (Maeno et al., 2000). FITC-AV-positive 
cells were classified as any cell that showed green fluorescence around a portion of the 
cell membrane. Cells that had a bright green staining pattern around the full 
circumference of the cell were termed “halo” cells and counted as a subset of FITC-AV-
positive cells. aC3-positive cells were identified by red fluorescence within the 
cytoplasm and the nucleus.  
Chi2 analysis of the count data (Table 5.1) show that there is a significant difference 
between the number of FITC-AV-positive and halo-positive cells between the ANO5 
and Control knockdown C2C12 in staurosporine and staurosporine+EGTA treated 
conditions (in both cases p < 0.001, Figure 5.6 A. and B.) confirming the findings of 
previous experimentation. There is also a statistically significant difference in the 
number of FITC-AV-positive cells between clones in EGTA and untreated conditions 
(EGTA p < 0.03, Untreated p < 0.001), though there is no significant difference in the 
number of halo-positive cells in these conditions (EGTA p < 0.15, Untreated p < 0.8).  
Statistical analysis of the aC3 data shows that there is no significant difference in the 
number of aC3-positive cells between the ANO5 and Control knockdown clones in the 
staurosporine only condition (p < 0.99), though there is a statistically significant 
difference in each other treatment condition (staurosporine+EGTA p < 0.01, EGTA p < 
0.001, Untreated p < 0.001, Figure 5.6 C.). Additionally the number of FITC-AV and 
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aC3-positive cells in the EGTA and Untreated conditions, is marginally higher in ANO5 
clones than Control (Figure 5.6 A. B. and C.). This is also the case for the number of 
aC3-positive cells in the staurosporine condition.  
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Figure 5.5 Example images of FITC-AV+aC3 stained Control and ANO5 knockdown C2C12. 
Labels on right hand column images also apply to left hand column. In each image white 
arrows indicate examples of cells counted as “halo” cells, Blue arrows indicate examples of 
cells counted as FITC-AV-positive cells. Images are taken at x20 magnification (scale bars 
indicate 50µm). Biological N = 6. Technical N = 2.  
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Clone Treatment Total Cells AV cells Halo Cells aC3 Cells 
ANO5 Stspn+EGTA+AV+anti-C3 250 9 1 99 
 
Stspn+EGTA+anti-C3 294 1 0 139 
 
Stspn+AV+anti-C3 677 85 19 198 
 
Stspn+anti-C3 652 0 0 242 
 
EGTA+AV+anti-C3 992 10 3 38 
 
EGTA+anti-C3 1090 0 0 74 
 
Untreated+AV+anti-C3 1274 15 2 17 
 
Untreated+anti-C3 1235 0 0 26 
CON Stspn+EGTA+AV+anti-C3 449 124 44 136 
 
Stspn+EGTA+anti-C3 416 0 0 154 
 
Stspn+AV+anti-C3 512 132 41 150 
 
Stspn+anti-C3 1349 0 0 408 
 
EGTA+AV+anti-C3 1582 8 2 7 
 
EGTA+anti-C3 1501 0 0 15 
 
Untreated+AV+anti-C3 1575 6 2 9 
 
Untreated+anti-C3 1452 0 0 8 
Table 5.1 Count data of total number of cells per clone per treatment condition. “AV Cells” 
indicate the number of cells showing any green fluorescence. “Halo Cells” indicate the number 
of cells with green fluorescence around their entire circumference. “aC3 Cells” indicate the 
number of cells showing any red fluorescence. Staurosporine is abbreviated as “Stspn” 
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Figure 5.6 Bar graphs of the percentage of FITC-AV, halo and aC3-positive cells for each 
treatment condition. Blue bars represent ANO5 knockdown data. Red bars represent Control 
C2C12 data. A. Percentage of AnnexinV-positive cells. B. Percentage of “Halo”-positive cells 
C. Percentage of aC3-positive cells. Staurosporine is abbreviated as “Stspn”. Significant 
differences calculated using Chi2 Statistic. *** indicates significance with p < 0.001, ** 
indicates significance with p < 0.01, * indicates significance with p < 0.03, all at 1 degree of 
freedom. NS indicates no significant difference between data. Lines indicate calculated 
standard error. Biological N = 6. Technical N = 1.  
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5.5 Phosphatidylserine exposure potential of patient myoblasts investigated using 
FITC-AV staining 
To investigate the impairment of PS exposure in a more biologically relevant model, the 
FITC-AV assay was repeated using patient myoblasts. Four myoblast lines were 
obtained from the Newcastle Biobank; one from a healthy patient control and one each 
from patients with confirmed genetic diagnoses of LGMD2L (ANO5), LGD2B (DYSF) 
and LGMD2A (Calpain 3, CAPN3).  
Identifying FITC-AV-positive cells was less straight forward for these cell lines than for 
knockdown C2C12 clones. The cells were more prone to aggregate following apoptosis 
treatment, leading to a higher level of background associated with the images (Figure 
5.7). Despite the differences in cellular response, patient images were still blinded and 
counted for FITC-AV positivity as per knockdown C2C12 protocols.  
Count data from these myoblasts show that across all cell lines the highest percentage of 
FITC-AV-positive cells remains in staurosporine+EGTA and staurosporine treated 
conditions. Little or no FITC-AV positivity is detected in EGTA and untreated 
conditions (Figure 5.8). However, the percentage of FITC-AV-positive cells were 
highest in DYSF patient myoblasts while the lowest were in the control patient 
myoblasts. Additionally the percentage of FITC-AV-positive cells in ANO5 patient 
myoblasts were low in the staurosporine+EGTA treatment condition but very similar to 
DYSF levels in the staurosporine only condition. The disparity in the number of FITC-
AV-positive cells between ANO5, DYSF and CAPN3 patient and control patient lines 
may be due to experimenter error during cell counting caused by high background from 
cells aggregating following apoptosis. As such an alternative assay was sought to asses 
PS exposure ability in patient myoblasts.  
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Figure 5.7 Example images of FITC-AV staining for each patient myoblast line. Labels on right 
hand column images apply across the row. Images are taken at x20 magnification (scale bars 
indicate 50µm). Biological N = 4. Technical N = 1. 
 
Figure 5.8 Bar graph of the percentage of patient myoblast cells counted as FITC-AV-positive. 
Blue bars represent ANO5 patient myoblast data. Red bars represent DYSF patient myoblast 
data. Green bars represent CAPN3 patient myoblast data. Purple bars represent control 
myoblast data. Staurosporine is abbreviated as “Stspn”. Lines indicate calculated standard 
error. Biological N = 4. Technical N = 1.   
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
14.00%
16.00%
18.00%
Stspn+EGTA Stspn EGTA Untreated
P
o
si
ti
ve
 C
e
lls
 (
%
)
Treatment
ANO5
DYSF
CAPN
CON
 161 
5.6 Flow cytometry analysis of phosphatidylserine exposure of knockdown C2C12 
and patient myoblasts 
To overcome the issue of inconsistent staining of patient myoblasts using the 
established in situ assay, flow cytometry analysis was used to investigate the exposure 
of PS in patient cells.  
Consistency between samples was maintained by first creating a template programme 
which was used to collect all subsequent data sets. The template included compensation 
vales for the two lasers used to account for spectral overlap between the FITC-AV and 
Propidium Iodide (PI) fluorochrome dyes. The compensation values were set by altering 
the voltage of the detector so that the mean fluorescence of the corresponding dye was 
within the expected portion of the final P2 scatter plot. For example, when the FITC-
AV only sample (Solution 2) was analysed the gates were set so that fluorescence was 
detected only in the Q3 and Q4 portions of the graph. 
5.6.1 Optimisation of apoptosis induction in patient myoblasts 
To optimise the protocol, wild type C2C12 and control patient myoblasts were treated 
with 1µM of staurosporine at 1 hour intervals for 4 hours (Figure 5.9). The percentage 
of FITC-AV-positive cells were identified as the proportion of events recorded in the 
Q4 portion of the FITC-AV against PI scatter graph. These data show that the 
percentage of FITC-AV wild type C2C12 peaks after 1 hour of treatment. Beyond this 
time point, more and more cells become late apoptotic indicated by increased PI 
positivity and movement out of the Q4 portion of the scatter plot into the Q2 portion 
(Figure 5.9 A.).  
Under the same treatment conditions however, the percentage of FITC-AV-positive 
control patient myoblasts remains unchanged. Staurosporine concentration was 
therefore increased to 50µM and the same time series repeated. These data show that 
four hours of incubation are required before the percentage of FITC-AV-positive 
myoblasts begins to increase (Figure 5.9 B.). Due to time restrictions on the project, 
longer time points were not investigated. Four hour treatment with 50µM staurosporine 
was used for all subsequent investigation of patient myoblasts responses to apoptotic 
stimuli. 
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Figure 5.9 Differences in the increase of FITC-AV cells over time between wild type C2C12 and 
control patient myoblasts. A. Scatter graphs of wild type C2C12 and control patient myoblasts 
at 0 hour, 1 hour and 4 hour time points. Wild Type C2C12 data shows a more pronounced 
increase in FITC-AV and PI over the time course than control patient myoblasts. B. Line graph 
of the proportion of cells within Q4 during a time course of staurosporine treatment. Blue line 
represents WT C2C12 treated with 1µM staurosporine. Red line represents control patient 
myoblasts treated with 1µM staurosporine. Green line represents patient myoblasts treated with 
50µM staurosporine. Lines indicate calculated standard error. Biological N = 3. Technical N = 
1.  
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5.6.2 Flow cytometry investigation of FITC-AV stained patient myoblasts 
The optimised flow cytometry apoptosis protocol was used on six patient myoblast lines, 
three ANO5 and three DYSF all as age and gender matched as possible, kindly provided 
by the Muscle Tissue Culture Collection team in Munich, headed by Dr Sabine Krause 
(Table 5.2). Three new healthy patient controls were also obtained from the Newcastle 
Biobank. 
Each myoblast line was subjectively gated to remove debris and doublet events from the 
data and select the target cell population of interest. Two scatter plots were used to gate 
these data. Each point, or “event”, on these graphs indicated the data recorded for an 
individual cell (Figure 5.10 A. and B.). The first graph plotted Forward Scatter Area 
(FSC-A) against Side Scatter Area (SSC-A), providing a representation of the 
morphology of the events in the prepared sample. The P1 populations were selected 
from these data, identified as the group of events clustering in the lower left corner of 
the graph (around ~50-100 units on both FSC-A and SSC-A axis). 
The P1 data was plotted on the second scatter graph to further interrogate the 
morphology of the cell population and to exclude doublet events. This graph plotted 
FSC-A against Forward Scatter Height (FSC-H) allowing for exclusion of events which 
were “taller” than they were “wide”, for example two cells which were stuck together in 
the flow path of the laser and read as one event. This sub-selected population was the P2 
population which was used to create the experimental scatter graphs which plotted 
FITC-AV against PI.  
All cell lines were prepared under five different conditions; Untreated/Unstained, 
Untreated/PI, Untreated/FITC-AV, Untreated/FITC-AV+PI and Staurosporine/FITC-
AV+PI. The Untreated/Unstained and Untreated/FITC-AV+PI conditions respectively 
controlled for the background autofluorescence and apoptosis levels in the cell lines 
(Figure 5.10 C. and D.). The single dye treatment conditions were used to confirm that 
the set compensation values of the selected lasers were accurate and were specifically 
detecting the respective positively stained cells (Figure 5.10 E. and F.).  
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Cell Line ID 
Age at 
Biopsy 
Gender 
Mutations 
C052-11N-MC000000 31 Male Healthy Control 
C093-13N-MC000000 39 Male Healthy Control 
C128-13N-MC000000 40 Male Healthy Control 
2 DYSF 1015 32 Male 
Homozygote frameshift mutation,  
Exon 26: 3152delG  
3 DYSF 1015 58 Female 
Exon 6: 610C>T (Arg204X) 
Exon 12: 1120G>C (Val374Leu) 
7 DYSF 1015 39 Female 
Exon 27: c.2875C>T = p.Arg959Trp, 
heterozygote  
Exon 28: c.2932G>T = p.Glu978Stop, 
heterozygote 
1 ANO5 1015 42 Male 
Exon5: c.191dupA bzw. 
p.Asn64LysfsX15,  
Exon 6: c.295-1 G>A heterozygote 
2 ANO5 1015 44 Male 
Exon 7 c.368C>T = p.Ser123Leu,  
Exon 11: c.1063C>T = p.Leu355Phe, 
heterozygote 
3 ANO5 1015 36 Male 
Exon 5: c.191dupA (p.Asn64LysfsX15);  
Exon 4: c.172 C>T (p.Arg58Trp) 
heterozygote 
Table 5.2 Details of primary patient myoblasts used in this project. DYSF and ANO5 patient 
myoblasts and mutation data were kindly provided by Dr Sabine Krause’s team in Munich from 
their patient cohort. Control patient myoblasts were kindly provided by the Newcastle Biobank 
at the John Walton Muscular Dystrophy Research Centre. 
To maintain consistency between samples and between cell lines, the same template 
programme that was created using the data from the wild type C2C12 was used for all 
patient samples. The validity of the template was confirmed by running the control 
patient myoblasts first and visually confirming that the template was correctly 
compensated.  
Data from P1 and P2 scatter plots show that following staurosporine treatment the 
morphology of all the myoblast lines becomes less defined (Figure 5.11). While a clear 
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population is still definable in the P1 scatter plot across all cell lines, allowing for 
selection of a P1 population, the distribution of events are spread across the graph.  
The change in myoblast morphology is confirmed in the P2 selection scatter graphs 
(Figure 5.11 B.). Here the pattern of recorded events on the scatter plot suggests that 
following staurosporine treatment, there is an increase in the number of cells with a 
height-to-area disparity. Though there is a clearly identified population of cells which 
conform to the expected width and height, allowing for selection of the P2 population.  
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Figure 5.10 Examples of flow cytometry gating work flow. A. Scatter graph of P1 gating, FSC-A 
against SSC-A. B. Scatter graph of P2 gating, FCS-A against FSC-H. C.-F. Final population 
scatter graphs, C. Untreated/Unstained control; D. Untreated/FITC-AV+PI background control; 
E. Untreated/PI only background control; F. Untreated/FITC-AV only background control. Axis 
labelled 2-488/530/30-A displays FITC-AV fluorescence intensity. Axis labelled 2-488/585/42-A 
displays PI fluorescence intensity. All axis’ are on a logarithmic scale.  
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Figure 5.11 Example of the change in control myoblast morphology following 4 hour 
staurosporine treatment. A. Example P1 gated scatter graphs (FSC-A against SSC-A) of both 
untreated and staurosporine treated conditions. B. Example P2 gated scatter graphs (FSC-A 
against FSC-H) of both untreated and staurosporine treated conditions. Red dots indicate P1 
gated population. Green dots indicate P2 gated population. All graph axis’ are all on a 
logarithmic scale.  
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The data from the PI only (Figure 5.12) and FITC-AV only stained control scatter 
graphs (Figure 5.13) show that the majority of events remain in Q3. This indicates that 
the majority of cells show little AV or PI positivity and suggests that they are still viable, 
i.e. non-apoptotic, which has been observed before in earlier time series experiments. 
The PI only data for the control patient lines show that the majority of other events fall 
within Q1, the portion of the graph expected for that dye. There are however a number 
of events in the DYSF and ANO5 lines which are also detected in the Q4 and Q2 
portions of the graph. This is not the case for the FITC-AV only condition, where all 
cell lines showed events only within the Q3 and Q4 portions of the graph. This indicates 
that there is some background in the FITC-AV laser detection, most likely generated by 
events included in the P1 and P2 populations which were undergoing early apoptosis. 
However, as these events were not distributed across the length of the FITC axis and 
instead restricted to just outside the designated Q1 and Q3 sections of the graph, the 
compensations applied to the laser detectors were not altered. This ensured more 
accurate reproducibility between cell lines. 
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Figure 5.12 Scatter graphs of PI stained untreated control, DYSF and ANO5 patient myoblasts. 
Axis labels indicate the laser/detector parameters used. Axis labelled 2-488/530/30-A displays 
FITC-AV fluorescence intensity. Axis labelled 2-488/585/42-A displays PI fluorescence intensity. 
All axis’ are on a logarithmic scale. Biological N = 9. Technical N = 1. 
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Figure 5.13 Scatter graphs of FITC-AV stained untreated control, DYSF and ANO5 patient 
myoblasts. Axis labels indicate the laser/detector parameters used. Axis labelled 2-488/530/30-
A displays FITC-AV fluorescence intensity. Axis labelled 2-488/585/42-A displays PI 
fluorescence intensity. All axis’ are on a logarithmic scale. Biological N = 9. Technical N = 1.  
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The data from the experimental scatter graphs for the Staurosporine/FITC-AV+PI 
condition again consistently show that the majority of events are recorded within the Q3 
portion of the graph (Figure 5.14), indicating the majority of cells show little AV or PI 
positivity. There are however a number of events recorded within the other portions of 
the graphs indicating the apoptotic events positively stained by FITC-AV and PI.  
In control myoblasts, while a portion of events are recorded in the Q4 portion of the 
graph, a clear population of cells are located in the Q1 and Q2 portions of the graph 
forming a pattern resembling an upside down “L”. This suggests that control myoblasts, 
or more likely a subset of them, are becoming PI-positive before they become FITC-
AV-positive.  
There is a less consistent pattern of distribution between the DYSF and ANO5 myoblast 
lines. The 3DYSF line shows a clear population of cells which have moved through Q4 
and are transitioning up to Q2. In 2DYSF and 7DYSF lines however, while there could 
be a similar movement of cells as in 3DYSF, the majority of events outside of the Q3 
portion of the graph appear roughly equally across Q1, 2 and 4.  
This roughly equal distribution of events is also seen in the ANO5 lines, with no clear 
pattern of cellular movement. However, there appears to be a reduced number of cells in 
portions Q1, 2, and 4 of the graphs compared to the DYSF lines.  
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Figure 5.14 Scatter graphs of PI ad FITC-AV stained staurosporine treated control, DYSF and 
ANO5 patient myoblasts. Gated population data of the staurosporine treated samples. Axis 
labels indicate the laser/detector parameters used. Axis labelled 2-488/530/30-A displays FITC-
AV fluorescence intensity. Axis labelled 2-488/585/42-A displays PI fluorescence intensity. All 
axis’ are on a logarithmic scale. Biological N = 9. Technical N = 1.  
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5.6.3 Statistical analysis of flow cytometry analysis data 
The same Chi2 statistic used in sections 2.6.2 and 5.4 was again used to statistically 
analyse the gathered flow cytometry data (Table 5.3). The focus of these experiments 
were to investigate the difference in FITC-AV binding between patient lines and control 
myoblasts. To estimate the number of FITC-AV-positive cells the proportion of cells in 
the Q4 portion of the scatter graph was used. However to more fully understand the data 
and the differences between the Control and patient cell lines, Chi2 values were 
calculated between ANO5 and Control and DYSF and Control patient lines for each 
quadrant, for each of the five treatment conditions. The hypothesis tested was therefore 
modified to “There is a difference in the proportion of events present in a given scatter 
graph quadrant between patient and healthy control myoblasts”, with the main 
hypothesis to be tested being “There is a difference in the proportion of events present 
in Q4 between patient and healthy control myoblasts”. 
These data confirm that there are highly significant differences in the proportion of 
events in the relative quadrant of the scatter graph between patient and control 
myoblasts in the majority of treatment conditions (Figure 5.15). The exceptions are the 
DYSF myoblasts in Q1 in the Untreated/PI+FITC-AV condition (p < 0.15, Figure 5.15 
C.) and both patient myoblast lines in the Q1 and Q2 portions of the Untreated/FITC-
AV condition (Figure 5.15 B.). This is the case for the latter quadrants as there are no 
control myoblast events in these quadrants of the scatter plot under these treatment 
conditions, meaning that calculation of an expected value, and therefore a Chi2 statistic, 
is not possible.  
Data from the two control conditions (PI and FITC-AV only) show the baseline 
distribution of myoblasts across all lines. In the Untreated/FITC-AV condition all 
myoblasts outside of Q3 appear in Q4, indicating the single staining of FITC-AV 
(Figure 5.15 B.). Higher percentages of FITC-AV-positive cells in Q4 than in the 
Untreated/FITC-AV+PI condition can be explained by the absence of a PI stain. Cells 
that may potentially be PI-positive as well are unable to be detected, meaning they are 
located in Q4 rather than in Q2. Data for the Untreated/PI condition confirm previous 
observations that while there are a percentage of cells (<3%) in the Q1 portion of the 
graph as expected, there are also cells present in both Q2 and Q4 portions of the scatter 
graph (Figure 5.15 A.). These data indicate background fluorescence detected by the 
FITC-AV detector. The reason for such a low percentage of PI-positive cells is due to 
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PI expression in late apoptotic cells. As apoptosis was not induced in these cells, PI 
expression is expected to be low. 
The Untreated/FITC-AV+PI data indicate the base level of apoptosis in the myoblasts. 
In all cell lines, while there are elevated percentages of cells in Q1 and Q2, the largest 
percentage is found in Q4 (Figure 5.15 C.). Intriguingly, DYSF myoblasts consistently 
show the highest percentage positivity compared to ANO5 and control lines. The lowest 
percentage positivity are found in the control patient myoblasts. ANO5 patient myoblast 
percentage are shown to be statistically significantly different than control patient 
myoblasts, but do not have percentages as high as the DYSF lines.  
This finding is repeated in the Stauro/FITC-AV+PI condition, though there is an 
increase in the percentage positivity across cell lines and quadrants, indicating the effect 
of staurosporine treatment (Figure 5.15 D.). The observation made of control myoblasts 
having a different pattern of movement through Q1 and Q2 is also seen in these 
alternative displays of the data. The percentage of control myoblast cells is generally 
higher in Q1 than compared to the ANO5 and DYSF patient myoblasts. Though small 
this is a statistically significant difference, supporting the observation that when treated 
with staurosporine a subset of the control patient myoblasts moves into Q1. However 
the highest percentage of these cells is still within Q4 also suggesting that another 
population of cells is reacting to the staurosporine in the same way as the patient 
myoblasts. 
Additionally, these data support previous in situ microscopy data showing that control 
patient myoblasts have the lowest percentage of FITC-AV positivity across cell lines. 
This suggests that there is an underlying difference in the response of control myoblasts 
and patient myoblasts to staurosporine treatment. Consequently it is not possible to say 
if loss of ANO5 affects PS exposure in patient myoblasts.  
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Figure 5.15 Percentages of cells present in different portions of scatter graphs for each 
treatment condition. Percentages are calculated from the P2 population of cells. A. 
Untreated/PI; B. Untreated/FITC-AV; C. Untreated/FITC-AV+PI; D. Stauro/FITC-AV+PI. 
Blue bars represent control patient myoblasts. Red bars represent DYSF patient myoblasts. 
Green bars represent ANO5 patient myoblasts. Specific cell line ID codes are given in the 
legend in A. *** indicates significance with p < 0.001, ** indicates significance with p < 0.01, 
* indicates significance with p < 0.09, all at 2 degrees of freedom. Lines indicate calculated 
standard error. Biological N = 9. Technical N = 1.  
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A. Untreated_Unstained 
Cell Line 
Population 
P1 P2 Q1 Q2 Q3 Q4 
cMyoB_C128_13N-MC 9350 9127 0 0 9059 68 
cMyoB_C052_11N-MC 9302 9022 0 0 8978 44 
cMyoB_C093_13N-MC 9097 8778 0 0 8674 104 
MpMyoB_2DYSF 5260 4206 0 8 4033 165 
MpMyoB_3DYSF 4986 3995 0 7 3818 170 
MpMyoB_7DYSF 5042 4193 0 3 4094 96 
MpMyoB_1ANO5 8174 7458 1 1 7346 110 
MpMyoB_2ANO5 6523 5541 0 5 5431 105 
MpMyoB_3ANO5 8477 8188 0 1 8061 126 
B. UnT_PI 
Cell Line 
Population 
P1 P2 Q1 Q2 Q3 Q4 
cMyoB_C128_13N-MC 9333 9039 113 1 8867 58 
cMyoB_C052_11N-MC 9493 9154 137 1 8971 45 
cMyoB_C093_13N-MC 9197 8810 47 1 8646 116 
MpMyoB_2DYSF 5322 4287 64 64 4091 68 
MpMyoB_3DYSF 5299 4279 102 13 3974 190 
MpMyoB_7DYSF 4870 4007 32 8 3846 121 
MpMyoB_1ANO5 8268 7568 20 2 7386 160 
MpMyoB_2ANO5 6447 5429 39 31 5267 92 
MpMyoB_3ANO5 8528 8268 22 0 8108 138 
C. UnT_AV 
Cell Line 
Population 
P1 P2 Q1 Q2 Q3 Q4 
cMyoB_C128_13N-MC 9311 8940 0 0 8725 215 
cMyoB_C052_11N-MC 9452 8923 0 0 8646 277 
cMyoB_C093_13N-MC 9080 8644 0 0 8306 338 
MpMyoB_2DYSF 5288 4291 0 4 3981 306 
MpMyoB_3DYSF 5059 3999 0 2 3475 522 
MpMyoB_7DYSF 4797 3902 0 1 3518 383 
MpMyoB_1ANO5 8197 7515 0 1 7137 377 
MpMyoB_2ANO5 6316 5309 0 6 5046 257 
MpMyoB_3ANO5 8586 8336 0 1 7889 446 
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D. UnT_AV+PI 
Cell Line 
Population 
P1 P2 Q1 Q2 Q3 Q4 
cMyoB_C128_13N-MC 9179 8744 38 74 8453 179 
cMyoB_C052_11N-MC 9458 9020 61 104 8628 227 
cMyoB_C093_13N-MC 9126 8637 19 34 8356 228 
MpMyoB_2DYSF 5373 4324 13 64 4051 196 
MpMyoB_3DYSF 4985 3904 10 86 3407 401 
MpMyoB_7DYSF 4706 3895 9 37 3482 367 
MpMyoB_1ANO5 8186 7505 3 14 7120 368 
MpMyoB_2ANO5 6020 4979 13 39 4697 230 
MpMyoB_3ANO5 8518 8250 18 21 7907 304 
E. Stauro_AV+PI 
Cell Line 
Population 
P1 P2 Q1 Q2 Q3 Q4 
cMyoB_C128_13N-MC 7953 7034 168 96 6554 216 
cMyoB_C052_11N-MC 8366 7083 143 176 6467 297 
cMyoB_C093_13N-MC 8064 7420 75 61 6976 308 
MpMyoB_2DYSF 3896 3064 42 39 2765 218 
MpMyoB_3DYSF 3481 2388 17 88 1935 348 
MpMyoB_7DYSF 3839 2960 54 78 2595 233 
MpMyoB_1ANO5 6449 4954 51 18 4530 355 
MpMyoB_2ANO5 4333 3321 41 39 3012 229 
MpMyoB_3ANO5 7138 6191 25 17 5873 276 
Table 5.3 Raw flow cytometry counts for each gated population of each patient cell line under 
each treatment condition.  
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5.7 Investigation of ANO5 translocation during apoptosis 
As ANO5 is an intracellularly expressed protein, how the knockdown of ANO5 affects 
PS exposure at the plasma membrane is unclear (Duran et al., 2012). One hypothesis is 
that ANO5 is located to specific vesicle populations which move to the sarcolemma 
when the cell is stimulated by apoptotic signals. To test this hypothesis, the localisation 
of ANO5 to specific vesicle compartments and the subsequent movement of these 
organelle populations to the plasma membrane following apoptotic stimulation was 
investigated using transient transfection of Myc-tagged ANO5 in tandem with dyes 
which label the cell lysosomes. 
5.7.1 Lysotracker staining optimisation 
LysoTracker Red DND99 is a red dye which localises to the lysosomes of cells (Diwu 
et al., 1994). Optimisation of staining was carried out on wild type C2C12. These data 
show that staining was successful at all concentrations (70, 60 and 50nM) though with 
different signal to background ratios, depending on concentration and length of staining 
(Figure 5.16). The pattern of staining follows a punctate pattern within the cytoplasm of 
the cells. Rapid signal loss was an issue when imaging however, especially at higher 
magnifications so more detailed investigation could not be made. From these data, 
staining with 70nM of lysotracker for 1 hour was chosen as optimal conditions. These 
conditions gave the brightest signal-to-noise staining of lysosomes and so, it was hoped, 
the longest retention of signal when combined with immunofluorescence staining.  
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Figure 5.16 Optimisation of LysoTracker concentrations and treatment time. Left hand column 
indicates 1 hour of LysoTracker treatment. Right hand column indicates 30 minutes of 
LysoTracker treatment All images are taken at x20 magnification (scale bars = 50µm). 
Biological N = 4. Technical N = 2.  
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5.7.2 Tandem ANO5-Myc immunofluorescence and Lysotracker staining 
Localisation of anoctamin 5 in relation to lysosomes was investigated using tandem 
LysoTracker and standard IF staining of ANO5 and GFP constructs transiently 
transfected into wild type C2C12.  
Micrographs of C2C12 stained with both Lysotracker and 9E10 primary antibody show 
that transfection of and staining for the ANO5-Myc construct was successful (Figure 
5.17). The pattern of Myc staining is the same as has been observed previously; a 
punctate pattern throughout the cytoplasm but with concentrations of staining close to 
the nucleus. This staining pattern is not present in untransfected and only with 
secondary antibody-stained conditions suggesting that this is true signal. There appears 
to be some LysoTracker positivity in the co-stained condition, but only a few 
fluorescent spots are observable and are present in only in Myc-negative cells. 
However, untransfected cells stained with LysoTracker show the same staining pattern 
as untransfected and unstained cells. This suggests that the staining seen in the 
LysoTracker only stained cells are background, most likely caused by rapid bleaching 
of the LysoTracker signal. It is therefore likely that all the Lysotracker staining is 
background. These data suggest that while transfection and staining of the ANO5-Myc 
construct was successful, accurate detection of the lyosomes using the selected 
LysoTracker staining parameters failed.  
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Figure 5.17 LysoTracker colocalisation with ANO5-Myc. Red fluorescence indicates 
LysoTracker stain. Green fluorescence indicates 9E10 (anti-Myc) antibody + alexa fluor 488 
secondary antibody. All images are taken at x40 magnification (scale bars = 50µm). Biological 
N = 3. Technical N = 1.  
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5.7.3 ANO5-Myc and GFP co-expression during apoptosis 
Movement of ANO5 during apoptosis was still investigated by observing expression of 
Myc tagged ANO5 before and after induction of apoptosis. This was achieved by 
sequentially combining the transfection, apoptosis induction and immunofluorescent 
staining protocols of previous experimentation. ANO5-Myc constructs were transiently 
transfected into wild type C2C12 and then either fixed and imaged or treated with 
staurosporine and EGTA combinations to induce apoptosis. Slides were incubated for 4 
hours under normal tissue culture conditions before standard fixation and IF staining. 
GFP constructs were also transfected into C2C12 as transfection controls and as a 
control for construct retention following apoptosis induction. The GFP construct was 
used for this purpose as it has a higher transfection efficiency (~50%) compared to 
tagged ANO5 constructs (~7-10%). It was hoped that the higher transfection efficiency 
would mean that a proportion of GFP-positive cells would be retained even following 
apoptosis induction.  
Results show that transfected ANO5-Myc and GFP constructs remain detectable 
following apoptotic treatments (Figure 5.18). The number of detectable transfectants 
appears to be related to the initial transfection efficiency as while a number of GFP-
positive cells were detectable post-treatment, only one or two ANO5-Myc-positive cells 
remained post-treatment. 
From the transfectants remaining in each apoptosis treatment condition, it is clear that 
transfected cells undergo the same processes post-treatment such as shrinking of the 
cytoplasm. However Myc-positive staining appears to remain throughout the cytoplasm, 
with no observable concentrations of expression near the plasma membrane. GFP 
transfected into C2C12 also show no change in expression pattern post-treatment. 
Expression of these GFP constructs remains within the cytoplasm of the cells with only 
the additional Myc tag staining being detected on the membrane.  
These results therefore suggest that while it is still possible to detect transfected ANO5-
Myc and GFP constructs post-apoptosis treatment, there appears to be no difference in 
the localisation of ANO5 between apoptotic and non-apoptotic C2C12.   
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Figure 5.18 Translocation of overexpressed ANO5-Myc during apoptosis. Red fluorescence is 
of 9E10 (anti-Myc) antibody + alexa fluor 594 secondary antibody. Green fluorescence is of 
GFP fluorescence and is only present in GFP transfected cells. Staurosporine and EGTA 
combinations used to induce apoptosis are indicated. All images are taken at x63 magnification 
(scale bars = 20µm). Biological N = 2. Technical N = 1.  
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5.8 Discussion 
The low FITC-AV and phalloidin positivity detected in D1 C2C12 is not surprising as 
relatively little expression of these proteins is expected at this time point (van der Ven et 
al., 1992). Phalloidin is well established as a marker of F-actin (Faulstich et al., 1988; 
Huang et al., 1992) and the expression pattern in these data are consistent with reports 
from the literature (van der Ven et al., 1992; Engler et al., 2004). However the detected 
expression of FITC-AV is different from that reported in the literature. While expected 
to form aggregates on the external leaflet of the plasma membrane (Jeong and Conboy, 
2011), the localisation of these aggregates is not at cell-cell contact points, where fusion 
would be expected to occur (van den Eijnde et al., 2001).  
An explanation for the localisation of FITC-AV aggregates to the longitudinal portion 
of forming myotubes may be that these are actually collections of excess FITC-AV and 
that these aggregates are not binding to PS. Increased levels of FITC-AV fluorescence 
from these aggregates may also mean that true fluorescence signal of PS bound FITC-
AV remains undetected or overlooked. To account for this, sites of expected fusion 
were specifically investigated for low levels of FITC-AV but found no detectable FITC-
AV staining. This ultimately suggests that this particular assay was not suitable to detect 
PS exposure during myoblast differentiation. An alternative, more sensitive assay may 
be more effective and identify sites of PS exposure during differentiation.  
The FITC-AV assay was successfully utilised in apoptosis experiments with 
knockdown C2C12. The statistically significant difference in the number of FITC-AV-
positive cells between ANO5 and control knockdown C2C12 suggests that knockdown 
of ANO5 is reducing the ability of C2C12 to expose PS at the plasma membrane. 
Additionally, the non-significant difference in the number of aC3-positive cells in the 
experimental, staurosporine only condition also suggests that the knockdown 
specifically affects PS exposure. However, the statistically significant differences in 
aC3 positivity in staurosporine+EGTA, EGTA only and untreated conditions opposes 
this conclusion and instead suggests that knocking down ANO5 may be having a 
general effect on the apoptotic pathway of the cells.  
One explanation for the significant difference in the number of aC3-positive cells in 
these conditions may lie in the observation that the number of FITC-AV-positive cells is 
higher in ANO5 knockdown C2C12 in the EGTA only and untreated conditions. This 
may suggest that the ANO5 knockdown C2C12 have an increased rate of apoptosis over 
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the control knockdowns leading to increased aC3 activation and a significant difference 
in the aC3 values for the same experimental conditions.  
The statistically significant aC3 values could also be explained by the relatively 
restricted number of knockdown clones compared. Increasing the number of 
knockdown clones compared would increase the accuracy of the Chi2 statistic, for both 
aC3 and FITC-AV positivity. This would ultimately increase the validity of the finding 
that knocking down ANO5 specifically impacts PS exposure in C2C12. Additionally, a 
second marker of apoptosis could be run to confirm these data. Poly(ADP-Ribose) 
Polymerase-1 (PARP-1) would be a good choice as it is activates a caspase-independent 
apoptotic pathway(Yu et al., 2002). This would be a useful additional confirmation step 
as other studies investigating the utility of various apoptotic markers have found 
variability in the correlation between the expression of markers and visible apoptotic 
morphology in the same cells (Holubec et al., 2005). 
The microscopy protocol for this assay was insufficient for detecting differences 
between patient myoblast lines. It was hoped that flow cytometry analysis in tandem 
with a larger number of patient myoblast lines would allow for successful investigation 
of PS exposure in these cells. However as the majority of myoblasts remain in Q3 
across all cell lines, indicating that these cells remain viable, these data ultimately show 
that a better method of apoptosis induction, such as by the Fas/Fas-L pathway (Waring 
and Mullbacher, 1999), should be applied in future work. Investigation of alternative 
apoptosis induction methods would also be useful in understanding whether loss of 
ANO5 and DYSF makes myoblasts more susceptible to staurosporine than control lines, 
explaining the larger percentage population values for patient myoblasts. 
The protocol could be further optimised by using time series data rather than single time 
point data. To maintain consistency with in situ data these experiments only sought to 
collect single time point data. But time series data would more accurately show the 
response of the cells from the moment of treatment through to a desired end point, 
potentially right up to death of the entire population.  
Possible explanations for the differences seen between patient lines, such as an apparent 
sub-population of cells moving through Q1 to Q2 in control patient myoblast lines but 
not in ANO5 and DYSF patient lines, include differences in the constituent sub 
populations of cells between control and patient lines. This leads to an altered overall 
population in the control patient myoblasts which becomes PI-positive quicker than 
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AV-positive. To combat this issue preliminary cell sorting before running the assay 
would increase the purity of the primary myoblast population. Using a series of 
cytometry suitable dyes targeted against cell specific antigens, it would be possible to 
pre-screen the total cell population specifically for myoblasts. Flow cytometry is an 
exceptionally powerful tool, with the ability to record data from several colours 
simultaneously. Using only two colour channels in these experiments, while appropriate 
for the assay used, did not utilise the full power of this technology. Other assays have 
used multiple dyes to select for populations of a single cell type, for example for 
phenotype experiments involving t-cell populations (Chattopadhyay and Roederer, 
2012). In tandem with an optimal method of inducing apoptosis, selecting stains for 
specific cell populations would allow for a greater understanding of the cellular 
dynamics at play during apoptosis between these patient lines.  
Ultimately, flow cytometry is still a very powerful tool for investigating apoptosis and 
with a more rigorously optimised protocol this technology has the potential to be very 
informative and provide a very good follow up to this study. Indeed, flow cytometry has 
been used by other researchers to investigate ANO6 and its role in phospholipid 
scrambling in blood cells (Fujii et al., 2015). 
The question of how the intracellular protein ANO5 is affecting the arrangement of 
phospholipids in the plasma membrane remains unanswered as ANO5-Myc does not 
relocate following staurosporine treatment. Despite this, one possible explanation for 
the change in PS exposure between ANO5 and Control knockdown C2C12 cell clones 
might be that ANO5 regulates the phospholipid scrambling pathway rather than acting 
as a phospholipid scramblase its self. Conflicting research on ANO6 function has shown 
it both exhibiting and lacking scramblase function in different cell lines (Suzuki et al., 
2010; Segawa et al., 2011; Yang et al., 2012). This has led to the suggestion that it is 
not a scramblase but rather a regulator of other scramblase proteins (Yang et al., 2012). 
It is therefore possible that the role of ANO5 is also as a regulator of scramblases. 
To answer this important question, a potential improvement to the protocol would be to 
include a positive control more suitable for vesicle translocation. The GFP construct 
used in this experimentation is a very good control for transfection efficiency but does 
not control for altered localisation during apoptosis. Using targeted antibody staining to 
identify vesicle compartments rather than using fluorescently tagged markers such as 
LysoTracker might improve the stability of signal and allow for increased examination 
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of the trafficking of internal compartments. 
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Chapter 6 Discussion 
6.1 Localisation of anoctamin 5 
6.1.1 Attempted identification of an ANO5 specific antibody 
The first aim of this research project was to identify the specific intracellular 
localisation of anoctamin 5. Without a confirmed antibody against anoctamin 5, the first 
step of this research was to characterise nine commercially sourced antibodies and 
identify the most suitable for detecting anoctamin 5. As none of these antibodies proved 
to be useful in immunofluorescence or western blot investigation, tagged anoctamin 5 
constructs were instead utilised.  
The identification of a suitable anoctamin 5 antibody has eluded the research field for 
several years. While several papers claim to have used or developed ANO5 antibodies 
(Mizuta et al., 2007; Gyobu et al., 2015; Tian et al., 2015; Griffin et al., 2016), no 
consensus had been reached on a reliable antibody prior to the start of this project. This 
appears to stem from the historic use of antibodies in diagnosing patients and the initial 
failures of developed ANO5 antibodies to do so (Bolduc et al., 2010; Milone et al., 
2012).  
However some antibodies now appear to show consensus in western blotting 
experiments of myoblasts and muscle extracts. Both Mizuta et al. (2007) and Gyobu et 
al. (2015) consistently detect ANO5 at approximately 100kDa in myoblasts, while 
Gyobu et al. (2015) and Griffin et al. (2016) detect broad bands around 400-500kDa in 
BN PAGE and western blot of muscle tissue respectively. Griffin et al. (2016) in 
particular detect a very broad smear in muscle tissue which they suggest is due to post 
translational modifications such as glycosylation and ubiquitination. Similar consistency 
between histological examinations using ANO5 antibodies is less clear. Recent papers 
have reported the use of ANO5 antibodies for immunofluorescent localisation but such 
work is currently limited (Tian et al., 2015). To our knowledge, no review of currently 
available ANO5 antibodies has been conducted, though would perhaps identify a 
consensus antibody at least suitable for research purposes.  
6.1.2 Localisation investigation using fluorescently tagged anoctamin 5 
Fluorescently tagged anoctamin 5 constructs were successfully localised to the 
endoplasmic reticulum, in line with predicted localisation (Tsutsumi et al., 2004), and 
partially localised to the t-tubules in cell culture models. However, electroporation 
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experiments, which other members of the John Walton Muscular Dystrophy Research 
Centre had used to successfully express mini-dystrophin constructs in mouse tissue, 
were unsuccessful. Scudieri et al. (2015) suggest that adding tags to constructs can alter 
their localisation. In their paper investigating ANO6 function, the authors suggest this is 
as an explanation for the conflicting reports of ANO6 localisation. Additionally, 
disagreement in the localisation of DYSF following membrane wounding between 
Bansal et al. (2003) and Klinge et al. (2007) has been suggested to be due to the epitope 
tagging of DYSF in the latter study (Cooper and McNeil, 2015). It is therefore possible 
that in the current project, the Myc tag has affected ANO5 protein expression, reducing 
the retention of the constructs within mouse muscle.  
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6.2 Function of anoctamin 5 
6.2.1 Knock down of anoctamin 5 affects the abundance of annexin A2 in C2C12 cells 
The data from the current study suggest that the knock down of ANO5 alters the 
abundance of annexin A2 in C2C12, to our knowledge the first instance of a 
relationship between these two proteins. Annexin A2 often appears in the literature 
involved with LGMDs and sarcolemmal repair (Draeger et al., 2010; Roostalu and 
Strahle, 2012; Demonbreun et al., 2015). Along with annexin A1, it has been identified 
as a binding partner of dysferlin suggesting an involvement in LGMD2B pathology 
(Lennon et al., 2003; Cagliani et al., 2005). Wound repair and ANXA2 distribution in 
the sarcolemma are both significantly disrupted in dysferlin deficient mice (Bansal et al., 
2003; Lennon et al., 2003; Han and Campbell, 2007). Very recent research has further 
expanded on the role of ANXA2 in myofibril repair and regeneration. Defour et al. 
(2017) have identified ANXA2 as responsible for myofibril repair and the pro-
inflammatory response. ANXA2-deficient mice showed reduced body and muscle mass, 
decreased grip and forelimb strengths increasing muscle weakness which with age 
relative to wild type counterparts. Defour et al. (2017) also compared the ANXA2-
deficient mice to DYSF-deficient mice and found reduced histopathology, fewer 
regenerating fibres and differences in inflammatory gene expression. Defour et al. 
(2017) suggest that the lack of myofibril repair and inflammatory response in ANXA2-
deficient mice is due to the pro-inflammatory role of ANXA2 in myofiber repair when 
expressed extracellularly. 
Understanding of the role of annexins in plasma membrane processes is increasing and 
the data from this study further strengthens the argument of a relationship between 
ANXA2 and the limb girdle muscular dystrophies. These data also support the 
suggestions of similar functions or a close association between anoctamin 5 and 
dysferlin as both these intracellular proteins have now been suggested as interacting 
with annexin A2 in pathways resulting in changes at the plasma membrane (Roostalu 
and Strahle, 2012). However protein interaction screening or improved co-localisation 
experiments would help clarify the particular roles each of these causative genes plays 
in LGMD pathology and especially address the question of whether a direct protein-
protein interaction exists between these proteins.  
The possible effect on annexin A2 abundance is also of interest as the monomere has 
been found to be involved with chloride channel regulation (Kubista et al., 1999) while 
 192 
the ANXA2/S00A10 heterotetramere has been suggested to be responsible for ion 
channel trafficking from intracellular sites to the plasma membrane and speculated to be 
required to tether ion channel to cytoskeleton of the plasma membrane (Gerke et al., 
2005). Annexin A2 has been localised to lipid rafts within the plasma membrane 
(Oliferenko et al., 1999). Lipid rafts are small, highly dynamic and transient regions of 
the membrane (Pierini and Maxfield, 2001) suggested as being involved in recruiting 
signalling cascade proteins (Cherukuri et al., 2001).  
Finally, annexin A2 has also been suggested as necessary for osteoblastic mineralization. 
Gillette and Nielsen-Preiss (2004) identified that overexpression of ANXA2 resulted in 
increased alkaline phosphatase activity and mineralisation of osteoblasts. Given that 
dominant mutations in ANO5 lead to the bone disease Gnathodiaphyseal dysplasia 
(GDD), investigation of the relationship between anoctamin 5 and annexin A2 in 
osteoblasts should be undertaken. 
6.2.2 Knocking down anoctamin 5 reduces the phospholipid scramblase ability of 
C2C12 
Following establishment of a knock down C2C12 line, specific investigation of 
anoctamin 5 function as a phospholipid scramblase was pursued. This investigation was 
undertaken due to the close homology between ANO5 and ANO6 and the established 
phospholipid scramblase function of ANO6. The working hypothesis was that impaired 
scramblase function during apoptosis led to impaired immune response, increased 
inflammation processes and dystrophic pathology. These data confirm that ANO5 
knock down affects PS exposure which could lead to an impaired apoptotic response or 
inflammatory response during myofiber regeneration seen in some LGMD2L patients 
(Hicks et al., 2011). 
6.1.1 A hypothetical vesicle population containing anoctamin 5 and annexin A2 
The initial hypothesis of anoctamin 5 functioning as a phospholipid scramblase, can 
now be expanded to include the altered annexin A2 abundance in ANO5 knock down 
C2C12. Annexin A2 aggregate vesicles and lipid rafts to the cytosolic side of the 
plasma membrane in a calcium dependent manner (Babiychuk and Draeger, 2000) and 
have been suggested as intracellular calcium sensors (Monastyrskaya et al., 2007). 
Furthermore, annexin A2 has been found to be required for binding and aggregation of 
vesicles containing PS (Blackwood and Ernst, 1990; Menke et al., 2005). Annexin A2 
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may hypothetically act as a calcium sensor in vesicles containing anoctamin 5 and PS. 
Upon increase in internal calcium concentration annexin A2 traffics the vesicle to the 
plasma membrane and facilitates fusion of the vesicle with the plasma membrane. 
Anoctamin 5 and PS are then inserted into the plasma membrane where anoctamin 5 
scrambles the membrane, exposing the excess PS. ANXA2 expression disruption by the 
loss of ANO5 would then impair beneficial accumulation of vesicles, which has been 
observed by electron microscopy investigation of muscle biopsies of two Finnish 
LGMD2L patients (Mahjneh et al., 2010). A similar model for PS trafficking to the 
membrane during apoptosis has been suggested by Mirnikjoo et al. (2009b). The 
authors suggest that a pseudo-membrane repair response occurs following increases in 
intracellular calcium which involves the fusion of PS rich lysosomes to the plasma 
membrane.  
However, this hypothesis conflicts with the data that overexpressed ANO5-Myc is 
intracellularly located and does not traffic to the plasma membrane during apoptosis. 
While the addition of the Myc tag may be affecting the true intracellular localisation of 
ANO5, an alternative hypothesis may be that anoctamin 5 is not trafficked to the plasma 
membrane but rather fulfils an intracellular scramblase function which has a 
downstream impact on PS exposure at the plasma membrane. While investigation of 
internal PS exposure, and by extension intracellular scramblase activity, is very difficult 
because of the inherent changes to lipid structure caused by transfecting probes and 
other molecules directed against PS, evidence suggests that scramblase activity is 
required for exposing PS to the cytosol following synthesis in the ER (Leventis and 
Grinstein, 2010). Hypothetically, if anoctamin 5 controlled scramblase activity was 
impaired in the ER then there may be a reduction in total cellular PS, leading to the 
observed PS reduction at the plasma membrane.  
There are however inconsistencies with this counter theory. For example, while PS is 
one of the lowest phospholipids in terms of overall abundance (Leventis and Grinstein, 
2010), the majority of PS produced is immediately trafficked to the mitochondria where 
it is degraded by decarboxylation to produce phosphatidylethanolamine (PE) (Tamura et 
al., 2012; Vance and Tasseva, 2013). So while impaired production of PS may not 
significantly affect its own directly associated functions, it would have a knock on effect 
by impairing PE production which has been shown to be embryonic lethal in mice and 
lead to fragmented mitochondria (Steenbergen et al., 2005). PS has been suggested as 
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important for other intracellular processes, but these are regulated by ATP dependant 
flippases and not scramblases (Leventis and Grinstein, 2010).   
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6.3 A role for anoctamin 5 containing vesicles in plasma membrane repair 
Investigation of anoctamin 5 presence in such a vesicle population and its response to 
plasma membrane wounding has recently been carried out, research which was 
unknown during the write up of this project. Tian et al. (2015) localised endogenous 
anoctamin5 to an unknown intracellular vesicle population using immunofluorescence 
techniques as well as commercially purchased antibodies against anoctamin 5. The 
pattern of localisation reported by Tian et al. (2015) is the same as the localisation 
experiments reported in this project. However the authors found that the pattern of 
anoctamin 5 localisation was not consistent with the pattern of lysosome localisation 
(identified by co-staining with the lysosome marker LAMP2), supporting the possibility 
of a novel vesicle population containing anoctamin 5.  
Tian et al. (2015) further establish that anoctamin 5 translocates to the plasma 
membrane following wounding with saponin. They suggest that anoctamin 5 is 
responding to the increased calcium concentrations following wounding due to its 
function as a CaCC. However, they also report that anoctamin 5 only translocates to the 
plasma membrane during wounding events. Increases in intracellular calcium are not 
enough to move anoctamin 5 to the plasma membrane. Their assumption that anoctamin 
5 functions as a CaCC is also odd given the close homology with ANO6 (Hartzell et al., 
2009) and the increasing understanding that all anoctamins other than ANO1 and ANO2 
are more likely phospholipid scramblases than CaCCs (Whitlock and Hartzell, 2016a). 
Additionally, the authors used kidney (HEK293) and lung (CFBE) cells to investigate 
anoctamin 5 localisation during membrane repair rather than a muscle cell line. They 
justify this choice by showing exogenous expression of anoctamin 5 in these cells and 
citing similar previous findings by Tsutsumi et al. (2004). This is still an unusual 
selection however as while Tsutsumi et al. (2004) do report expression of anoctamin 5 
in these tissues, they also report four to twelve times higher anoctamin 5 expression in 
skeletal muscle and bone tissues. Tian et al. (2015) also acknowledge the known 
LGMD and MMD dystrophies caused by recessive anoctamin 5 mutations, which 
further compounds this less than optimal choice of cell lines. 
6.3.1 Relation to other membrane repair proteins 
The very recent identification of the complex interaction of dysferlin and annexin 
family members in membrane repair (Roostalu and Strahle, 2012; Demonbreun et al., 
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2016b), in tandem with these data reported by Tian et al. (2015) support the likelihood 
of anoctamin 5 localisation to an unknown vesicle population. Furthermore they 
tantalisingly suggest a position for anoctamin 5 within the repair pathway.  
Evidence in both mouse (Demonbreun et al., 2016b) and zebrafish (Roostalu and 
Strahle, 2012) models suggest that following plasma membrane wounding there is 
ordered, independent, recruitment of dysferlin enriched vesicles followed by 
accumulation of annexin A6. In mice this is through the formation of a “shoulder” 
region adjacent to the injury site and a “repair cap” above the injury site (respectively 
formed by the accumulation of DYSF and ANXA6) while in zebrafish Dysf and Anxa6 
(the zebrafish orthologs of their respective human genes) accumulation at the site of 
damage form a seal. In both species, this then prompts the recruitment of annexin A2 
and annexin A1. Indeed zebrafish deficient for either Dysf or Anxa6 fail to recruit 
Anxa2a or Anxa1a (again, the zebrafish orthologs of their respective human genes) to 
the wound site (Roostalu and Strahle, 2012).  
Hypothetically, it may be that the recruitment of ANXA2 prompts the recruitment of 
ANO5 contained in the cytoplasmic vesicle population. Under the current hypothesis 
this occurs simultaneously with PS recruitment but currently all that has been confirmed 
is that PS enrichment of the injury site is preceded by both DYSF and the annexins 
(Demonbreun et al., 2016b). Further investigation is required to confirm the presence of 
PS in the same vesicles as ANO5.  
Additionally, while it has been suggested that endosomes and exocytosis of lysosomes 
are involved in wound repair (Reddy et al., 2001; Idone et al., 2008), the exact identity 
of this anoctamin 5 containing vesicle population is unclear. In zebrafish, intracellular 
vesicles detected by marking proteins including Lamp1 and 2, Laptm4a and specific 
Rab family members (1a, 5a, 6a, 7 and 27a) do not play a role in wound healing 
(Roostalu and Strahle, 2012) and anoctamin 5 did not co-localise with LAMP2 in vivo 
supporting the suggestion that it is not contained within a lysosome (Tian et al., 2015).  
Furthermore, while Demonbreun et al. (2016b) suggest that exposure of PS leads to 
phagocytosis and the inflammatory response, further work should be carried out to 
understand if this is the precise purpose of PS exposure or if membrane fusion with 
satellite cells is the specific end point. Perhaps ANO5 scrambling varies depending on 
the situation of the cell. Finally, how the repair patch is removed currently remains 
unknown (Cooper and McNeil, 2015).   
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6.4 Interrogation of developed ANO5 knockout mouse models 
Within the last few years, two different groups simultaneously published 
characterisations of ANO5 knock out mouse lines, the first publications of in depth 
investigation of such a model (Gyobu et al., 2015; Xu et al., 2015). Xu et al. (2015) 
validated the knock out using rt-PCR of mRNA with four different primer sets, none of 
which detected ANO5 in knock out samples. Gyobu et al. (2015) also used PCR using 
one forward and two reverse primers (one against the wild type and one against the 
mutant allele) to identify the ANO5 knock out genotype mice. However both authors 
also report that their models do not recapitulate the muscular dystrophy phenotypes of 
patients in either muscle histology or contractile response (Table 6.1), despite Xu et al. 
(2015) investigating older 18 month old mice at rest. Xu et al. (2015) also investigated 
potential protective effects from increased expression in other anoctamins but found no 
increase over that observed in the wild type mice. Gyobu et al. (2015) however reported 
reduced fertility due to decreased sperm motility in their model. While ANO5-/- sperm 
morphology was unchanged and the sperm could still move, their velocity was 
significantly reduced compared to wild type derived sperm. The authors suggest that the 
decreased motility is due to the effect of ANO5 on spermatogenesis. Although these 
mouse models obviously do not represent a suitable phenocopy of the human disorder, 
one might speculate about their suitability in unravelling proteins (beyond the 
anoctamin family) protecting skeletal muscle from vulnerability. Unbiased protein 
profiling utilizing different muscle derived from knock-out animals and wildtype-
littermates would represent a promising step towards this goal. 
The lack of an overt phenotype is unsurprising as other mouse models for more severe 
muscular dystrophies have only a mild phenotype when compared to patients. For 
example the mdx mouse, the standard model of Duchenne, lacks the replacement of 
muscle by fatty infiltrate seen in patients, as well as showing improved muscle 
regeneration (Coulton et al., 1988). Proposed explanations for a comparatively reduced 
phenotype in the mdx mouse include other proteins, such as utrophin and sarcoglycan, 
compensating for the loss of dystrophin in mice (Grady et al., 1997; Li et al., 2009) and 
a species specific protective/compensatory mechanism in the mouse muscle (McGreevy 
et al., 2015). Both authors acknowledge that anoctamin 5 may not fulfil the same 
function in mice as it does in humans due to the general differences in human and 
murine physiology. Xu et al. (2015) suggest that genetic, environmental, metabolic and 
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immunological differences between mice and humans may contribute to the differences 
in phenotype.  
Recently, Griffin et al. (2016) also developed an ANO5 knock out mouse model, 
though histological and clinical examination revealed that their model exhibited several 
phenotypes consistent with the LGMD2L presentation in patients (Table 6.1). As with 
the other models, ANO5 knock out was confirmed via RT-PCR, here with primers 
spanning exons 10-14 and 17-20 (>99% reduction in ANO5). Mice were found to have 
high CK levels (~2 fold higher than wild types), variable muscle force contraction (~15% 
reduced diaphragm muscle contraction, but unaffected in extensor disitorum longus 
(EDL) and tibialis anterior (TA) muscle), reduced muscle fibre diameter in 
gastrocnemius (GAS) and TA muscle and reduced exercise tolerance. Furthermore 
Griffin et al. (2016) also report impaired myoblast fusion as well as muscle regeneration 
following cardiotoxin injection, subsequently rescued by AAV delivery of human 
ANO5-FLAG. The development of all three of these models are steps forward but the 
most recent model will be of greatest benefit in the study of ANO5 function. 
 
 
 
 
 
 
 
 
 
 
Table 6.1 Comparison of the different ANO5 knockout mouse models developed since the 
beginning of this project. Authors and models are presented in order of online publication date; 
Gyobu et al. (2015) 14th December, Xu et al. (2015) 21st December and Griffin et al. (2016) 
11th March.  
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 Gyobu et al. (2015) Xu et al. (2015) Griffin et al. (2016) 
Reported Age 
of Mice (assay 
dependant) 
6-7 months (histological 
examination)  
7-10 months (CK 
extractions)  
2-6 months (sperm 
examination)  
3 months (fertility 
assessment, 5 months 
post breeding);  
7, 14, and 21 day time 
points 
4, 8 and 18 month time 
points 
1, 3, 7, 14, 30 and 90 
day time points 
7.5, 10 month time 
points  
Details of 
Knockout 
ANO5 Exon 2 replaced 
with neo-loxP cassette; 
C57BL6/J ES cells 
positive for the vector 
were injected into 
BALB/c mice 
blastocysts, 
ANO5+/NeoFRT mice 
crossed with CAG-CRE 
mice to obtain ANO5+/- 
mouse which was then 
backcrossed to obtain 
target 
Exon 1 and 1.6kb 
upstream of ANO5 
replaced with neomycin 
selection casstte, 
C57BL6/J mouse 
background 
backcrossed for 6 
generations to generate 
homozygotes 
Null ANO5 transcript 
created by splicing to 
lacZ trapping element 
after exon 8, C57BL6 
mouse background 
backcrossed for 4 
generations to the wild 
type to generate 
homozygotes 
Muscle 
Examined 
Only tibialis anterior 
muscle mentioned 
though testis also 
investigated 
Gastrocnemius and 
quadriceps muscle 
(molecular and 
histopathological 
examination) 
Gastrocnemius and 
tibialis anterior (Muscle 
mass)  
Extensor Digitorum 
Longus (contractile 
measurements) 
cardic muscle also 
investigated  
Tibialis anterior muscle 
(electron microscopy, 
morphometrics) 
Gastrocnemius muscle 
(morphometrics)  
Quadriceps Muscle 
(SDH staining)  
FDB muscle 
(membrane repair)  
Extensor Digitorum 
Longus (force 
generation) 
Phenotype No dystrophy 
phenotype observed  
Defect in sperm motility 
suggested to be due to 
faulty spermatogenesis,. 
ANO5+/+ females bred 
with ANO5-/- males 
produced approximately 
half as many pups 
compared with ANO5+/+ 
and  ANO-/- females 
bred with ANO5+/+ 
males 
No dystrophy 
phenotype observed: 
muscle mass, 
musculature unaffected, 
nonstatisitcally 
significant central 
nucleation of 
quadriceps, DYSF and 
DGC unaffected, 
cellular repair 
unaffected, cardiac 
abilities unaffected 
Dystrophy phenotype 
observed: 
Mild histopathology, 
variable muscle 
weakness, exercise 
intolerance, impaired 
regeneration and 
elevated CK levels 
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A possible reason for the different observed pathologies in the three models may be the 
genetic background of the mice. While all three had a C57NL6 background, both the Xu 
et al. (2015) and Gyobu et al. (2015) models were on the C57NL6/J substrain. Detailed 
investigation has been conducted on the effect of the genetic background of a mouse on 
its phenotype. Coley et al. (2016) compared the functional, histological, biochemical 
and molecular phenotypes of mdx mice against D2-mdx mice, mdx mice bred on a 
DBA/2J background rather than a C57BL/10 background. The authors found that 
functionally mdx mice displayed a hypertrophic phenotype while D2-mdx mice showed 
an atrophic phenotype. Furthermore Demonbreun et al. (2016a) identified different 
membrane repair abilities between 129T2/SvEmsJ and C57BL/6J mouse strains both 
bred to be dysferlin-deficient. Macrophage infiltration and movement of ANXA6 to the 
site of injury were both increased in the C57BL/6J mouse, suggesting that this 
background intensifies the dysferlin pathology. 
Unlike other C57NL6 substrains, the C57NL6/J substrain has been found to have a 
functional deletion in the nicotinamide nucleotide transhydrogenase (Nnt) gene (Toye et 
al., 2005; Freeman et al., 2006b). The Nnt gene is responsible for insulin secretion and 
detoxification of reactive oxygen species (Freeman et al., 2006a; Freeman et al., 2006b), 
making the C57NL6/J substrain physiologically different to the other models. 
Furthermore, several single nucleotide polymorphisms (SNPs) have been found to be 
different between several C57NL/6 subtypes, highlighting the need to carefully consider 
the genetic heritage of a mouse before its implementation in developing a new model 
(Mekada et al., 2009).  
A more likely explanation though is Griffin et al. (2016) own suggestion that their 
model accurately replicates the LGMD2L phenotype because of the location of the 
disruption. Xu et al. (2015) and Gyobu et al. (2015) inserted disruptions in exons 1 and 
2 respectively, while Griffin et al. (2016) targeted exons 8 and 9 and admit that they 
therefore cannot exclude the possibility of partial transcription of ANO5 preceding 
these exons. As the common causative c.191dupA mutation for LGMD2L is located on 
exon 5 they continue by suggesting that this partial transcript may result in pathology. 
No further investigation of this theory or the stability of the transcript is mentioned by 
Griffin et al. (2016) and so a vital route of further investigation would be following up 
on this possibility.  
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Given the stronger pathological implications of the location of the mutation, this is the 
more likely reason for the differences in the models. However the differences in the 
genetic backgrounds of the mice should still be kept in mind when using these mice in 
future research, especially if studies compare between them.  
6.4.1 Implications of new ANO5 models to this project 
During their investigation, Xu et al. (2015) also used microarray analysis to identify 81 
upregulated genes and 893 downregulated genes in their knock out model. From these 
genes the authors identify several which are involved with lipid metabolism and suggest 
that anoctamin 5 might play a role in metabolic homeostasis and the complement 
pathway. In the context of the current study, while S100A4 and Hspb27 were not 
among the lists of up or down regulated genes, ANXA2 is identified as down regulated 
by just over 4-fold. While this finding further supports a link between ANO5 and 
ANXA2 abundance, the reduced transcription of ANXA2 found by Xu et al. (2015) 
would appear to conflict with the observed increase in spot intensity seen in the 2D gels 
of the current study. However transcription and translation of a protein are not 
necessarily correlated. Disparity in the correlation between protein and transcript 
abundances have reported, suggested to be due to post-translational modification or 
degradation of the proteins (de Sousa Abreu et al., 2009). Given the increased 
understanding of the role of annexins in membrane fusion and membrane repair, the 
downregulation of ANXA2 recorded in the Xu et al. (2015) model requires further 
investigation and a clearer understanding of its relationship to the overall expression of 
annexin A2. Simultaneous investigation of both ANXA2 transcript and protein 
abundances the Xu et al. (2015) model may reveal that an increased abundance of 
protein occurs from reduced transcript. 
Griffin et al. (2016) and Gyobu et al. (2015) report conflicting localisation for FLAG-
tagged ANO5 in their investigations. Griffin et al. (2016) observed sarcolemmal 
localisation following AAV delivery to rescue membrane repair while Gyobu et al. 
(2015) identified ER localisation in C2C12 and mouse skeletal muscle. Gyobu et al. 
(2015) suggest that this is the natural localisation of ANO5 and support this finding 
with an ANO1/ANO5 chimera, created by altering the SCRD region of ANO5 with the 
corresponding region in ANO1, localising to the plasma membrane which is the 
recorded localisation of ANO1. However, Gyobu et al. (2015) also report that the 
chimera shows strong scramblase function, conflicting with the established function of 
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ANO1 but supporting the established functions of the other anoctamin family members 
(Whitlock and Hartzell, 2016a) and the membrane repair defects reported by Griffin et 
al. (2016). Given that the sarcolemmal localisation of FLAG-ANO5 reported by Griffin 
et al. (2016) was during investigation of the ability of transfected ANO5 to rescue 
membrane repair, these findings suggest that the localisation of ANO5 may be 
dependent on the situation of and pressures on the tissue at that time, supporting the 
possibility of ANO5 existing in a transient vesicle population. Moreover, membrane 
proteins are produced in the ER and it is thus not a surprise that plasma membrane 
resident proteins can also be detected in the ER/Golgi system; especially not under 
circumstances like forced over-expresssion via transient transfection.   
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6.5 Identification of anoctamin5 function through investigation of GDD 
GDD, the rare bone disease characterised by sclerosis of tubular bones, cemento-
osseous lesions in the jaw bone and skeletal fragility (Akasaka et al., 1969; Riminucci 
et al., 2001) caused by autosomal dominant mutations in ANO5 (Akasaka et al., 1969), 
is a relatively unexplored research avenue in terms of identifying anoctamin 5 
functionality. But, if the ultimate aim is to understand functionality in general, then 
investigation of anoctamin 5 in the context of GDD does allow for a second or parallel 
route for understanding anoctamin 5 if not the LGMD2L phenotype specifically. While 
phenotypically very different, differences in expression and protein-protein interactions 
between ANO5 and GDD patients could be illuminating.  
Intriguingly anoctamin 6 has been shown to be important for mineralisation of 
osteoblasts in mice (Ehlen et al., 2013). Two lines of ANO6 null mice were found to 
have delayed bone formation both pre and post-natally as well as deformities of the long 
bones, ribs and skull. Furthermore, PS exposure was found to also be impaired in the 
osteoblasts of ANO6 null mice. Ehlen et al. (2013) explain that osteoblast 
mineralisation is thought to be promoted by the formation of matrix vesicles (Gillette 
and Nielsen-Preiss, 2004; Genge et al., 2008) and that in hypertrophic chondrocytes 
scrambling of the plasma membrane is responsible for the release of these matrix 
vesicles (Damek-Poprawa et al., 2006). They note that Scott Syndrome patients have a 
bleeding disorder rather than bone deformity and suggest that the differences in 
phenotype between ANO6 null mice and these patients may be due to differences in 
anoctamin 6 function between mice and humans. They explain that while they did not 
investigate a bleeding phenotype in these mice, they did not observe any obvious 
instances of increased bleeding, for example in females following birth. 
Given this function of anoctamin 6 in osteoclasts, similar investigation of the 
phospholipid scrambling ability of ANO5 null osteoclasts is imperative. While the three 
different ANO5 null mouse models could be utilised and compared to track their bone 
formation, ideally an additional ANO5 mouse model with dominant mutations, and 
therefore more accurately replicating human GDD mutations, would be of use. 
Confirmation of the similarity of these mice to the GDD phenotype as well as 
investigation of scramblase activity in primary osteoclasts would confirm that 
anoctamin 5 is involved with redistribution of the plasma membrane and that it is the 
specific tissue in which it is expressed which determines its final function.  
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6.6 Investigation of asymptomatic anoctamin 5 patients to identify potential 
compensatory/protective pathways 
The goal of any translational research is to improve the diagnosis, treatment, or quality 
of life for patients. This has become especially important for anoctamin 5 as the 
frequency of ANO5 mutations within patient populations are now understood to be 
higher than previously thought (Hicks et al., 2011). This has led to the suggestion that 
genetic screening for ANO5 should be a priority for patients presenting with even a 
suspected LGMD2L pathology, namely late age onset of asymmetrical limb-girdle 
weakness and significantly elevated creatine kinase (CK) levels (Sarkozy et al., 2013; 
van der Kooi et al., 2013).  
Significantly elevated CK levels have also often been noted in asymptomatic 
individuals positive for ANO5 mutations (Sarkozy et al., 2013). These individuals were 
often screened due to their relatedness to LGMD2L patients, who were in turn identified 
due to re-interrogation of patient data with new screening techniques for ANO5 
mutations (van der Kooi et al., 2013). Investigating anoctamin 5 function in these 
asymptomatic individuals may help to explain why they remain asymptomatic, despite 
having ANO5 mutations and CK levels equivalent to LGMD2L patients.  
Also of interest to the progression of ANO5 is the relationship between exercise and the 
onset of LGMD2L. Cases have been reported of either high exercise ability of patients 
(Mahjneh et al., 2010) or exercise intolerance before the onset of LGMD2L pathology 
(Milone et al., 2012). Given the increasing evidence of the role of ANO5 at the 
sarcolemma, the link between exercise ability preceding onset is worth investigation 
especially with the availability of a reliable mouse model. A particularly intriguing case 
was recently reported by Blackburn et al. (2016) where they describe a 22 year old 
female athlete with progressive muscle weakness and back pain during exercise. 
Subsequent genetic analysis revealed two previously reported frameshift mutations in 
ANO5. Blackburn et al. (2016) note this is an intriguing case given the comparatively 
early age of onset and severity of pathology. The case is also of interest as the patient is 
female who are not often affected by LGMD pathology, but also as these are previously 
reported mutations, highlighting the lack of a genotype phenotype correlation.  
While there has as yet been no clear genotype/phenotype correlation in 
anoctaminopathy patients, investigation of the other anoctamins suggests that genotype 
changes may alter their function. Scudieri et al. (2015) have identified differences in 
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expression and phospholipid scramblase and ion channel function between three 
different variants of ANO6. Alternative splice variants of ANO1 and 2 have also been 
shown to have reduced CaCC functionality (Ferrera et al., 2009; Ponissery Saidu et al., 
2013). Variation in anoctamin sequences may therefore lead to variability of function. 
Deeper investigation of the correlation and differences between mutations of 
anoctaminopathy patients and their phenotypes may reveal further routes of 
investigation.   
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6.7 Future Work 
Several routes of follow up should be pursued to fully understand the scramblase 
function of anoctamin 5 and how this fits with the other anoctamin family members. 
First, in silico modelling of the structure of anoctamin 5 can be carried out to confirm its 
structural similarity to other anoctamins with investigated structures such as anoctamin 
6 and the TMEM16 homologue from Nectaria haematococca (nhTMEM16) (Brunner et 
al., 2014). Secondly, LGMD2L patient derived cells, and potentially the knock down 
cells developed in this project, could be further characterised using electrophysiology 
investigation for their response to changes in calcium. Identification of a high affinity 
anoctamin 5 antibody would also be of great benefit to both academic research and the 
simplicity and speed of patient diagnosis. Alternatively, methods of protein localisation 
that do not require an antibody, such as LOPIT, could be utilised to answer outstanding 
questions about anoctamin 5 localisation. Finally, investigation of the specificity of 
ANO5 as a phospholipid scramblase should be investigated, given the increasing 
evidence for a relationship between ANO5, phospholipid scrambling, DYSF, annexins, 
membrane fusion and repair. This is of particular interest now that several ANO5 mouse 
models are available to examine this function. 
6.7.1 Structural investigation of anoctamin 5 through in silico modelling 
In silico modelling of anoctamin 5 structure would allow for direct comparisons with 
the structures of other anoctamins which have already been investigated. Brunner et al. 
(2014) used x-ray crystallography to characterise the structure of nhTMEM16, a 
homologue of the anoctamins in the fungus Nectria haematococca, and identify 
conserved regions found throughout the family. Yu et al. (2015) also recently identified 
the sequence within anoctamin 6 which they suggest is responsible for phospholipid 
scramblase activity. Through a series of electrophysiology studies, they confirmed that 
the amino acid sequence between amino acids 525 -559 in anoctamin 6 was able to 
confer anoctamin 1 with robust phospholipid scramblase activity in the presence of 
excess calcium. Anoctamin 1 is normally negative for scramblase activity. Furthermore, 
within this region, which they term the scrambling domain (SCRD), nine amino acids 
are essential for the phospholipid scrambling activity in anoctamin 6. They also suggest 
that the weak non-selective ion channel activity observed for anoctamin 6 by previous 
studies is a by-product of the scramblase activity and is not the function of anoctamin 6.  
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Bethel and Grabe (2016) have recently built on the understanding of this domain by 
identifying two regions in the SCRD of nhTMEM, termed the SC and SE sites, which are 
facilitate movement of lipids from one leaflet to the other. The sites are each located at 
either end of the scrambling pore but within the sequence of the SCRD domain; the SC 
at the cytoplasmic leaflet and the SE at the extracellular leaflet. Both sites are conserved 
in all mammalian anoctamins, though the key basic and acidic residues of the SE site 
have flipped positions compared to the model nhTMEM. Bethel and Grabe (2016) argue 
that it is the opposite charges of the residues which is important rather than the order of 
the charge. The SC site meanwhile, is only present in mammalian anoctamins with 
scramblase function, therefore excluding ANO1 and 2. This suggests that there are 
additional structural factors required for the correct function of ANOs.  
While in depth structural modelling would take time, the clear importance of this region 
to the specific function of anoctamins means that immediate work could and should be 
undertaken into the homology of this region between anoctamin 5 and anoctamin 6.  
6.7.2 Electrophysiology studies to investigate intracellular calcium handling of 
anoctamin 5 
Through electrophysiological experimentation of anoctamin 6, ion channel activity 
thought to be associated with robust phospholipid scramblase activity has been found to 
be a by-product rather than a direct function. Additionally simultaneous imaging of cells 
during patch clamp experiments has clarified the relationship between calcium increase 
and activation of phospholipid scrambling (Yu et al., 2015). It would therefore be 
pertinent to use electrophysiological experiments to further understanding of the 
anoctamin 5 reaction to increases of intracellular calcium in over expressing and knock 
down cells. Patient derived cells, or the ANO5 knock down C2C12 lines developed as 
part of this project, could be investigated using such techniques, yielding results 
relatively quickly.  
While anoctamin 5 has not shown any channel forming ability thus far (Tran et al., 
2014), anoctamin 6 channel activity was only observed after delayed activation and 
under much higher concentrations of calcium than required for anoctamin 1 and 
anoctamin 2 activation. Investigation of this function in anoctamin 5 would also have to 
allow for a considerable difference from those observed for anoctamin 1 and anoctamin 
2. Furthermore, Brunner et al. (2014) suggest that while calcium binding is most likely 
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common across the anoctamin family there may be additional modes of regulation for 
the specific family members. As anoctamin 5 is the only anoctamin to be strongly 
expressed in musculoskeletal tissue, it may have a more specific method of activation 
than the other anoctamins.  
Ultimately, identifying the relationship between increases in internal calcium 
concentration, scramblase activity and any potential channel formation in ANO5 
deficient cells would resolve questions around anoctamin 5 such as its intracellular 
localisation despite its scramblase function. This would then increase the understanding 
in relation to the other anoctamins, such as anoctamin 6 which it is closely related to 
and anoctamin 7 which is also intracellularly localised (Duran and Hartzell, 2011).  
6.7.3 Utility and characterisation of potential anoctamin 5 antibody  
While work is ongoing to develop an anoctamin 5 antibody, none are currently 
commercially available. Western blotting results appear to be consistent between a few 
developed antibodies (Mizuta et al., 2007; Gyobu et al., 2015; Griffin et al., 2016), but 
a review of the histological suitability of all currently available antibodies would be of 
great benefit. From a research perspective, consensus on a reliable ANO5 antibody 
would lead to resolution of several questions about this protein for example subcellular 
localisation and differential expression during processes such as apoptosis and 
differentiation. To our knowledge, no such review of currently published ANO5 
antibodies has been conducted but would perhaps be a useful step in understanding the 
remaining issues surrounding a suitable anoctamin 5 antibody. Additionally a reliable 
antibody would impact on patient diagnosis as diagnosis could be achieved by western 
blot or immunohistochemistry. As such it would be of considerable value to diagnostic 
labs who would be able to finally incorporate antibody tests for anoctamin 5 into routine 
screens. Of course, precise data concerning the subcellular localisation of ANO5 would 
be beneficial in terms of a reliable evaluation of developed antibodies. 
6.7.4 Localisation of ANO5 using LOPIT, an isotope tagging method 
Given the difficulty in identifying a suitable anoctamin 5 antibody and the potential 
interference to protein-to-protein interactions caused by tagging ANO5, an alternative 
method for investigating anoctamin 5 localisation should be used. While fractionation 
methods are an alternative possibility, they have an inherent “blind spot” when 
investigating proteins in the endomembrane system, such as membrane proteins. For 
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example organelles would be either so similar in size or are in such a constant state of 
flux, moving from the ER to the membrane (Wu et al., 2004; Sadowski et al., 2006), 
that distinguishing between “resident” or “transient” proteins in a pure fraction would 
be very difficult. However, LOPIT (localisation of organelle proteins by isotope 
tagging), developed by Sadowski et al. (2006), combines amine-specific stable isotope 
tagging, 2D liquid chromatography and MS/MS to localise proteins to a particular 
subcellular compartment and as such offers high specificity with no need for an 
antibody. LOPIT works by comparing the MS/MS data from the target protein against 
the MS/MS data of known subcellular organelle markers distributed along a gradient. A 
protein is considered to localise to a specific subcellular compartment when the MS/MS 
profiles of the two proteins matches. While accurately localising transient proteins (for 
example, proteins that traffic between the ER and Golgi) is still tricky with this 
procedure, LOPIT is still of considerably use given the current situation of anoctamin 5 
antibody research. Additional studies focussing on (new) protein-binding partners of 
ANO5 would also strengthen the understanding of its subcellular localisation and thus 
be helpful for the interpretation of the LOPIT data addressing the endogenous ANO5 
protein.  
6.7.5 Further investigation of the ANO5 knock out mouse and specificity of ANO5 as a 
phospholipid scramblase 
The development of three ANO5 knock out mouse is also very encouraging for future 
studies. While the models developed by Xu et al. (2015) and Gyobu et al. (2015) do not 
have dystrophic phenotypes they can still be used as a basis for further investigation, 
and are arguably of more interest than the Griffin et al. (2016) model in terms of 
identifying compensatory mechanisms and developing therapies for LGMD2L patients. 
Xu et al. (2015) and Gyobu et al. (2015) show that they have successfully knocked out 
ANO5 in their models perhaps suggesting that the lack of a dystrophy in their models 
may be due to a compensatory or protective mechanism. Broad examination of the 
relative expression of other proteins in these models may identify other proteins which 
take over the functions of ANO5 and prevent the dystrophic phenotype. Further 
comparison with the Griffin et al. (2016) model and patient derived cells would then 
reveal more about the interplay between ANO5 and related proteins.  
Additionally, further characterisation of all three mouse models in regard to their 
phospholipid scrambling ability and membrane repair ability is essential. Investigation 
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of scramblase ability was limited across these animal models, while developing 
evidence suggests that it should be routine. Xu et al. (2015) did not investigate 
scramblase function at all and while Gyobu et al. (2015) did, only the ability of various 
anoctamins and their chimeras expressed in Ba/F3 cells (murine pro-B cells) are 
reported. Despite the lack of an overt dystrophic phenotype in the Xu et al. (2015) and 
Gyobu et al. (2015) mice, investigation for impaired phospholipid scrambling would 
still be informative. Based on the results of the current study and those of Griffin et al. 
(2016) whose model displayed impaired muscle repair processes and myoblast fusion, 
further investigation of all these models from the specific perspective of phospholipid 
scrambling is essential. Specific questions in the research field that currently remain but 
which could be investigated using these models include the specificity of the 
anoctamins and the lipids that they transport and if calcium is the only essential 
requirement for anoctamin mediated phospholipid scrambling (Whitlock and Hartzell, 
2016a). 
Finally, all of these models also provide a source of primary material for research, as 
has been achieved with other anoctamin mouse models (Yu et al., 2015). While not 
eliminating the need for patient samples, a more readily available source of primary 
material for study would be invaluable for the longitudinal studies required to fully 
investigate anoctaminopathy phenotypes. 
6.7.6 Investigation of ANO5 function in plasma membrane repair 
Within the last couple of years, multiple labs have identified new links between 
anoctamin 5, PS, annexin and dysferlin, namely the formation of repair patches and 
increased exposure of PS following wounding (Roostalu and Strahle, 2012; Tian et al., 
2015; Demonbreun et al., 2016b). Further investigation into the role of anoctamin 5 in 
plasma membrane resealing should therefore be carried out. Specific identification of 
anoctamin 5 localisation in relation to dysferlin, PS and annexins A1, A2 and A6 before, 
during and following wounding would be illuminating and potentially validate the 
proposed hypothetical vesicle population.  
Given the observation of the highly ordered accumulation of proteins to the site of 
repair, it may be that ANXA2 is the sensor for the recruitment of the vesicle population 
to the site of injury, detecting the accumulation of ANXA6. Comparison of recruitment 
of membrane repair proteins in DYSF, ANXA6 and ANO5-null mice following 
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wounding would be of benefit as well as the localisation of these proteins in each of 
these mice.   
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6.8 Conclusions 
Based on these data presented in the current project, anoctamin 5 is an internally 
expressed protein, which is involved in phospholipid scrambling of PS due to apoptotic 
stimuli. Abundance of annexin A2 has been identified as altered by the knock down of 
ANO5. Because of the association of annexin A2 with vesicle population aggregation 
and membrane fusion and repair, this may suggest that anoctamin 5 is trafficked to the 
plasma membrane when required. Knock down of ANO5 alters the composition of the 
internal vesicles in which it is held, affecting the function or binding of annexin A2. 
This research provides first steps towards understanding anoctamin 5 function and 
suggests an involvement in phospholipid scrambling.  
Since the end of the experimental phase of this project several papers have been 
published which shed light on questions surrounding anoctamin 5, namely the 
phospholipid scramblase ability of the other anoctamin family members particularly 
ANO6 (Scudieri et al., 2015; Yu et al., 2015), what role phospholipid scramblases play 
in muscle (Demonbreun et al., 2015) and the relationship between ANO5, DYSF, 
ANXA2 and muscle regeneration (Griffin et al., 2016). The data presented in this thesis 
compliment these discoveries and provide the first step in confirming and understanding 
ANO5 as a phospholipid scramblase.  
If carried out again with the information now available, this project would most likely 
have focussed less on the involvement of ANO5 as a phospholipid scramblase in 
apoptosis and rather on further investigating its role in membrane repair or membrane 
fusion. Prior to the start of this project however, investigation of apoptosis was the 
simplest route of investigation to identify ANO5 function as a scramblase. Future work 
should use the information gleaned here (knock down of ANO5 in C2C12 effects 
ANXA2 abundance as well as a loss of scramblase function) as well as, if possible, the 
developed ANO5 deficient mouse model (Griffin et al., 2016) to more fully investigate 
and understand phospholipid scramblase ability of ANO5 in relation to apoptosis, 
membrane repair and membrane fusion pathways.   
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